#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


#Text=Neural Correlates of Inhibition and Reward are Negatively Associated
#Text=Individuals with impulsive and addictive disorders, including drug addiction, binge eating/obesity, and problem gambling, exhibit both impaired control over behavior and heightened sensitivity to reward.
1-1	0-6	Neural	_	
1-2	7-17	Correlates	_	
1-3	18-20	of	_	
1-4	21-31	Inhibition	_	
1-5	32-35	and	_	
1-6	36-42	Reward	_	
1-7	43-46	are	_	
1-8	47-57	Negatively	_	
1-9	58-68	Associated	_	
1-10	69-80	Individuals	_	
1-11	81-85	with	_	
1-12	86-95	impulsive	_	
1-13	96-99	and	_	
1-14	100-109	addictive	_	
1-15	110-119	disorders	_	
1-16	119-120	,	_	
1-17	121-130	including	_	
1-18	131-135	drug	_	
1-19	136-145	addiction	_	
1-20	145-146	,	_	
1-21	147-152	binge	_	
1-22	153-159	eating	_	
1-23	159-160	/	_	
1-24	160-167	obesity	_	
1-25	167-168	,	_	
1-26	169-172	and	_	
1-27	173-180	problem	_	
1-28	181-189	gambling	_	
1-29	189-190	,	_	
1-30	191-198	exhibit	_	
1-31	199-203	both	_	
1-32	204-212	impaired	_	
1-33	213-220	control	_	
1-34	221-225	over	_	
1-35	226-234	behavior	_	
1-36	235-238	and	_	
1-37	239-249	heightened	_	
1-38	250-261	sensitivity	_	
1-39	262-264	to	_	
1-40	265-271	reward	_	
1-41	271-272	.	_	

#Text=However, it is not known whether such deviation in inhibitory and reward circuitry among clinical populations is a cause or consequence of the disorders.
2-1	273-280	However	_	
2-2	280-281	,	_	
2-3	282-284	it	_	
2-4	285-287	is	_	
2-5	288-291	not	_	
2-6	292-297	known	_	
2-7	298-305	whether	_	
2-8	306-310	such	_	
2-9	311-320	deviation	_	
2-10	321-323	in	_	
2-11	324-334	inhibitory	_	
2-12	335-338	and	_	
2-13	339-345	reward	_	
2-14	346-355	circuitry	_	
2-15	356-361	among	_	
2-16	362-370	clinical	_	
2-17	371-382	populations	_	
2-18	383-385	is	_	
2-19	386-387	a	_	
2-20	388-393	cause	_	
2-21	394-396	or	_	
2-22	397-408	consequence	_	
2-23	409-411	of	_	
2-24	412-415	the	_	
2-25	416-425	disorders	_	
2-26	425-426	.	_	

#Text=Recent evidence suggests that these constructs may be related at the neural level, and together, increase risk for engaging in maladaptive behaviors.
3-1	427-433	Recent	_	
3-2	434-442	evidence	_	
3-3	443-451	suggests	_	
3-4	452-456	that	_	
3-5	457-462	these	_	
3-6	463-473	constructs	_	
3-7	474-477	may	_	
3-8	478-480	be	_	
3-9	481-488	related	_	
3-10	489-491	at	_	
3-11	492-495	the	_	
3-12	496-502	neural	_	
3-13	503-508	level	_	
3-14	508-509	,	_	
3-15	510-513	and	_	
3-16	514-522	together	_	
3-17	522-523	,	_	
3-18	524-532	increase	_	
3-19	533-537	risk	_	
3-20	538-541	for	_	
3-21	542-550	engaging	_	
3-22	551-553	in	_	
3-23	554-565	maladaptive	_	
3-24	566-575	behaviors	_	
3-25	575-576	.	_	

#Text=The current study examined the degree to which brain function during inhibition relates to brain function during receipt of reward in healthy young adults who have not yet developed problem behaviors.
4-1	577-580	The	_	
4-2	581-588	current	_	
4-3	589-594	study	_	
4-4	595-603	examined	_	
4-5	604-607	the	_	
4-6	608-614	degree	_	
4-7	615-617	to	_	
4-8	618-623	which	_	
4-9	624-629	brain	_	
4-10	630-638	function	_	
4-11	639-645	during	_	
4-12	646-656	inhibition	_	
4-13	657-664	relates	_	
4-14	665-667	to	_	
4-15	668-673	brain	_	
4-16	674-682	function	_	
4-17	683-689	during	_	
4-18	690-697	receipt	_	
4-19	698-700	of	_	
4-20	701-707	reward	_	
4-21	708-710	in	_	
4-22	711-718	healthy	_	
4-23	719-724	young	_	
4-24	725-731	adults	_	
4-25	732-735	who	_	
4-26	736-740	have	_	
4-27	741-744	not	_	
4-28	745-748	yet	_	
4-29	749-758	developed	_	
4-30	759-766	problem	_	
4-31	767-776	behaviors	_	
4-32	776-777	.	_	

#Text=Participants completed the stop signal task to assess inhibitory control and the doors task to assess reactivity to monetary reward (win vs loss) during functional magnetic resonance imaging (fMRI).
5-1	778-790	Participants	_	
5-2	791-800	completed	_	
5-3	801-804	the	_	
5-4	805-809	stop	_	
5-5	810-816	signal	_	
5-6	817-821	task	_	
5-7	822-824	to	_	
5-8	825-831	assess	_	
5-9	832-842	inhibitory	_	
5-10	843-850	control	_	
5-11	851-854	and	_	
5-12	855-858	the	_	
5-13	859-864	doors	_	
5-14	865-869	task	_	
5-15	870-872	to	_	
5-16	873-879	assess	_	
5-17	880-890	reactivity	_	
5-18	891-893	to	_	
5-19	894-902	monetary	_	
5-20	903-909	reward	_	
5-21	910-911	(	_	
5-22	911-914	win	_	
5-23	915-917	vs	_	
5-24	918-922	loss	_	
5-25	922-923	)	_	
5-26	924-930	during	_	
5-27	931-941	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[1]	
5-28	942-950	magnetic	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[1]	
5-29	951-960	resonance	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[1]	
5-30	961-968	imaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[1]	
5-31	969-970	(	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[1]	
5-32	970-974	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[1]	
5-33	974-975	)	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[1]	
5-34	975-976	.	_	

#Text=Brain activation during response inhibition was negatively correlated with brain activation during reward.
6-1	977-982	Brain	_	
6-2	983-993	activation	_	
6-3	994-1000	during	_	
6-4	1001-1009	response	_	
6-5	1010-1020	inhibition	_	
6-6	1021-1024	was	_	
6-7	1025-1035	negatively	_	
6-8	1036-1046	correlated	_	
6-9	1047-1051	with	_	
6-10	1052-1057	brain	_	
6-11	1058-1068	activation	_	
6-12	1069-1075	during	_	
6-13	1076-1082	reward	_	
6-14	1082-1083	.	_	

#Text=Specifically, less brain activation in right prefrontal regions during inhibition, including the right inferior frontal gyrus, middle frontal gyrus, and supplementary motor area, was associated with greater brain activation in left ventral striatum during receipt of monetary reward.
7-1	1084-1096	Specifically	_	
7-2	1096-1097	,	_	
7-3	1098-1102	less	_	
7-4	1103-1108	brain	_	
7-5	1109-1119	activation	_	
7-6	1120-1122	in	_	
7-7	1123-1128	right	_	
7-8	1129-1139	prefrontal	_	
7-9	1140-1147	regions	_	
7-10	1148-1154	during	_	
7-11	1155-1165	inhibition	_	
7-12	1165-1166	,	_	
7-13	1167-1176	including	_	
7-14	1177-1180	the	_	
7-15	1181-1186	right	_	
7-16	1187-1195	inferior	_	
7-17	1196-1203	frontal	_	
7-18	1204-1209	gyrus	_	
7-19	1209-1210	,	_	
7-20	1211-1217	middle	_	
7-21	1218-1225	frontal	_	
7-22	1226-1231	gyrus	_	
7-23	1231-1232	,	_	
7-24	1233-1236	and	_	
7-25	1237-1250	supplementary	_	
7-26	1251-1256	motor	_	
7-27	1257-1261	area	_	
7-28	1261-1262	,	_	
7-29	1263-1266	was	_	
7-30	1267-1277	associated	_	
7-31	1278-1282	with	_	
7-32	1283-1290	greater	_	
7-33	1291-1296	brain	_	
7-34	1297-1307	activation	_	
7-35	1308-1310	in	_	
7-36	1311-1315	left	_	
7-37	1316-1323	ventral	_	
7-38	1324-1332	striatum	_	
7-39	1333-1339	during	_	
7-40	1340-1347	receipt	_	
7-41	1348-1350	of	_	
7-42	1351-1359	monetary	_	
7-43	1360-1366	reward	_	
7-44	1366-1367	.	_	

#Text=Moreover, these associations were stronger in binge drinkers compared to non-binge drinkers.
8-1	1368-1376	Moreover	_	
8-2	1376-1377	,	_	
8-3	1378-1383	these	_	
8-4	1384-1396	associations	_	
8-5	1397-1401	were	_	
8-6	1402-1410	stronger	_	
8-7	1411-1413	in	_	
8-8	1414-1419	binge	_	
8-9	1420-1428	drinkers	_	
8-10	1429-1437	compared	_	
8-11	1438-1440	to	_	
8-12	1441-1450	non-binge	_	
8-13	1451-1459	drinkers	_	
8-14	1459-1460	.	_	

#Text=These findings suggest that the systems are related even before the onset of impulsive or addictive disorders.
9-1	1461-1466	These	_	
9-2	1467-1475	findings	_	
9-3	1476-1483	suggest	_	
9-4	1484-1488	that	_	
9-5	1489-1492	the	_	
9-6	1493-1500	systems	_	
9-7	1501-1504	are	_	
9-8	1505-1512	related	_	
9-9	1513-1517	even	_	
9-10	1518-1524	before	_	
9-11	1525-1528	the	_	
9-12	1529-1534	onset	_	
9-13	1535-1537	of	_	
9-14	1538-1547	impulsive	_	
9-15	1548-1550	or	_	
9-16	1551-1560	addictive	_	
9-17	1561-1570	disorders	_	
9-18	1570-1571	.	_	

#Text=As such, it is possible that the association between inhibitory and reward circuitry may be a prospective marker of risk.
10-1	1572-1574	As	_	
10-2	1575-1579	such	_	
10-3	1579-1580	,	_	
10-4	1581-1583	it	_	
10-5	1584-1586	is	_	
10-6	1587-1595	possible	_	
10-7	1596-1600	that	_	
10-8	1601-1604	the	_	
10-9	1605-1616	association	_	
10-10	1617-1624	between	_	
10-11	1625-1635	inhibitory	_	
10-12	1636-1639	and	_	
10-13	1640-1646	reward	_	
10-14	1647-1656	circuitry	_	
10-15	1657-1660	may	_	
10-16	1661-1663	be	_	
10-17	1664-1665	a	_	
10-18	1666-1677	prospective	_	
10-19	1678-1684	marker	_	
10-20	1685-1687	of	_	
10-21	1688-1692	risk	_	
10-22	1692-1693	.	_	

#Text=Introduction
#Text=Impulsive and addictive behaviors, including drug and alcohol addiction, binge eating/obesity, and problem gambling are characterized by both impaired control over behavior and heightened reward sensitivity.
11-1	1694-1706	Introduction	_	
11-2	1707-1716	Impulsive	_	
11-3	1717-1720	and	_	
11-4	1721-1730	addictive	_	
11-5	1731-1740	behaviors	_	
11-6	1740-1741	,	_	
11-7	1742-1751	including	_	
11-8	1752-1756	drug	_	
11-9	1757-1760	and	_	
11-10	1761-1768	alcohol	_	
11-11	1769-1778	addiction	_	
11-12	1778-1779	,	_	
11-13	1780-1785	binge	_	
11-14	1786-1792	eating	_	
11-15	1792-1793	/	_	
11-16	1793-1800	obesity	_	
11-17	1800-1801	,	_	
11-18	1802-1805	and	_	
11-19	1806-1813	problem	_	
11-20	1814-1822	gambling	_	
11-21	1823-1826	are	_	
11-22	1827-1840	characterized	_	
11-23	1841-1843	by	_	
11-24	1844-1848	both	_	
11-25	1849-1857	impaired	_	
11-26	1858-1865	control	_	
11-27	1866-1870	over	_	
11-28	1871-1879	behavior	_	
11-29	1880-1883	and	_	
11-30	1884-1894	heightened	_	
11-31	1895-1901	reward	_	
11-32	1902-1913	sensitivity	_	
11-33	1913-1914	.	_	

#Text=These two constructs are often considered as independent risk factors for problem behaviors, but neurobiological theories propose that the two may be related, perhaps exerting reciprocal influences on each other to promote inappropriate or maladaptive behavior.
12-1	1915-1920	These	_	
12-2	1921-1924	two	_	
12-3	1925-1935	constructs	_	
12-4	1936-1939	are	_	
12-5	1940-1945	often	_	
12-6	1946-1956	considered	_	
12-7	1957-1959	as	_	
12-8	1960-1971	independent	_	
12-9	1972-1976	risk	_	
12-10	1977-1984	factors	_	
12-11	1985-1988	for	_	
12-12	1989-1996	problem	_	
12-13	1997-2006	behaviors	_	
12-14	2006-2007	,	_	
12-15	2008-2011	but	_	
12-16	2012-2027	neurobiological	_	
12-17	2028-2036	theories	_	
12-18	2037-2044	propose	_	
12-19	2045-2049	that	_	
12-20	2050-2053	the	_	
12-21	2054-2057	two	_	
12-22	2058-2061	may	_	
12-23	2062-2064	be	_	
12-24	2065-2072	related	_	
12-25	2072-2073	,	_	
12-26	2074-2081	perhaps	_	
12-27	2082-2090	exerting	_	
12-28	2091-2101	reciprocal	_	
12-29	2102-2112	influences	_	
12-30	2113-2115	on	_	
12-31	2116-2120	each	_	
12-32	2121-2126	other	_	
12-33	2127-2129	to	_	
12-34	2130-2137	promote	_	
12-35	2138-2151	inappropriate	_	
12-36	2152-2154	or	_	
12-37	2155-2166	maladaptive	_	
12-38	2167-2175	behavior	_	
12-39	2175-2176	.	_	

#Text=This hypothesis is supported by evidence that inhibition and reward share overlapping neural circuitry, and that both are strongly linked to the dopamine system.
13-1	2177-2181	This	_	
13-2	2182-2192	hypothesis	_	
13-3	2193-2195	is	_	
13-4	2196-2205	supported	_	
13-5	2206-2208	by	_	
13-6	2209-2217	evidence	_	
13-7	2218-2222	that	_	
13-8	2223-2233	inhibition	_	
13-9	2234-2237	and	_	
13-10	2238-2244	reward	_	
13-11	2245-2250	share	_	
13-12	2251-2262	overlapping	_	
13-13	2263-2269	neural	_	
13-14	2270-2279	circuitry	_	
13-15	2279-2280	,	_	
13-16	2281-2284	and	_	
13-17	2285-2289	that	_	
13-18	2290-2294	both	_	
13-19	2295-2298	are	_	
13-20	2299-2307	strongly	_	
13-21	2308-2314	linked	_	
13-22	2315-2317	to	_	
13-23	2318-2321	the	_	
13-24	2322-2330	dopamine	_	
13-25	2331-2337	system	_	
13-26	2337-2338	.	_	

#Text=Importantly, this relative imbalance between hypoactive inhibitory functioning and hyperactive reward functioning may be present before the onset of a disorder.
14-1	2339-2350	Importantly	_	
14-2	2350-2351	,	_	
14-3	2352-2356	this	_	
14-4	2357-2365	relative	_	
14-5	2366-2375	imbalance	_	
14-6	2376-2383	between	_	
14-7	2384-2394	hypoactive	_	
14-8	2395-2405	inhibitory	_	
14-9	2406-2417	functioning	_	
14-10	2418-2421	and	_	
14-11	2422-2433	hyperactive	_	
14-12	2434-2440	reward	_	
14-13	2441-2452	functioning	_	
14-14	2453-2456	may	_	
14-15	2457-2459	be	_	
14-16	2460-2467	present	_	
14-17	2468-2474	before	_	
14-18	2475-2478	the	_	
14-19	2479-2484	onset	_	
14-20	2485-2487	of	_	
14-21	2488-2489	a	_	
14-22	2490-2498	disorder	_	
14-23	2498-2499	.	_	

#Text=If so, this neural profile could serve as an important marker of risk, as well as provide a potential target for prevention mechanisms.
15-1	2500-2502	If	_	
15-2	2503-2505	so	_	
15-3	2505-2506	,	_	
15-4	2507-2511	this	_	
15-5	2512-2518	neural	_	
15-6	2519-2526	profile	_	
15-7	2527-2532	could	_	
15-8	2533-2538	serve	_	
15-9	2539-2541	as	_	
15-10	2542-2544	an	_	
15-11	2545-2554	important	_	
15-12	2555-2561	marker	_	
15-13	2562-2564	of	_	
15-14	2565-2569	risk	_	
15-15	2569-2570	,	_	
15-16	2571-2573	as	_	
15-17	2574-2578	well	_	
15-18	2579-2581	as	_	
15-19	2582-2589	provide	_	
15-20	2590-2591	a	_	
15-21	2592-2601	potential	_	
15-22	2602-2608	target	_	
15-23	2609-2612	for	_	
15-24	2613-2623	prevention	_	
15-25	2624-2634	mechanisms	_	
15-26	2634-2635	.	_	

#Text=Functional neuroimaging studies provide consistent evidence implicating altered inhibition and reward circuitry in addiction and impulse control disorders.
16-1	2636-2646	Functional	_	
16-2	2647-2659	neuroimaging	_	
16-3	2660-2667	studies	_	
16-4	2668-2675	provide	_	
16-5	2676-2686	consistent	_	
16-6	2687-2695	evidence	_	
16-7	2696-2707	implicating	_	
16-8	2708-2715	altered	_	
16-9	2716-2726	inhibition	_	
16-10	2727-2730	and	_	
16-11	2731-2737	reward	_	
16-12	2738-2747	circuitry	_	
16-13	2748-2750	in	_	
16-14	2751-2760	addiction	_	
16-15	2761-2764	and	_	
16-16	2765-2772	impulse	_	
16-17	2773-2780	control	_	
16-18	2781-2790	disorders	_	
16-19	2790-2791	.	_	

#Text=For instance, individuals who abuse drugs show hypoactivation of prefrontal regions involved in inhibitory control, including the right inferior frontal gyrus (IFG), supplementary motor area (SMA), and dorsolateral prefrontal cortex (DLPFC), during response inhibition.
17-1	2792-2795	For	_	
17-2	2796-2804	instance	_	
17-3	2804-2805	,	_	
17-4	2806-2817	individuals	_	
17-5	2818-2821	who	_	
17-6	2822-2827	abuse	_	
17-7	2828-2833	drugs	_	
17-8	2834-2838	show	_	
17-9	2839-2853	hypoactivation	_	
17-10	2854-2856	of	_	
17-11	2857-2867	prefrontal	_	
17-12	2868-2875	regions	_	
17-13	2876-2884	involved	_	
17-14	2885-2887	in	_	
17-15	2888-2898	inhibitory	_	
17-16	2899-2906	control	_	
17-17	2906-2907	,	_	
17-18	2908-2917	including	_	
17-19	2918-2921	the	_	
17-20	2922-2927	right	_	
17-21	2928-2936	inferior	_	
17-22	2937-2944	frontal	_	
17-23	2945-2950	gyrus	_	
17-24	2951-2952	(	_	
17-25	2952-2955	IFG	_	
17-26	2955-2956	)	_	
17-27	2956-2957	,	_	
17-28	2958-2971	supplementary	_	
17-29	2972-2977	motor	_	
17-30	2978-2982	area	_	
17-31	2983-2984	(	_	
17-32	2984-2987	SMA	_	
17-33	2987-2988	)	_	
17-34	2988-2989	,	_	
17-35	2990-2993	and	_	
17-36	2994-3006	dorsolateral	_	
17-37	3007-3017	prefrontal	_	
17-38	3018-3024	cortex	_	
17-39	3025-3026	(	_	
17-40	3026-3031	DLPFC	_	
17-41	3031-3032	)	_	
17-42	3032-3033	,	_	
17-43	3034-3040	during	_	
17-44	3041-3049	response	_	
17-45	3050-3060	inhibition	_	
17-46	3060-3061	.	_	

#Text=Similar hypoactivation of frontal regions during inhibition has also been observed in problem gamblers, individuals with internet gaming disorder, and adults and adolescents with bulimia nervosa, compared to healthy controls.
18-1	3062-3069	Similar	_	
18-2	3070-3084	hypoactivation	_	
18-3	3085-3087	of	_	
18-4	3088-3095	frontal	_	
18-5	3096-3103	regions	_	
18-6	3104-3110	during	_	
18-7	3111-3121	inhibition	_	
18-8	3122-3125	has	_	
18-9	3126-3130	also	_	
18-10	3131-3135	been	_	
18-11	3136-3144	observed	_	
18-12	3145-3147	in	_	
18-13	3148-3155	problem	_	
18-14	3156-3164	gamblers	_	
18-15	3164-3165	,	_	
18-16	3166-3177	individuals	_	
18-17	3178-3182	with	_	
18-18	3183-3191	internet	_	
18-19	3192-3198	gaming	_	
18-20	3199-3207	disorder	_	
18-21	3207-3208	,	_	
18-22	3209-3212	and	_	
18-23	3213-3219	adults	_	
18-24	3220-3223	and	_	
18-25	3224-3235	adolescents	_	
18-26	3236-3240	with	_	
18-27	3241-3248	bulimia	_	
18-28	3249-3256	nervosa	_	
18-29	3256-3257	,	_	
18-30	3258-3266	compared	_	
18-31	3267-3269	to	_	
18-32	3270-3277	healthy	_	
18-33	3278-3286	controls	_	
18-34	3286-3287	.	_	

#Text=Individuals with addictive and impulse control disorders also display heightened activation of reward regions, including the ventral striatum (VS) and medial prefrontal cortex (mPFC), in response to disorder-specific rewarding stimuli.
19-1	3288-3299	Individuals	_	
19-2	3300-3304	with	_	
19-3	3305-3314	addictive	_	
19-4	3315-3318	and	_	
19-5	3319-3326	impulse	_	
19-6	3327-3334	control	_	
19-7	3335-3344	disorders	_	
19-8	3345-3349	also	_	
19-9	3350-3357	display	_	
19-10	3358-3368	heightened	_	
19-11	3369-3379	activation	_	
19-12	3380-3382	of	_	
19-13	3383-3389	reward	_	
19-14	3390-3397	regions	_	
19-15	3397-3398	,	_	
19-16	3399-3408	including	_	
19-17	3409-3412	the	_	
19-18	3413-3420	ventral	_	
19-19	3421-3429	striatum	_	
19-20	3430-3431	(	_	
19-21	3431-3433	VS	_	
19-22	3433-3434	)	_	
19-23	3435-3438	and	_	
19-24	3439-3445	medial	_	
19-25	3446-3456	prefrontal	_	
19-26	3457-3463	cortex	_	
19-27	3464-3465	(	_	
19-28	3465-3469	mPFC	_	
19-29	3469-3470	)	_	
19-30	3470-3471	,	_	
19-31	3472-3474	in	_	
19-32	3475-3483	response	_	
19-33	3484-3486	to	_	
19-34	3487-3504	disorder-specific	_	
19-35	3505-3514	rewarding	_	
19-36	3515-3522	stimuli	_	
19-37	3522-3523	.	_	

#Text=For instance, individuals who abuse drugs display heightened activation in reward circuitry while viewing images of drugs and drug cues.
20-1	3524-3527	For	_	
20-2	3528-3536	instance	_	
20-3	3536-3537	,	_	
20-4	3538-3549	individuals	_	
20-5	3550-3553	who	_	
20-6	3554-3559	abuse	_	
20-7	3560-3565	drugs	_	
20-8	3566-3573	display	_	
20-9	3574-3584	heightened	_	
20-10	3585-3595	activation	_	
20-11	3596-3598	in	_	
20-12	3599-3605	reward	_	
20-13	3606-3615	circuitry	_	
20-14	3616-3621	while	_	
20-15	3622-3629	viewing	_	
20-16	3630-3636	images	_	
20-17	3637-3639	of	_	
20-18	3640-3645	drugs	_	
20-19	3646-3649	and	_	
20-20	3650-3654	drug	_	
20-21	3655-3659	cues	_	
20-22	3659-3660	.	_	

#Text=Problem gamblers and individuals with internet gaming disorder also show heightened activation of reward circuitry when viewing images related to gambling or gaming, respectively, and obese individuals show greater reward response to food cues.
21-1	3661-3668	Problem	_	
21-2	3669-3677	gamblers	_	
21-3	3678-3681	and	_	
21-4	3682-3693	individuals	_	
21-5	3694-3698	with	_	
21-6	3699-3707	internet	_	
21-7	3708-3714	gaming	_	
21-8	3715-3723	disorder	_	
21-9	3724-3728	also	_	
21-10	3729-3733	show	_	
21-11	3734-3744	heightened	_	
21-12	3745-3755	activation	_	
21-13	3756-3758	of	_	
21-14	3759-3765	reward	_	
21-15	3766-3775	circuitry	_	
21-16	3776-3780	when	_	
21-17	3781-3788	viewing	_	
21-18	3789-3795	images	_	
21-19	3796-3803	related	_	
21-20	3804-3806	to	_	
21-21	3807-3815	gambling	_	
21-22	3816-3818	or	_	
21-23	3819-3825	gaming	_	
21-24	3825-3826	,	_	
21-25	3827-3839	respectively	_	
21-26	3839-3840	,	_	
21-27	3841-3844	and	_	
21-28	3845-3850	obese	_	
21-29	3851-3862	individuals	_	
21-30	3863-3867	show	_	
21-31	3868-3875	greater	_	
21-32	3876-3882	reward	_	
21-33	3883-3891	response	_	
21-34	3892-3894	to	_	
21-35	3895-3899	food	_	
21-36	3900-3904	cues	_	
21-37	3904-3905	.	_	

#Text=Interestingly, there is also evidence that individuals with addictive disorders display a blunted response to non-disorder-related reward, including monetary and sexual reward, and pleasant emotional stimuli.
22-1	3906-3919	Interestingly	_	
22-2	3919-3920	,	_	
22-3	3921-3926	there	_	
22-4	3927-3929	is	_	
22-5	3930-3934	also	_	
22-6	3935-3943	evidence	_	
22-7	3944-3948	that	_	
22-8	3949-3960	individuals	_	
22-9	3961-3965	with	_	
22-10	3966-3975	addictive	_	
22-11	3976-3985	disorders	_	
22-12	3986-3993	display	_	
22-13	3994-3995	a	_	
22-14	3996-4003	blunted	_	
22-15	4004-4012	response	_	
22-16	4013-4015	to	_	
22-17	4016-4036	non-disorder-related	_	
22-18	4037-4043	reward	_	
22-19	4043-4044	,	_	
22-20	4045-4054	including	_	
22-21	4055-4063	monetary	_	
22-22	4064-4067	and	_	
22-23	4068-4074	sexual	_	
22-24	4075-4081	reward	_	
22-25	4081-4082	,	_	
22-26	4083-4086	and	_	
22-27	4087-4095	pleasant	_	
22-28	4096-4105	emotional	_	
22-29	4106-4113	stimuli	_	
22-30	4113-4114	.	_	

#Text=This suggests that the relative values of different rewards may change as the disorders develop.
23-1	4115-4119	This	_	
23-2	4120-4128	suggests	_	
23-3	4129-4133	that	_	
23-4	4134-4137	the	_	
23-5	4138-4146	relative	_	
23-6	4147-4153	values	_	
23-7	4154-4156	of	_	
23-8	4157-4166	different	_	
23-9	4167-4174	rewards	_	
23-10	4175-4178	may	_	
23-11	4179-4185	change	_	
23-12	4186-4188	as	_	
23-13	4189-4192	the	_	
23-14	4193-4202	disorders	_	
23-15	4203-4210	develop	_	
23-16	4210-4211	.	_	

#Text=In sum, individuals with addiction and impulse control disorders display hypoactivation of inhibitory circuitry, coupled with hyperactivation of reward circuitry to disorder-specific stimuli, compared to healthy controls.
24-1	4212-4214	In	_	
24-2	4215-4218	sum	_	
24-3	4218-4219	,	_	
24-4	4220-4231	individuals	_	
24-5	4232-4236	with	_	
24-6	4237-4246	addiction	_	
24-7	4247-4250	and	_	
24-8	4251-4258	impulse	_	
24-9	4259-4266	control	_	
24-10	4267-4276	disorders	_	
24-11	4277-4284	display	_	
24-12	4285-4299	hypoactivation	_	
24-13	4300-4302	of	_	
24-14	4303-4313	inhibitory	_	
24-15	4314-4323	circuitry	_	
24-16	4323-4324	,	_	
24-17	4325-4332	coupled	_	
24-18	4333-4337	with	_	
24-19	4338-4353	hyperactivation	_	
24-20	4354-4356	of	_	
24-21	4357-4363	reward	_	
24-22	4364-4373	circuitry	_	
24-23	4374-4376	to	_	
24-24	4377-4394	disorder-specific	_	
24-25	4395-4402	stimuli	_	
24-26	4402-4403	,	_	
24-27	4404-4412	compared	_	
24-28	4413-4415	to	_	
24-29	4416-4423	healthy	_	
24-30	4424-4432	controls	_	
24-31	4432-4433	.	_	

#Text=Several recent imaging studies suggest that inhibition and reward circuits are closely linked, particularly in addicted populations.
25-1	4434-4441	Several	_	
25-2	4442-4448	recent	_	
25-3	4449-4456	imaging	_	
25-4	4457-4464	studies	_	
25-5	4465-4472	suggest	_	
25-6	4473-4477	that	_	
25-7	4478-4488	inhibition	_	
25-8	4489-4492	and	_	
25-9	4493-4499	reward	_	
25-10	4500-4508	circuits	_	
25-11	4509-4512	are	_	
25-12	4513-4520	closely	_	
25-13	4521-4527	linked	_	
25-14	4527-4528	,	_	
25-15	4529-4541	particularly	_	
25-16	4542-4544	in	_	
25-17	4545-4553	addicted	_	
25-18	4554-4565	populations	_	
25-19	4565-4566	.	_	

#Text=Compared to healthy controls, individuals with alcohol dependence show less functional connectivity between DLPFC (a region strongly implicated in inhibitory control) and VS during monetary reward.
26-1	4567-4575	Compared	_	
26-2	4576-4578	to	_	
26-3	4579-4586	healthy	_	
26-4	4587-4595	controls	_	
26-5	4595-4596	,	_	
26-6	4597-4608	individuals	_	
26-7	4609-4613	with	_	
26-8	4614-4621	alcohol	_	
26-9	4622-4632	dependence	_	
26-10	4633-4637	show	_	
26-11	4638-4642	less	_	
26-12	4643-4653	functional	_	
26-13	4654-4666	connectivity	_	
26-14	4667-4674	between	_	
26-15	4675-4680	DLPFC	_	
26-16	4681-4682	(	_	
26-17	4682-4683	a	_	
26-18	4684-4690	region	_	
26-19	4691-4699	strongly	_	
26-20	4700-4710	implicated	_	
26-21	4711-4713	in	_	
26-22	4714-4724	inhibitory	_	
26-23	4725-4732	control	_	
26-24	4732-4733	)	_	
26-25	4734-4737	and	_	
26-26	4738-4740	VS	_	
26-27	4741-4747	during	_	
26-28	4748-4756	monetary	_	
26-29	4757-4763	reward	_	
26-30	4763-4764	.	_	

#Text=Moreover, lower frontal-striatal connectivity in alcohol dependent individuals is associated with greater activation of VS during reward.
27-1	4765-4773	Moreover	_	
27-2	4773-4774	,	_	
27-3	4775-4780	lower	_	
27-4	4781-4797	frontal-striatal	_	
27-5	4798-4810	connectivity	_	
27-6	4811-4813	in	_	
27-7	4814-4821	alcohol	_	
27-8	4822-4831	dependent	_	
27-9	4832-4843	individuals	_	
27-10	4844-4846	is	_	
27-11	4847-4857	associated	_	
27-12	4858-4862	with	_	
27-13	4863-4870	greater	_	
27-14	4871-4881	activation	_	
27-15	4882-4884	of	_	
27-16	4885-4887	VS	_	
27-17	4888-4894	during	_	
27-18	4895-4901	reward	_	
27-19	4901-4902	.	_	

#Text=These findings suggest that greater behavioral sensitivity to reward could be due in part to dampened prefrontal regulation of striatal reward responses.
28-1	4903-4908	These	_	
28-2	4909-4917	findings	_	
28-3	4918-4925	suggest	_	
28-4	4926-4930	that	_	
28-5	4931-4938	greater	_	
28-6	4939-4949	behavioral	_	
28-7	4950-4961	sensitivity	_	
28-8	4962-4964	to	_	
28-9	4965-4971	reward	_	
28-10	4972-4977	could	_	
28-11	4978-4980	be	_	
28-12	4981-4984	due	_	
28-13	4985-4987	in	_	
28-14	4988-4992	part	_	
28-15	4993-4995	to	_	
28-16	4996-5004	dampened	_	
28-17	5005-5015	prefrontal	_	
28-18	5016-5026	regulation	_	
28-19	5027-5029	of	_	
28-20	5030-5038	striatal	_	
28-21	5039-5045	reward	_	
28-22	5046-5055	responses	_	
28-23	5055-5056	.	_	

#Text=It is not known whether aberrant functioning of inhibition and reward circuitry in these disorders is a cause or consequence of the disorder.
29-1	5057-5059	It	_	
29-2	5060-5062	is	_	
29-3	5063-5066	not	_	
29-4	5067-5072	known	_	
29-5	5073-5080	whether	_	
29-6	5081-5089	aberrant	_	
29-7	5090-5101	functioning	_	
29-8	5102-5104	of	_	
29-9	5105-5115	inhibition	_	
29-10	5116-5119	and	_	
29-11	5120-5126	reward	_	
29-12	5127-5136	circuitry	_	
29-13	5137-5139	in	_	
29-14	5140-5145	these	_	
29-15	5146-5155	disorders	_	
29-16	5156-5158	is	_	
29-17	5159-5160	a	_	
29-18	5161-5166	cause	_	
29-19	5167-5169	or	_	
29-20	5170-5181	consequence	_	
29-21	5182-5184	of	_	
29-22	5185-5188	the	_	
29-23	5189-5197	disorder	_	
29-24	5197-5198	.	_	

#Text=Preliminary prospective studies show that individuals with less engagement of inhibitory control regions during response inhibition as well as greater activation in reward regions during monetary reward are more likely to exhibit substance use later in life, suggesting a potential causal relationship.
30-1	5199-5210	Preliminary	_	
30-2	5211-5222	prospective	_	
30-3	5223-5230	studies	_	
30-4	5231-5235	show	_	
30-5	5236-5240	that	_	
30-6	5241-5252	individuals	_	
30-7	5253-5257	with	_	
30-8	5258-5262	less	_	
30-9	5263-5273	engagement	_	
30-10	5274-5276	of	_	
30-11	5277-5287	inhibitory	_	
30-12	5288-5295	control	_	
30-13	5296-5303	regions	_	
30-14	5304-5310	during	_	
30-15	5311-5319	response	_	
30-16	5320-5330	inhibition	_	
30-17	5331-5333	as	_	
30-18	5334-5338	well	_	
30-19	5339-5341	as	_	
30-20	5342-5349	greater	_	
30-21	5350-5360	activation	_	
30-22	5361-5363	in	_	
30-23	5364-5370	reward	_	
30-24	5371-5378	regions	_	
30-25	5379-5385	during	_	
30-26	5386-5394	monetary	_	
30-27	5395-5401	reward	_	
30-28	5402-5405	are	_	
30-29	5406-5410	more	_	
30-30	5411-5417	likely	_	
30-31	5418-5420	to	_	
30-32	5421-5428	exhibit	_	
30-33	5429-5438	substance	_	
30-34	5439-5442	use	_	
30-35	5443-5448	later	_	
30-36	5449-5451	in	_	
30-37	5452-5456	life	_	
30-38	5456-5457	,	_	
30-39	5458-5468	suggesting	_	
30-40	5469-5470	a	_	
30-41	5471-5480	potential	_	
30-42	5481-5487	causal	_	
30-43	5488-5500	relationship	_	
30-44	5500-5501	.	_	

#Text=Another way to investigate the relationships between these processes before problematic behaviors develop is to examine engagement of prefrontal regions during response inhibition in relation to engagement of reward circuitry during receipt of reward in healthy, non-disordered populations.
31-1	5502-5509	Another	_	
31-2	5510-5513	way	_	
31-3	5514-5516	to	_	
31-4	5517-5528	investigate	_	
31-5	5529-5532	the	_	
31-6	5533-5546	relationships	_	
31-7	5547-5554	between	_	
31-8	5555-5560	these	_	
31-9	5561-5570	processes	_	
31-10	5571-5577	before	_	
31-11	5578-5589	problematic	_	
31-12	5590-5599	behaviors	_	
31-13	5600-5607	develop	_	
31-14	5608-5610	is	_	
31-15	5611-5613	to	_	
31-16	5614-5621	examine	_	
31-17	5622-5632	engagement	_	
31-18	5633-5635	of	_	
31-19	5636-5646	prefrontal	_	
31-20	5647-5654	regions	_	
31-21	5655-5661	during	_	
31-22	5662-5670	response	_	
31-23	5671-5681	inhibition	_	
31-24	5682-5684	in	_	
31-25	5685-5693	relation	_	
31-26	5694-5696	to	_	
31-27	5697-5707	engagement	_	
31-28	5708-5710	of	_	
31-29	5711-5717	reward	_	
31-30	5718-5727	circuitry	_	
31-31	5728-5734	during	_	
31-32	5735-5742	receipt	_	
31-33	5743-5745	of	_	
31-34	5746-5752	reward	_	
31-35	5753-5755	in	_	
31-36	5756-5763	healthy	_	
31-37	5763-5764	,	_	
31-38	5765-5779	non-disordered	_	
31-39	5780-5791	populations	_	
31-40	5791-5792	.	_	

#Text=That is, a risk profile for future problematic behaviors may be poor prefrontal regulation of reward circuitry.
32-1	5793-5797	That	_	
32-2	5798-5800	is	_	
32-3	5800-5801	,	_	
32-4	5802-5803	a	_	
32-5	5804-5808	risk	_	
32-6	5809-5816	profile	_	
32-7	5817-5820	for	_	
32-8	5821-5827	future	_	
32-9	5828-5839	problematic	_	
32-10	5840-5849	behaviors	_	
32-11	5850-5853	may	_	
32-12	5854-5856	be	_	
32-13	5857-5861	poor	_	
32-14	5862-5872	prefrontal	_	
32-15	5873-5883	regulation	_	
32-16	5884-5886	of	_	
32-17	5887-5893	reward	_	
32-18	5894-5903	circuitry	_	
32-19	5903-5904	.	_	

#Text=The current study examined the degree to which brain function during inhibition relates to brain function during reward in healthy young adults with no history of addictive or impulse control disorders.
33-1	5905-5908	The	_	
33-2	5909-5916	current	_	
33-3	5917-5922	study	_	
33-4	5923-5931	examined	_	
33-5	5932-5935	the	_	
33-6	5936-5942	degree	_	
33-7	5943-5945	to	_	
33-8	5946-5951	which	_	
33-9	5952-5957	brain	_	
33-10	5958-5966	function	_	
33-11	5967-5973	during	_	
33-12	5974-5984	inhibition	_	
33-13	5985-5992	relates	_	
33-14	5993-5995	to	_	
33-15	5996-6001	brain	_	
33-16	6002-6010	function	_	
33-17	6011-6017	during	_	
33-18	6018-6024	reward	_	
33-19	6025-6027	in	_	
33-20	6028-6035	healthy	_	
33-21	6036-6041	young	_	
33-22	6042-6048	adults	_	
33-23	6049-6053	with	_	
33-24	6054-6056	no	_	
33-25	6057-6064	history	_	
33-26	6065-6067	of	_	
33-27	6068-6077	addictive	_	
33-28	6078-6080	or	_	
33-29	6081-6088	impulse	_	
33-30	6089-6096	control	_	
33-31	6097-6106	disorders	_	
33-32	6106-6107	.	_	

#Text=Specifically, we used fMRI to examine associations between brain activation during response inhibition and during monetary reward.
34-1	6108-6120	Specifically	_	
34-2	6120-6121	,	_	
34-3	6122-6124	we	_	
34-4	6125-6129	used	_	
34-5	6130-6134	fMRI	_	
34-6	6135-6137	to	_	
34-7	6138-6145	examine	_	
34-8	6146-6158	associations	_	
34-9	6159-6166	between	_	
34-10	6167-6172	brain	_	
34-11	6173-6183	activation	_	
34-12	6184-6190	during	_	
34-13	6191-6199	response	_	
34-14	6200-6210	inhibition	_	
34-15	6211-6214	and	_	
34-16	6215-6221	during	_	
34-17	6222-6230	monetary	_	
34-18	6231-6237	reward	_	
34-19	6237-6238	.	_	

#Text=Brain activation during inhibition was assessed using the stop signal task.
35-1	6239-6244	Brain	_	
35-2	6245-6255	activation	_	
35-3	6256-6262	during	_	
35-4	6263-6273	inhibition	_	
35-5	6274-6277	was	_	
35-6	6278-6286	assessed	_	
35-7	6287-6292	using	_	
35-8	6293-6296	the	_	
35-9	6297-6301	stop	_	
35-10	6302-6308	signal	_	
35-11	6309-6313	task	_	
35-12	6313-6314	.	_	

#Text=This task activates right-lateralized frontal regions known to be involved in inhibitory control, including DLPFC, IFG, and SMA, and less frontal activation is associated with poor inhibition.
36-1	6315-6319	This	_	
36-2	6320-6324	task	_	
36-3	6325-6334	activates	_	
36-4	6335-6352	right-lateralized	_	
36-5	6353-6360	frontal	_	
36-6	6361-6368	regions	_	
36-7	6369-6374	known	_	
36-8	6375-6377	to	_	
36-9	6378-6380	be	_	
36-10	6381-6389	involved	_	
36-11	6390-6392	in	_	
36-12	6393-6403	inhibitory	_	
36-13	6404-6411	control	_	
36-14	6411-6412	,	_	
36-15	6413-6422	including	_	
36-16	6423-6428	DLPFC	_	
36-17	6428-6429	,	_	
36-18	6430-6433	IFG	_	
36-19	6433-6434	,	_	
36-20	6435-6438	and	_	
36-21	6439-6442	SMA	_	
36-22	6442-6443	,	_	
36-23	6444-6447	and	_	
36-24	6448-6452	less	_	
36-25	6453-6460	frontal	_	
36-26	6461-6471	activation	_	
36-27	6472-6474	is	_	
36-28	6475-6485	associated	_	
36-29	6486-6490	with	_	
36-30	6491-6495	poor	_	
36-31	6496-6506	inhibition	_	
36-32	6506-6507	.	_	

#Text=Brain activation during receipt of monetary reward was assessed using the doors task, which reliably activates regions involved in reward, including VS.
37-1	6508-6513	Brain	_	
37-2	6514-6524	activation	_	
37-3	6525-6531	during	_	
37-4	6532-6539	receipt	_	
37-5	6540-6542	of	_	
37-6	6543-6551	monetary	_	
37-7	6552-6558	reward	_	
37-8	6559-6562	was	_	
37-9	6563-6571	assessed	_	
37-10	6572-6577	using	_	
37-11	6578-6581	the	_	
37-12	6582-6587	doors	_	
37-13	6588-6592	task	_	
37-14	6592-6593	,	_	
37-15	6594-6599	which	_	
37-16	6600-6608	reliably	_	
37-17	6609-6618	activates	_	
37-18	6619-6626	regions	_	
37-19	6627-6635	involved	_	
37-20	6636-6638	in	_	
37-21	6639-6645	reward	_	
37-22	6645-6646	,	_	
37-23	6647-6656	including	_	
37-24	6657-6659	VS	_	
37-25	6659-6660	.	_	

#Text=We hypothesized that less prefrontal activation during response inhibition would be associated with greater activation of reward circuitry during monetary reward.
38-1	6661-6663	We	_	
38-2	6664-6676	hypothesized	_	
38-3	6677-6681	that	_	
38-4	6682-6686	less	_	
38-5	6687-6697	prefrontal	_	
38-6	6698-6708	activation	_	
38-7	6709-6715	during	_	
38-8	6716-6724	response	_	
38-9	6725-6735	inhibition	_	
38-10	6736-6741	would	_	
38-11	6742-6744	be	_	
38-12	6745-6755	associated	_	
38-13	6756-6760	with	_	
38-14	6761-6768	greater	_	
38-15	6769-6779	activation	_	
38-16	6780-6782	of	_	
38-17	6783-6789	reward	_	
38-18	6790-6799	circuitry	_	
38-19	6800-6806	during	_	
38-20	6807-6815	monetary	_	
38-21	6816-6822	reward	_	
38-22	6822-6823	.	_	

#Text=Additionally, we conducted exploratory analyses to examine these associations separately in binge and non-binge drinkers.
39-1	6824-6836	Additionally	_	
39-2	6836-6837	,	_	
39-3	6838-6840	we	_	
39-4	6841-6850	conducted	_	
39-5	6851-6862	exploratory	_	
39-6	6863-6871	analyses	_	
39-7	6872-6874	to	_	
39-8	6875-6882	examine	_	
39-9	6883-6888	these	_	
39-10	6889-6901	associations	_	
39-11	6902-6912	separately	_	
39-12	6913-6915	in	_	
39-13	6916-6921	binge	_	
39-14	6922-6925	and	_	
39-15	6926-6935	non-binge	_	
39-16	6936-6944	drinkers	_	
39-17	6944-6945	.	_	

#Text=As binge drinkers are a population at risk for developing substance use disorders, these analyses provided some insight as to whether associations between brain function during inhibition and reward related to risk for addictive and impulse control disorders.
40-1	6946-6948	As	_	
40-2	6949-6954	binge	_	
40-3	6955-6963	drinkers	_	
40-4	6964-6967	are	_	
40-5	6968-6969	a	_	
40-6	6970-6980	population	_	
40-7	6981-6983	at	_	
40-8	6984-6988	risk	_	
40-9	6989-6992	for	_	
40-10	6993-7003	developing	_	
40-11	7004-7013	substance	_	
40-12	7014-7017	use	_	
40-13	7018-7027	disorders	_	
40-14	7027-7028	,	_	
40-15	7029-7034	these	_	
40-16	7035-7043	analyses	_	
40-17	7044-7052	provided	_	
40-18	7053-7057	some	_	
40-19	7058-7065	insight	_	
40-20	7066-7068	as	_	
40-21	7069-7071	to	_	
40-22	7072-7079	whether	_	
40-23	7080-7092	associations	_	
40-24	7093-7100	between	_	
40-25	7101-7106	brain	_	
40-26	7107-7115	function	_	
40-27	7116-7122	during	_	
40-28	7123-7133	inhibition	_	
40-29	7134-7137	and	_	
40-30	7138-7144	reward	_	
40-31	7145-7152	related	_	
40-32	7153-7155	to	_	
40-33	7156-7160	risk	_	
40-34	7161-7164	for	_	
40-35	7165-7174	addictive	_	
40-36	7175-7178	and	_	
40-37	7179-7186	impulse	_	
40-38	7187-7194	control	_	
40-39	7195-7204	disorders	_	
40-40	7204-7205	.	_	

#Text=Methods
#Text=Participants
#Text=Volunteers age 21–29 were recruited from the community through online and printed advertisements.
41-1	7206-7213	Methods	http://www.case.edu/ProvCaRe/provcare#StudyMethod	
41-2	7214-7226	Participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
41-3	7227-7237	Volunteers	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
41-4	7238-7241	age	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
41-5	7242-7244	21	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
41-6	7244-7245	–	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
41-7	7245-7247	29	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
41-8	7248-7252	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
41-9	7253-7262	recruited	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
41-10	7263-7267	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
41-11	7268-7271	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
41-12	7272-7281	community	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
41-13	7282-7289	through	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
41-14	7290-7296	online	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
41-15	7297-7300	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
41-16	7301-7308	printed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
41-17	7309-7323	advertisements	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	
41-18	7323-7324	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[2]	

#Text=This age range was selected to target young adults, as the study aimed to identify biomarkers of addiction vulnerability, and young adulthood is a known period of risk.
42-1	7325-7329	This	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
42-2	7330-7333	age	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
42-3	7334-7339	range	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
42-4	7340-7343	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
42-5	7344-7352	selected	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
42-6	7353-7355	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
42-7	7356-7362	target	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
42-8	7363-7368	young	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
42-9	7369-7375	adults	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
42-10	7375-7376	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
42-11	7377-7379	as	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
42-12	7380-7383	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
42-13	7384-7389	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
42-14	7390-7395	aimed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
42-15	7396-7398	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
42-16	7399-7407	identify	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
42-17	7408-7418	biomarkers	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
42-18	7419-7421	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
42-19	7422-7431	addiction	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
42-20	7432-7445	vulnerability	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
42-21	7445-7446	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
42-22	7447-7450	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
42-23	7451-7456	young	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
42-24	7457-7466	adulthood	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
42-25	7467-7469	is	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
42-26	7470-7471	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
42-27	7472-7477	known	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
42-28	7478-7484	period	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
42-29	7485-7487	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
42-30	7488-7492	risk	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
42-31	7492-7493	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	

#Text=Individuals younger than 21 were excluded to limit variability due to ongoing brain maturation in prefrontal regions of interest.
43-1	7494-7505	Individuals	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
43-2	7506-7513	younger	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
43-3	7514-7518	than	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
43-4	7519-7521	21	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
43-5	7522-7526	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
43-6	7527-7535	excluded	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
43-7	7536-7538	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
43-8	7539-7544	limit	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
43-9	7545-7556	variability	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
43-10	7557-7560	due	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
43-11	7561-7563	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
43-12	7564-7571	ongoing	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
43-13	7572-7577	brain	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
43-14	7578-7588	maturation	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
43-15	7589-7591	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
43-16	7592-7602	prefrontal	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
43-17	7603-7610	regions	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
43-18	7611-7613	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
43-19	7614-7622	interest	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
43-20	7622-7623	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	

#Text=Inclusion criteria were as follows: age 21–29, BMI between 19 and 26, at least a high school education, fluency in English, no current or past year DSM-IV diagnosis, no lifetime history of substance dependence or ADHD, no serious medical conditions, and no night shift work.
44-1	7624-7633	Inclusion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
44-2	7634-7642	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
44-3	7643-7647	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
44-4	7648-7650	as	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
44-5	7651-7658	follows	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
44-6	7658-7659	:	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
44-7	7660-7663	age	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
44-8	7664-7666	21	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
44-9	7666-7667	–	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
44-10	7667-7669	29	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
44-11	7669-7670	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
44-12	7671-7674	BMI	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
44-13	7675-7682	between	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
44-14	7683-7685	19	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
44-15	7686-7689	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
44-16	7690-7692	26	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
44-17	7692-7693	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
44-18	7694-7696	at	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
44-19	7697-7702	least	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
44-20	7703-7704	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
44-21	7705-7709	high	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
44-22	7710-7716	school	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
44-23	7717-7726	education	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
44-24	7726-7727	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
44-25	7728-7735	fluency	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
44-26	7736-7738	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
44-27	7739-7746	English	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
44-28	7746-7747	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
44-29	7748-7750	no	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
44-30	7751-7758	current	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
44-31	7759-7761	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
44-32	7762-7766	past	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
44-33	7767-7771	year	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
44-34	7772-7778	DSM-IV	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
44-35	7779-7788	diagnosis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
44-36	7788-7789	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
44-37	7790-7792	no	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
44-38	7793-7801	lifetime	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
44-39	7802-7809	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
44-40	7810-7812	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
44-41	7813-7822	substance	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
44-42	7823-7833	dependence	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
44-43	7834-7836	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
44-44	7837-7841	ADHD	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]|http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder[6]	
44-45	7841-7842	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
44-46	7843-7845	no	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
44-47	7846-7853	serious	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
44-48	7854-7861	medical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
44-49	7862-7872	conditions	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
44-50	7872-7873	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
44-51	7874-7877	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
44-52	7878-7880	no	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
44-53	7881-7886	night	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
44-54	7887-7892	shift	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
44-55	7893-7897	work	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
44-56	7897-7898	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	

#Text=Participants were excluded if they reported smoking more than five cigarettes per day or daily use of any medications other than birth control, contraindication for fMRI (e.g., metal in the body, claustrophobia), or left-handedness, or if they were pregnant, lactating, or planning to become pregnant in the next 3 months.
45-1	7899-7911	Participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
45-2	7912-7916	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
45-3	7917-7925	excluded	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
45-4	7926-7928	if	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
45-5	7929-7933	they	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
45-6	7934-7942	reported	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
45-7	7943-7950	smoking	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
45-8	7951-7955	more	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
45-9	7956-7960	than	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
45-10	7961-7965	five	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
45-11	7966-7976	cigarettes	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
45-12	7977-7980	per	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
45-13	7981-7984	day	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
45-14	7985-7987	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
45-15	7988-7993	daily	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
45-16	7994-7997	use	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
45-17	7998-8000	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
45-18	8001-8004	any	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
45-19	8005-8016	medications	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
45-20	8017-8022	other	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
45-21	8023-8027	than	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
45-22	8028-8033	birth	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
45-23	8034-8041	control	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
45-24	8041-8042	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
45-25	8043-8059	contraindication	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
45-26	8060-8063	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
45-27	8064-8068	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]|http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[8]	
45-28	8069-8070	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
45-29	8070-8073	e.g	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
45-30	8073-8074	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
45-31	8074-8075	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
45-32	8076-8081	metal	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
45-33	8082-8084	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
45-34	8085-8088	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
45-35	8089-8093	body	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
45-36	8093-8094	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
45-37	8095-8109	claustrophobia	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
45-38	8109-8110	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
45-39	8110-8111	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
45-40	8112-8114	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
45-41	8115-8130	left-handedness	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
45-42	8130-8131	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
45-43	8132-8134	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
45-44	8135-8137	if	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
45-45	8138-8142	they	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
45-46	8143-8147	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
45-47	8148-8156	pregnant	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
45-48	8156-8157	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
45-49	8158-8167	lactating	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
45-50	8167-8168	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
45-51	8169-8171	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
45-52	8172-8180	planning	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
45-53	8181-8183	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
45-54	8184-8190	become	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
45-55	8191-8199	pregnant	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
45-56	8200-8202	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
45-57	8203-8206	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
45-58	8207-8211	next	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
45-59	8212-8213	3	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
45-60	8214-8220	months	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
45-61	8220-8221	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	

#Text=Measures
#Text=Stop Signal Task
#Text=Participants performed the stop signal task during blood oxygen level dependent (BOLD) fMRI to assess brain activation during response inhibition.
46-1	8222-8230	Measures	_	
46-2	8231-8235	Stop	_	
46-3	8236-8242	Signal	_	
46-4	8243-8247	Task	_	
46-5	8248-8260	Participants	_	
46-6	8261-8270	performed	_	
46-7	8271-8274	the	_	
46-8	8275-8279	stop	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[9]	
46-9	8280-8286	signal	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[9]	
46-10	8287-8291	task	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[9]	
46-11	8292-8298	during	_	
46-12	8299-8304	blood	_	
46-13	8305-8311	oxygen	_	
46-14	8312-8317	level	_	
46-15	8318-8327	dependent	_	
46-16	8328-8329	(	_	
46-17	8329-8333	BOLD	_	
46-18	8333-8334	)	_	
46-19	8335-8339	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	
46-20	8340-8342	to	_	
46-21	8343-8349	assess	_	
46-22	8350-8355	brain	_	
46-23	8356-8366	activation	_	
46-24	8367-8373	during	_	
46-25	8374-8382	response	_	
46-26	8383-8393	inhibition	_	
46-27	8393-8394	.	_	

#Text=Participants were instructed to respond as quickly as possible to go signals (left- or right-pointing blue arrows), and to inhibit responses on trials in which a stop signal (up-pointing red arrow superimposed on the go arrow) occurred.
47-1	8395-8407	Participants	_	
47-2	8408-8412	were	_	
47-3	8413-8423	instructed	_	
47-4	8424-8426	to	_	
47-5	8427-8434	respond	_	
47-6	8435-8437	as	_	
47-7	8438-8445	quickly	_	
47-8	8446-8448	as	_	
47-9	8449-8457	possible	_	
47-10	8458-8460	to	_	
47-11	8461-8463	go	_	
47-12	8464-8471	signals	_	
47-13	8472-8473	(	_	
47-14	8473-8477	left	_	
47-15	8477-8478	-	_	
47-16	8479-8481	or	_	
47-17	8482-8496	right-pointing	_	
47-18	8497-8501	blue	_	
47-19	8502-8508	arrows	_	
47-20	8508-8509	)	_	
47-21	8509-8510	,	_	
47-22	8511-8514	and	_	
47-23	8515-8517	to	_	
47-24	8518-8525	inhibit	_	
47-25	8526-8535	responses	_	
47-26	8536-8538	on	_	
47-27	8539-8545	trials	_	
47-28	8546-8548	in	_	
47-29	8549-8554	which	_	
47-30	8555-8556	a	_	
47-31	8557-8561	stop	_	
47-32	8562-8568	signal	_	
47-33	8569-8570	(	_	
47-34	8570-8581	up-pointing	_	
47-35	8582-8585	red	_	
47-36	8586-8591	arrow	_	
47-37	8592-8604	superimposed	_	
47-38	8605-8607	on	_	
47-39	8608-8611	the	_	
47-40	8612-8614	go	_	
47-41	8615-8620	arrow	_	
47-42	8620-8621	)	_	
47-43	8622-8630	occurred	_	
47-44	8630-8631	.	_	

#Text=The duration of the delay between presentation of the go and stop signal (i.e., the stop signal delay) was adjusted to target a 50% successful inhibition rate.
48-1	8632-8635	The	_	
48-2	8636-8644	duration	_	
48-3	8645-8647	of	_	
48-4	8648-8651	the	_	
48-5	8652-8657	delay	_	
48-6	8658-8665	between	_	
48-7	8666-8678	presentation	_	
48-8	8679-8681	of	_	
48-9	8682-8685	the	_	
48-10	8686-8688	go	_	
48-11	8689-8692	and	_	
48-12	8693-8697	stop	_	
48-13	8698-8704	signal	_	
48-14	8705-8706	(	_	
48-15	8706-8709	i.e	_	
48-16	8709-8710	.	_	
48-17	8710-8711	,	_	
48-18	8712-8715	the	_	
48-19	8716-8720	stop	_	
48-20	8721-8727	signal	_	
48-21	8728-8733	delay	_	
48-22	8733-8734	)	_	
48-23	8735-8738	was	_	
48-24	8739-8747	adjusted	_	
48-25	8748-8750	to	_	
48-26	8751-8757	target	_	
48-27	8758-8759	a	_	
48-28	8760-8763	50%	_	
48-29	8764-8774	successful	_	
48-30	8775-8785	inhibition	_	
48-31	8786-8790	rate	_	
48-32	8790-8791	.	_	

#Text=Stop signal reaction time (SSRT) was calculated by subtracting the mean stop signal delay from the participant’s mean go reaction time.
49-1	8792-8796	Stop	_	
49-2	8797-8803	signal	_	
49-3	8804-8812	reaction	_	
49-4	8813-8817	time	_	
49-5	8818-8819	(	_	
49-6	8819-8823	SSRT	_	
49-7	8823-8824	)	_	
49-8	8825-8828	was	_	
49-9	8829-8839	calculated	_	
49-10	8840-8842	by	_	
49-11	8843-8854	subtracting	_	
49-12	8855-8858	the	_	
49-13	8859-8863	mean	_	
49-14	8864-8868	stop	_	
49-15	8869-8875	signal	_	
49-16	8876-8881	delay	_	
49-17	8882-8886	from	_	
49-18	8887-8890	the	_	
49-19	8891-8902	participant	_	
49-20	8902-8903	’	_	
49-21	8903-8904	s	_	
49-22	8905-8909	mean	_	
49-23	8910-8912	go	_	
49-24	8913-8921	reaction	_	
49-25	8922-8926	time	_	
49-26	8926-8927	.	_	

#Text=Longer SSRT indicates a longer time needed to inhibit a response, and thus poorer inhibitory control.
50-1	8928-8934	Longer	_	
50-2	8935-8939	SSRT	_	
50-3	8940-8949	indicates	_	
50-4	8950-8951	a	_	
50-5	8952-8958	longer	_	
50-6	8959-8963	time	_	
50-7	8964-8970	needed	_	
50-8	8971-8973	to	_	
50-9	8974-8981	inhibit	_	
50-10	8982-8983	a	_	
50-11	8984-8992	response	_	
50-12	8992-8993	,	_	
50-13	8994-8997	and	_	
50-14	8998-9002	thus	_	
50-15	9003-9009	poorer	_	
50-16	9010-9020	inhibitory	_	
50-17	9021-9028	control	_	
50-18	9028-9029	.	_	

#Text=Supplemental Figure S1 presents a schematic of the task and the main task parameters (go reaction time, stop signal delay, and SSRT).
51-1	9030-9042	Supplemental	_	
51-2	9043-9049	Figure	_	
51-3	9050-9052	S1	_	
51-4	9053-9061	presents	_	
51-5	9062-9063	a	_	
51-6	9064-9073	schematic	_	
51-7	9074-9076	of	_	
51-8	9077-9080	the	_	
51-9	9081-9085	task	_	
51-10	9086-9089	and	_	
51-11	9090-9093	the	_	
51-12	9094-9098	main	_	
51-13	9099-9103	task	_	
51-14	9104-9114	parameters	_	
51-15	9115-9116	(	_	
51-16	9116-9118	go	_	
51-17	9119-9127	reaction	_	
51-18	9128-9132	time	_	
51-19	9132-9133	,	_	
51-20	9134-9138	stop	_	
51-21	9139-9145	signal	_	
51-22	9146-9151	delay	_	
51-23	9151-9152	,	_	
51-24	9153-9156	and	_	
51-25	9157-9161	SSRT	_	
51-26	9161-9162	)	_	
51-27	9162-9163	.	_	

#Text=Behavioral task performance was considered valid if participants had a mean Go reaction time of 800ms or less, Go accuracy of at least 75%, and Stop accuracy between 25% and 75%.
52-1	9164-9174	Behavioral	_	
52-2	9175-9179	task	_	
52-3	9180-9191	performance	_	
52-4	9192-9195	was	_	
52-5	9196-9206	considered	_	
52-6	9207-9212	valid	_	
52-7	9213-9215	if	_	
52-8	9216-9228	participants	_	
52-9	9229-9232	had	_	
52-10	9233-9234	a	_	
52-11	9235-9239	mean	_	
52-12	9240-9242	Go	_	
52-13	9243-9251	reaction	_	
52-14	9252-9256	time	_	
52-15	9257-9259	of	_	
52-16	9260-9265	800ms	_	
52-17	9266-9268	or	_	
52-18	9269-9273	less	_	
52-19	9273-9274	,	_	
52-20	9275-9277	Go	_	
52-21	9278-9286	accuracy	_	
52-22	9287-9289	of	_	
52-23	9290-9292	at	_	
52-24	9293-9298	least	_	
52-25	9299-9302	75%	_	
52-26	9302-9303	,	_	
52-27	9304-9307	and	_	
52-28	9308-9312	Stop	_	
52-29	9313-9321	accuracy	_	
52-30	9322-9329	between	_	
52-31	9330-9333	25%	_	
52-32	9334-9337	and	_	
52-33	9338-9341	75%	_	
52-34	9341-9342	.	_	

#Text=Participants completed three task runs (80 go and 40 stop trials each), and each run required approximately 6 minutes to complete.
53-1	9343-9355	Participants	_	
53-2	9356-9365	completed	_	
53-3	9366-9371	three	_	
53-4	9372-9376	task	_	
53-5	9377-9381	runs	_	
53-6	9382-9383	(	_	
53-7	9383-9385	80	_	
53-8	9386-9388	go	_	
53-9	9389-9392	and	_	
53-10	9393-9395	40	_	
53-11	9396-9400	stop	_	
53-12	9401-9407	trials	_	
53-13	9408-9412	each	_	
53-14	9412-9413	)	_	
53-15	9413-9414	,	_	
53-16	9415-9418	and	_	
53-17	9419-9423	each	_	
53-18	9424-9427	run	_	
53-19	9428-9436	required	_	
53-20	9437-9450	approximately	_	
53-21	9451-9452	6	_	
53-22	9453-9460	minutes	_	
53-23	9461-9463	to	_	
53-24	9464-9472	complete	_	
53-25	9472-9473	.	_	

#Text=Doors Task
#Text=Participants completed the doors task during BOLD fMRI to assess brain activation during monetary reward and loss.
54-1	9474-9479	Doors	_	
54-2	9480-9484	Task	_	
54-3	9485-9497	Participants	_	
54-4	9498-9507	completed	_	
54-5	9508-9511	the	_	
54-6	9512-9517	doors	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[10]	
54-7	9518-9522	task	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[10]	
54-8	9523-9529	during	_	
54-9	9530-9534	BOLD	_	
54-10	9535-9539	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	
54-11	9540-9542	to	_	
54-12	9543-9549	assess	_	
54-13	9550-9555	brain	_	
54-14	9556-9566	activation	_	
54-15	9567-9573	during	_	
54-16	9574-9582	monetary	_	
54-17	9583-9589	reward	_	
54-18	9590-9593	and	_	
54-19	9594-9598	loss	_	
54-20	9598-9599	.	_	

#Text=Task procedures are described in detail in.
55-1	9600-9604	Task	_	
55-2	9605-9615	procedures	_	
55-3	9616-9619	are	_	
55-4	9620-9629	described	_	
55-5	9630-9632	in	_	
55-6	9633-9639	detail	_	
55-7	9640-9642	in	_	
55-8	9642-9643	.	_	

#Text=Briefly, two doors are presented on the screen, and participants are told that behind one of the doors is a monetary prize of $.50 (signaled by ‘↑’) and behind the other door is a loss of $.25 (signaled by ‘↓’).
56-1	9644-9651	Briefly	_	
56-2	9651-9652	,	_	
56-3	9653-9656	two	_	
56-4	9657-9662	doors	_	
56-5	9663-9666	are	_	
56-6	9667-9676	presented	_	
56-7	9677-9679	on	_	
56-8	9680-9683	the	_	
56-9	9684-9690	screen	_	
56-10	9690-9691	,	_	
56-11	9692-9695	and	_	
56-12	9696-9708	participants	_	
56-13	9709-9712	are	_	
56-14	9713-9717	told	_	
56-15	9718-9722	that	_	
56-16	9723-9729	behind	_	
56-17	9730-9733	one	_	
56-18	9734-9736	of	_	
56-19	9737-9740	the	_	
56-20	9741-9746	doors	_	
56-21	9747-9749	is	_	
56-22	9750-9751	a	_	
56-23	9752-9760	monetary	_	
56-24	9761-9766	prize	_	
56-25	9767-9769	of	_	
56-26	9770-9771	$	_	
56-27	9771-9774	.50	_	
56-28	9775-9776	(	_	
56-29	9776-9784	signaled	_	
56-30	9785-9787	by	_	
56-31	9788-9789	‘	_	
56-32	9789-9790	↑	_	
56-33	9790-9791	’	_	
56-34	9791-9792	)	_	
56-35	9793-9796	and	_	
56-36	9797-9803	behind	_	
56-37	9804-9807	the	_	
56-38	9808-9813	other	_	
56-39	9814-9818	door	_	
56-40	9819-9821	is	_	
56-41	9822-9823	a	_	
56-42	9824-9828	loss	_	
56-43	9829-9831	of	_	
56-44	9832-9833	$	_	
56-45	9833-9836	.25	_	
56-46	9837-9838	(	_	
56-47	9838-9846	signaled	_	
56-48	9847-9849	by	_	
56-49	9850-9851	‘	_	
56-50	9851-9852	↓	_	
56-51	9852-9853	’	_	
56-52	9853-9854	)	_	
56-53	9854-9855	.	_	

#Text=For each trial, participants are instructed to use a button box to choose one of the two doors.
57-1	9856-9859	For	_	
57-2	9860-9864	each	_	
57-3	9865-9870	trial	_	
57-4	9870-9871	,	_	
57-5	9872-9884	participants	_	
57-6	9885-9888	are	_	
57-7	9889-9899	instructed	_	
57-8	9900-9902	to	_	
57-9	9903-9906	use	_	
57-10	9907-9908	a	_	
57-11	9909-9915	button	_	
57-12	9916-9919	box	_	
57-13	9920-9922	to	_	
57-14	9923-9929	choose	_	
57-15	9930-9933	one	_	
57-16	9934-9936	of	_	
57-17	9937-9940	the	_	
57-18	9941-9944	two	_	
57-19	9945-9950	doors	_	
57-20	9950-9951	.	_	

#Text=They are told that they will either win or lose money based on their choices, and that they had a chance of winning between $0 and $15 total based on their performance.
58-1	9952-9956	They	_	
58-2	9957-9960	are	_	
58-3	9961-9965	told	_	
58-4	9966-9970	that	_	
58-5	9971-9975	they	_	
58-6	9976-9980	will	_	
58-7	9981-9987	either	_	
58-8	9988-9991	win	_	
58-9	9992-9994	or	_	
58-10	9995-9999	lose	_	
58-11	10000-10005	money	_	
58-12	10006-10011	based	_	
58-13	10012-10014	on	_	
58-14	10015-10020	their	_	
58-15	10021-10028	choices	_	
58-16	10028-10029	,	_	
58-17	10030-10033	and	_	
58-18	10034-10038	that	_	
58-19	10039-10043	they	_	
58-20	10044-10047	had	_	
58-21	10048-10049	a	_	
58-22	10050-10056	chance	_	
58-23	10057-10059	of	_	
58-24	10060-10067	winning	_	
58-25	10068-10075	between	_	
58-26	10076-10078	$0	_	
58-27	10079-10082	and	_	
58-28	10083-10086	$15	_	
58-29	10087-10092	total	_	
58-30	10093-10098	based	_	
58-31	10099-10101	on	_	
58-32	10102-10107	their	_	
58-33	10108-10119	performance	_	
58-34	10119-10120	.	_	

#Text=In actuality, the subjects’ performance had no impact on outcomes.
59-1	10121-10123	In	_	
59-2	10124-10133	actuality	_	
59-3	10133-10134	,	_	
59-4	10135-10138	the	_	
59-5	10139-10147	subjects	_	
59-6	10147-10148	’	_	
59-7	10149-10160	performance	_	
59-8	10161-10164	had	_	
59-9	10165-10167	no	_	
59-10	10168-10174	impact	_	
59-11	10175-10177	on	_	
59-12	10178-10186	outcomes	_	
59-13	10186-10187	.	_	

#Text=The task consisted of 30 predetermined Wins and 30 Losses presented in a pseudorandom order over two runs.
60-1	10188-10191	The	_	
60-2	10192-10196	task	_	
60-3	10197-10206	consisted	_	
60-4	10207-10209	of	_	
60-5	10210-10212	30	_	
60-6	10213-10226	predetermined	_	
60-7	10227-10231	Wins	_	
60-8	10232-10235	and	_	
60-9	10236-10238	30	_	
60-10	10239-10245	Losses	_	
60-11	10246-10255	presented	_	
60-12	10256-10258	in	_	
60-13	10259-10260	a	_	
60-14	10261-10273	pseudorandom	_	
60-15	10274-10279	order	_	
60-16	10280-10284	over	_	
60-17	10285-10288	two	_	
60-18	10289-10293	runs	_	
60-19	10293-10294	.	_	

#Text=The task required 15 minutes to complete, and all subjects earned $10.
61-1	10295-10298	The	_	
61-2	10299-10303	task	_	
61-3	10304-10312	required	_	
61-4	10313-10315	15	_	
61-5	10316-10323	minutes	_	
61-6	10324-10326	to	_	
61-7	10327-10335	complete	_	
61-8	10335-10336	,	_	
61-9	10337-10340	and	_	
61-10	10341-10344	all	_	
61-11	10345-10353	subjects	_	
61-12	10354-10360	earned	_	
61-13	10361-10364	$10	_	
61-14	10364-10365	.	_	

#Text=Timeline Follow-Back (TLFB)
#Text=Participants completed a retrospective timeline calendar of their alcohol consumption for the past month to assess daily patterns of drinking, including number of binge episodes.
62-1	10366-10374	Timeline	_	
62-2	10375-10386	Follow-Back	_	
62-3	10387-10388	(	_	
62-4	10388-10392	TLFB	_	
62-5	10392-10393	)	_	
62-6	10394-10406	Participants	_	
62-7	10407-10416	completed	_	
62-8	10417-10418	a	_	
62-9	10419-10432	retrospective	_	
62-10	10433-10441	timeline	_	
62-11	10442-10450	calendar	_	
62-12	10451-10453	of	_	
62-13	10454-10459	their	_	
62-14	10460-10467	alcohol	_	
62-15	10468-10479	consumption	_	
62-16	10480-10483	for	_	
62-17	10484-10487	the	_	
62-18	10488-10492	past	_	
62-19	10493-10498	month	_	
62-20	10499-10501	to	_	
62-21	10502-10508	assess	_	
62-22	10509-10514	daily	_	
62-23	10515-10523	patterns	_	
62-24	10524-10526	of	_	
62-25	10527-10535	drinking	_	
62-26	10535-10536	,	_	
62-27	10537-10546	including	_	
62-28	10547-10553	number	_	
62-29	10554-10556	of	_	
62-30	10557-10562	binge	_	
62-31	10563-10571	episodes	_	
62-32	10571-10572	.	_	

#Text=For each day, participants estimated the number of standard drinks they consumed, and days on which they consumed 5 (men) or 4 (women) or more drinks were considered binge episodes.
63-1	10573-10576	For	_	
63-2	10577-10581	each	_	
63-3	10582-10585	day	_	
63-4	10585-10586	,	_	
63-5	10587-10599	participants	_	
63-6	10600-10609	estimated	_	
63-7	10610-10613	the	_	
63-8	10614-10620	number	_	
63-9	10621-10623	of	_	
63-10	10624-10632	standard	_	
63-11	10633-10639	drinks	_	
63-12	10640-10644	they	_	
63-13	10645-10653	consumed	_	
63-14	10653-10654	,	_	
63-15	10655-10658	and	_	
63-16	10659-10663	days	_	
63-17	10664-10666	on	_	
63-18	10667-10672	which	_	
63-19	10673-10677	they	_	
63-20	10678-10686	consumed	_	
63-21	10687-10688	5	_	
63-22	10689-10690	(	_	
63-23	10690-10693	men	_	
63-24	10693-10694	)	_	
63-25	10695-10697	or	_	
63-26	10698-10699	4	_	
63-27	10700-10701	(	_	
63-28	10701-10706	women	_	
63-29	10706-10707	)	_	
63-30	10708-10710	or	_	
63-31	10711-10715	more	_	
63-32	10716-10722	drinks	_	
63-33	10723-10727	were	_	
63-34	10728-10738	considered	_	
63-35	10739-10744	binge	_	
63-36	10745-10753	episodes	_	
63-37	10753-10754	.	_	

#Text=From the TLFB we calculated subjects’ total number of binge-drinking days and average number of drinks per week over the past month.
64-1	10755-10759	From	_	
64-2	10760-10763	the	_	
64-3	10764-10768	TLFB	_	
64-4	10769-10771	we	_	
64-5	10772-10782	calculated	_	
64-6	10783-10791	subjects	_	
64-7	10791-10792	’	_	
64-8	10793-10798	total	_	
64-9	10799-10805	number	_	
64-10	10806-10808	of	_	
64-11	10809-10823	binge-drinking	_	
64-12	10824-10828	days	_	
64-13	10829-10832	and	_	
64-14	10833-10840	average	_	
64-15	10841-10847	number	_	
64-16	10848-10850	of	_	
64-17	10851-10857	drinks	_	
64-18	10858-10861	per	_	
64-19	10862-10866	week	_	
64-20	10867-10871	over	_	
64-21	10872-10875	the	_	
64-22	10876-10880	past	_	
64-23	10881-10886	month	_	
64-24	10886-10887	.	_	

#Text=Procedure
#Text=Participants were screened in the Human Behavioral Pharmacology Laboratory at the University of Chicago and provided informed consent.
65-1	10888-10897	Procedure	_	
65-2	10898-10910	Participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
65-3	10911-10915	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
65-4	10916-10924	screened	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
65-5	10925-10927	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
65-6	10928-10931	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
65-7	10932-10937	Human	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
65-8	10938-10948	Behavioral	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
65-9	10949-10961	Pharmacology	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
65-10	10962-10972	Laboratory	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
65-11	10973-10975	at	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
65-12	10976-10979	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
65-13	10980-10990	University	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
65-14	10991-10993	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
65-15	10994-11001	Chicago	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
65-16	11002-11005	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
65-17	11006-11014	provided	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
65-18	11015-11023	informed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
65-19	11024-11031	consent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
65-20	11031-11032	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	

#Text=As a separate part of the parent study, they completed four drug-challenge sessions in which they received amphetamine or placebo (presented elsewhere:).
66-1	11033-11035	As	_	
66-2	11036-11037	a	_	
66-3	11038-11046	separate	_	
66-4	11047-11051	part	_	
66-5	11052-11054	of	_	
66-6	11055-11058	the	_	
66-7	11059-11065	parent	_	
66-8	11066-11071	study	_	
66-9	11071-11072	,	_	
66-10	11073-11077	they	_	
66-11	11078-11087	completed	_	
66-12	11088-11092	four	_	
66-13	11093-11107	drug-challenge	_	
66-14	11108-11116	sessions	_	
66-15	11117-11119	in	_	
66-16	11120-11125	which	_	
66-17	11126-11130	they	_	
66-18	11131-11139	received	_	
66-19	11140-11151	amphetamine	_	
66-20	11152-11154	or	_	
66-21	11155-11162	placebo	_	
66-22	11163-11164	(	_	
66-23	11164-11173	presented	_	
66-24	11174-11183	elsewhere	_	
66-25	11183-11184	:	_	
66-26	11184-11185	)	_	
66-27	11185-11186	.	_	

#Text=Subjects then completed an fMRI session at the University of Illinois at Chicago.
67-1	11187-11195	Subjects	_	
67-2	11196-11200	then	_	
67-3	11201-11210	completed	_	
67-4	11211-11213	an	_	
67-5	11214-11218	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	
67-6	11219-11226	session	_	
67-7	11227-11229	at	_	
67-8	11230-11233	the	_	
67-9	11234-11244	University	_	
67-10	11245-11247	of	_	
67-11	11248-11256	Illinois	_	
67-12	11257-11259	at	_	
67-13	11260-11267	Chicago	_	
67-14	11267-11268	.	_	

#Text=They abstained from drugs, including alcohol, for 24h prior to the fMRI session, as verified by self-report, breath alcohol, and urine screens.
68-1	11269-11273	They	_	
68-2	11274-11283	abstained	_	
68-3	11284-11288	from	_	
68-4	11289-11294	drugs	_	
68-5	11294-11295	,	_	
68-6	11296-11305	including	_	
68-7	11306-11313	alcohol	_	
68-8	11313-11314	,	_	
68-9	11315-11318	for	_	
68-10	11319-11322	24h	_	
68-11	11323-11328	prior	_	
68-12	11329-11331	to	_	
68-13	11332-11335	the	_	
68-14	11336-11340	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	
68-15	11341-11348	session	_	
68-16	11348-11349	,	_	
68-17	11350-11352	as	_	
68-18	11353-11361	verified	_	
68-19	11362-11364	by	_	
68-20	11365-11376	self-report	_	
68-21	11376-11377	,	_	
68-22	11378-11384	breath	_	
68-23	11385-11392	alcohol	_	
68-24	11392-11393	,	_	
68-25	11394-11397	and	_	
68-26	11398-11403	urine	_	
68-27	11404-11411	screens	_	
68-28	11411-11412	.	_	

#Text=Upon arrival at the laboratory, they completed a scanner safety questionnaire and a practice round of the stop signal task.
69-1	11413-11417	Upon	_	
69-2	11418-11425	arrival	_	
69-3	11426-11428	at	_	
69-4	11429-11432	the	_	
69-5	11433-11443	laboratory	_	
69-6	11443-11444	,	_	
69-7	11445-11449	they	_	
69-8	11450-11459	completed	_	
69-9	11460-11461	a	_	
69-10	11462-11469	scanner	_	
69-11	11470-11476	safety	_	
69-12	11477-11490	questionnaire	_	
69-13	11491-11494	and	_	
69-14	11495-11496	a	_	
69-15	11497-11505	practice	_	
69-16	11506-11511	round	_	
69-17	11512-11514	of	_	
69-18	11515-11518	the	_	
69-19	11519-11523	stop	_	
69-20	11524-11530	signal	_	
69-21	11531-11535	task	_	
69-22	11535-11536	.	_	

#Text=They were then placed in the scanner, where they completed a battery of tasks, including the stop signal and doors tasks.
70-1	11537-11541	They	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[12]	
70-2	11542-11546	were	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[12]	
70-3	11547-11551	then	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[12]	
70-4	11552-11558	placed	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[12]	
70-5	11559-11561	in	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[12]	
70-6	11562-11565	the	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[12]	
70-7	11566-11573	scanner	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[12]	
70-8	11573-11574	,	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[12]	
70-9	11575-11580	where	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[12]	
70-10	11581-11585	they	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[12]	
70-11	11586-11595	completed	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[12]	
70-12	11596-11597	a	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[12]	
70-13	11598-11605	battery	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[12]	
70-14	11606-11608	of	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[12]	
70-15	11609-11614	tasks	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[12]	
70-16	11614-11615	,	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[12]	
70-17	11616-11625	including	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[12]	
70-18	11626-11629	the	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[12]	
70-19	11630-11634	stop	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[12]	
70-20	11635-11641	signal	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[12]	
70-21	11642-11645	and	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[12]	
70-22	11646-11651	doors	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[12]	
70-23	11652-11657	tasks	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[12]	
70-24	11657-11658	.	_	

#Text=All participants completed the stop signal task prior to the doors task.
71-1	11659-11662	All	_	
71-2	11663-11675	participants	_	
71-3	11676-11685	completed	_	
71-4	11686-11689	the	_	
71-5	11690-11694	stop	_	
71-6	11695-11701	signal	_	
71-7	11702-11706	task	_	
71-8	11707-11712	prior	_	
71-9	11713-11715	to	_	
71-10	11716-11719	the	_	
71-11	11720-11725	doors	_	
71-12	11726-11730	task	_	
71-13	11730-11731	.	_	

#Text=Upon completion of all sessions, participants were debriefed and paid for their time.
72-1	11732-11736	Upon	_	
72-2	11737-11747	completion	_	
72-3	11748-11750	of	_	
72-4	11751-11754	all	_	
72-5	11755-11763	sessions	_	
72-6	11763-11764	,	_	
72-7	11765-11777	participants	_	
72-8	11778-11782	were	_	
72-9	11783-11792	debriefed	_	
72-10	11793-11796	and	_	
72-11	11797-11801	paid	_	
72-12	11802-11805	for	_	
72-13	11806-11811	their	_	
72-14	11812-11816	time	_	
72-15	11816-11817	.	_	

#Text=The study was approved by the IRB at each institution.
73-1	11818-11821	The	_	
73-2	11822-11827	study	_	
73-3	11828-11831	was	_	
73-4	11832-11840	approved	_	
73-5	11841-11843	by	_	
73-6	11844-11847	the	_	
73-7	11848-11851	IRB	_	
73-8	11852-11854	at	_	
73-9	11855-11859	each	_	
73-10	11860-11871	institution	_	
73-11	11871-11872	.	_	

#Text=Imaging acquisition and processing
#Text=Participants were imaged using a 3T GE scanner with an 8-channel head coil array at the UIC Center for Magnetic Resonance Research.
74-1	11873-11880	Imaging	_	
74-2	11881-11892	acquisition	_	
74-3	11893-11896	and	_	
74-4	11897-11907	processing	_	
74-5	11908-11920	Participants	_	
74-6	11921-11925	were	_	
74-7	11926-11932	imaged	_	
74-8	11933-11938	using	_	
74-9	11939-11940	a	_	
74-10	11941-11943	3T	_	
74-11	11944-11946	GE	_	
74-12	11947-11954	scanner	_	
74-13	11955-11959	with	_	
74-14	11960-11962	an	_	
74-15	11963-11964	8	_	
74-16	11964-11965	-	_	
74-17	11965-11972	channel	_	
74-18	11973-11977	head	_	
74-19	11978-11982	coil	_	
74-20	11983-11988	array	_	
74-21	11989-11991	at	_	
74-22	11992-11995	the	_	
74-23	11996-11999	UIC	_	
74-24	12000-12006	Center	_	
74-25	12007-12010	for	_	
74-26	12011-12019	Magnetic	_	
74-27	12020-12029	Resonance	_	
74-28	12030-12038	Research	_	
74-29	12038-12039	.	_	

#Text=T1-weighted high-resolution anatomical images (BRAVO sequence with 1 × 1 × 1 mm3 voxels; repetition time, 9.3ms; echo time, 3.8ms; 220 × 220 mm field of view; flip angle, 13°) were acquired for co-registration and normalization to the MNI coordinate system.
75-1	12040-12042	T1	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[13]	
75-2	12042-12043	-	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[13]	
75-3	12043-12051	weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[13]	
75-4	12052-12067	high-resolution	_	
75-5	12068-12078	anatomical	_	
75-6	12079-12085	images	_	
75-7	12086-12087	(	_	
75-8	12087-12092	BRAVO	_	
75-9	12093-12101	sequence	_	
75-10	12102-12106	with	_	
75-11	12107-12108	1	_	
75-12	12109-12110	×	_	
75-13	12111-12112	1	_	
75-14	12113-12114	×	_	
75-15	12115-12116	1	_	
75-16	12117-12120	mm3	_	
75-17	12121-12127	voxels	_	
75-18	12127-12128	;	_	
75-19	12129-12139	repetition	_	
75-20	12140-12144	time	_	
75-21	12144-12145	,	_	
75-22	12146-12151	9.3ms	_	
75-23	12151-12152	;	_	
75-24	12153-12157	echo	_	
75-25	12158-12162	time	_	
75-26	12162-12163	,	_	
75-27	12164-12169	3.8ms	_	
75-28	12169-12170	;	_	
75-29	12171-12174	220	_	
75-30	12175-12176	×	_	
75-31	12177-12180	220	_	
75-32	12181-12183	mm	_	
75-33	12184-12189	field	_	
75-34	12190-12192	of	_	
75-35	12193-12197	view	_	
75-36	12197-12198	;	_	
75-37	12199-12203	flip	_	
75-38	12204-12209	angle	_	
75-39	12209-12210	,	_	
75-40	12211-12213	13	_	
75-41	12213-12214	°	_	
75-42	12214-12215	)	_	
75-43	12216-12220	were	_	
75-44	12221-12229	acquired	_	
75-45	12230-12233	for	_	
75-46	12234-12249	co-registration	_	
75-47	12250-12253	and	_	
75-48	12254-12267	normalization	_	
75-49	12268-12270	to	_	
75-50	12271-12274	the	_	
75-51	12275-12278	MNI	_	
75-52	12279-12289	coordinate	_	
75-53	12290-12296	system	_	
75-54	12296-12297	.	_	

#Text=Whole-brain functional imaging was performed with a standard T2*-sensitive echo planar imaging sequence (gradient-echo; repetition time, 2000ms; echo time, 22.2 ms; 64 × 64 matrix; 220 × 220 mm field of view; flip angle, 90°; 3 mm slice thickness with no gap, 44 axial slices).
76-1	12298-12309	Whole-brain	_	
76-2	12310-12320	functional	_	
76-3	12321-12328	imaging	_	
76-4	12329-12332	was	_	
76-5	12333-12342	performed	_	
76-6	12343-12347	with	_	
76-7	12348-12349	a	_	
76-8	12350-12358	standard	_	
76-9	12359-12361	T2	_	
76-10	12361-12362	*	_	
76-11	12362-12363	-	_	
76-12	12363-12372	sensitive	_	
76-13	12373-12377	echo	_	
76-14	12378-12384	planar	_	
76-15	12385-12392	imaging	_	
76-16	12393-12401	sequence	_	
76-17	12402-12403	(	_	
76-18	12403-12416	gradient-echo	_	
76-19	12416-12417	;	_	
76-20	12418-12428	repetition	_	
76-21	12429-12433	time	_	
76-22	12433-12434	,	_	
76-23	12435-12441	2000ms	_	
76-24	12441-12442	;	_	
76-25	12443-12447	echo	_	
76-26	12448-12452	time	_	
76-27	12452-12453	,	_	
76-28	12454-12458	22.2	_	
76-29	12459-12461	ms	_	
76-30	12461-12462	;	_	
76-31	12463-12465	64	_	
76-32	12466-12467	×	_	
76-33	12468-12470	64	_	
76-34	12471-12477	matrix	_	
76-35	12477-12478	;	_	
76-36	12479-12482	220	_	
76-37	12483-12484	×	_	
76-38	12485-12488	220	_	
76-39	12489-12491	mm	_	
76-40	12492-12497	field	_	
76-41	12498-12500	of	_	
76-42	12501-12505	view	_	
76-43	12505-12506	;	_	
76-44	12507-12511	flip	_	
76-45	12512-12517	angle	_	
76-46	12517-12518	,	_	
76-47	12519-12521	90	_	
76-48	12521-12522	°	_	
76-49	12522-12523	;	_	
76-50	12524-12525	3	_	
76-51	12526-12528	mm	_	
76-52	12529-12534	slice	_	
76-53	12535-12544	thickness	_	
76-54	12545-12549	with	_	
76-55	12550-12552	no	_	
76-56	12553-12556	gap	_	
76-57	12556-12557	,	_	
76-58	12558-12560	44	_	
76-59	12561-12566	axial	_	
76-60	12567-12573	slices	_	
76-61	12573-12574	)	_	
76-62	12574-12575	.	_	

#Text=Images were processed using SPM12 (Wellcome Trust Centre for Neuroimaging).
77-1	12576-12582	Images	_	
77-2	12583-12587	were	_	
77-3	12588-12597	processed	_	
77-4	12598-12603	using	_	
77-5	12604-12609	SPM12	_	
77-6	12610-12611	(	_	
77-7	12611-12619	Wellcome	_	
77-8	12620-12625	Trust	_	
77-9	12626-12632	Centre	_	
77-10	12633-12636	for	_	
77-11	12637-12649	Neuroimaging	_	
77-12	12649-12650	)	_	
77-13	12650-12651	.	_	

#Text=Standard preprocessing of functional images for both tasks included slice-time correction, spatial realignment to correct for head motion, coregistration to the participant’s T1 image and warping to MNI space, resampling to 2mm/side voxels and smoothing with an 8mm FWHM isotropic Gaussian kernel.
78-1	12652-12660	Standard	_	
78-2	12661-12674	preprocessing	_	
78-3	12675-12677	of	_	
78-4	12678-12688	functional	_	
78-5	12689-12695	images	_	
78-6	12696-12699	for	_	
78-7	12700-12704	both	_	
78-8	12705-12710	tasks	_	
78-9	12711-12719	included	_	
78-10	12720-12730	slice-time	_	
78-11	12731-12741	correction	_	
78-12	12741-12742	,	_	
78-13	12743-12750	spatial	_	
78-14	12751-12762	realignment	_	
78-15	12763-12765	to	_	
78-16	12766-12773	correct	_	
78-17	12774-12777	for	_	
78-18	12778-12782	head	_	
78-19	12783-12789	motion	_	
78-20	12789-12790	,	_	
78-21	12791-12805	coregistration	_	
78-22	12806-12808	to	_	
78-23	12809-12812	the	_	
78-24	12813-12824	participant	_	
78-25	12824-12825	’	_	
78-26	12825-12826	s	_	
78-27	12827-12829	T1	_	
78-28	12830-12835	image	_	
78-29	12836-12839	and	_	
78-30	12840-12847	warping	_	
78-31	12848-12850	to	_	
78-32	12851-12854	MNI	_	
78-33	12855-12860	space	_	
78-34	12860-12861	,	_	
78-35	12862-12872	resampling	_	
78-36	12873-12875	to	_	
78-37	12876-12879	2mm	_	
78-38	12879-12880	/	_	
78-39	12880-12884	side	_	
78-40	12885-12891	voxels	_	
78-41	12892-12895	and	_	
78-42	12896-12905	smoothing	_	
78-43	12906-12910	with	_	
78-44	12911-12913	an	_	
78-45	12914-12917	8mm	_	
78-46	12918-12922	FWHM	_	
78-47	12923-12932	isotropic	_	
78-48	12933-12941	Gaussian	_	
78-49	12942-12948	kernel	_	
78-50	12948-12949	.	_	

#Text=The general linear model was applied to the time series, convolved with the canonical hemodynamic response function and included a 128s high-pass filter.
79-1	12950-12953	The	_	
79-2	12954-12961	general	_	
79-3	12962-12968	linear	_	
79-4	12969-12974	model	_	
79-5	12975-12978	was	_	
79-6	12979-12986	applied	_	
79-7	12987-12989	to	_	
79-8	12990-12993	the	_	
79-9	12994-12998	time	_	
79-10	12999-13005	series	_	
79-11	13005-13006	,	_	
79-12	13007-13016	convolved	_	
79-13	13017-13021	with	_	
79-14	13022-13025	the	_	
79-15	13026-13035	canonical	_	
79-16	13036-13047	hemodynamic	_	
79-17	13048-13056	response	_	
79-18	13057-13065	function	_	
79-19	13066-13069	and	_	
79-20	13070-13078	included	_	
79-21	13079-13080	a	_	
79-22	13081-13085	128s	_	
79-23	13086-13095	high-pass	_	
79-24	13096-13102	filter	_	
79-25	13102-13103	.	_	

#Text=Condition effects were modeled with event-related regressors: correct go (Go) and stop (StopInh) trials, and incorrect go and stop trials for the stop signal task, and Win, Loss, and Fixation for the doors task.
80-1	13104-13113	Condition	_	
80-2	13114-13121	effects	_	
80-3	13122-13126	were	_	
80-4	13127-13134	modeled	_	
80-5	13135-13139	with	_	
80-6	13140-13153	event-related	_	
80-7	13154-13164	regressors	_	
80-8	13164-13165	:	_	
80-9	13166-13173	correct	_	
80-10	13174-13176	go	_	
80-11	13177-13178	(	_	
80-12	13178-13180	Go	_	
80-13	13180-13181	)	_	
80-14	13182-13185	and	_	
80-15	13186-13190	stop	_	
80-16	13191-13192	(	_	
80-17	13192-13199	StopInh	_	
80-18	13199-13200	)	_	
80-19	13201-13207	trials	_	
80-20	13207-13208	,	_	
80-21	13209-13212	and	_	
80-22	13213-13222	incorrect	_	
80-23	13223-13225	go	_	
80-24	13226-13229	and	_	
80-25	13230-13234	stop	_	
80-26	13235-13241	trials	_	
80-27	13242-13245	for	_	
80-28	13246-13249	the	_	
80-29	13250-13254	stop	_	
80-30	13255-13261	signal	_	
80-31	13262-13266	task	_	
80-32	13266-13267	,	_	
80-33	13268-13271	and	_	
80-34	13272-13275	Win	_	
80-35	13275-13276	,	_	
80-36	13277-13281	Loss	_	
80-37	13281-13282	,	_	
80-38	13283-13286	and	_	
80-39	13287-13295	Fixation	_	
80-40	13296-13299	for	_	
80-41	13300-13303	the	_	
80-42	13304-13309	doors	_	
80-43	13310-13314	task	_	
80-44	13314-13315	.	_	

#Text=Effects were estimated at each voxel, and for each subject.
81-1	13316-13323	Effects	_	
81-2	13324-13328	were	_	
81-3	13329-13338	estimated	_	
81-4	13339-13341	at	_	
81-5	13342-13346	each	_	
81-6	13347-13352	voxel	_	
81-7	13352-13353	,	_	
81-8	13354-13357	and	_	
81-9	13358-13361	for	_	
81-10	13362-13366	each	_	
81-11	13367-13374	subject	_	
81-12	13374-13375	.	_	

#Text=Individual contrast maps were created for each participant (StopInh>Go for the stop signal task, and Win>Loss for the doors task).
82-1	13376-13386	Individual	_	
82-2	13387-13395	contrast	_	
82-3	13396-13400	maps	_	
82-4	13401-13405	were	_	
82-5	13406-13413	created	_	
82-6	13414-13417	for	_	
82-7	13418-13422	each	_	
82-8	13423-13434	participant	_	
82-9	13435-13436	(	_	
82-10	13436-13443	StopInh	_	
82-11	13443-13444	>	_	
82-12	13444-13446	Go	_	
82-13	13447-13450	for	_	
82-14	13451-13454	the	_	
82-15	13455-13459	stop	_	
82-16	13460-13466	signal	_	
82-17	13467-13471	task	_	
82-18	13471-13472	,	_	
82-19	13473-13476	and	_	
82-20	13477-13480	Win	_	
82-21	13480-13481	>	_	
82-22	13481-13485	Loss	_	
82-23	13486-13489	for	_	
82-24	13490-13493	the	_	
82-25	13494-13499	doors	_	
82-26	13500-13504	task	_	
82-27	13504-13505	)	_	
82-28	13505-13506	.	_	

#Text=Volumes were identified as motion outliers based on image intensity difference (dvars) or framewise displacement (fd; >0.5mm) using FSL’s motion outlier tool.
83-1	13507-13514	Volumes	_	
83-2	13515-13519	were	_	
83-3	13520-13530	identified	_	
83-4	13531-13533	as	_	
83-5	13534-13540	motion	_	
83-6	13541-13549	outliers	_	
83-7	13550-13555	based	_	
83-8	13556-13558	on	_	
83-9	13559-13564	image	_	
83-10	13565-13574	intensity	_	
83-11	13575-13585	difference	_	
83-12	13586-13587	(	_	
83-13	13587-13592	dvars	_	
83-14	13592-13593	)	_	
83-15	13594-13596	or	_	
83-16	13597-13606	framewise	_	
83-17	13607-13619	displacement	_	
83-18	13620-13621	(	_	
83-19	13621-13623	fd	_	
83-20	13623-13624	;	_	
83-21	13625-13626	>	_	
83-22	13626-13631	0.5mm	_	
83-23	13631-13632	)	_	
83-24	13633-13638	using	_	
83-25	13639-13642	FSL	_	
83-26	13642-13643	’	_	
83-27	13643-13644	s	_	
83-28	13645-13651	motion	_	
83-29	13652-13659	outlier	_	
83-30	13660-13664	tool	_	
83-31	13664-13665	.	_	

#Text=Six head motion parameters from the SPM realignment and the FSL-tagged motion outlier files were included as regressors-of-no-interest.
84-1	13666-13669	Six	_	
84-2	13670-13674	head	_	
84-3	13675-13681	motion	_	
84-4	13682-13692	parameters	_	
84-5	13693-13697	from	_	
84-6	13698-13701	the	_	
84-7	13702-13705	SPM	_	
84-8	13706-13717	realignment	_	
84-9	13718-13721	and	_	
84-10	13722-13725	the	_	
84-11	13726-13736	FSL-tagged	_	
84-12	13737-13743	motion	_	
84-13	13744-13751	outlier	_	
84-14	13752-13757	files	_	
84-15	13758-13762	were	_	
84-16	13763-13771	included	_	
84-17	13772-13774	as	_	
84-18	13775-13800	regressors-of-no-interest	_	
84-19	13800-13801	.	_	

#Text=Data Analyses
#Text=Stop Signal Task
#Text=We conducted a second-level, random effects one sample t-test for StopInh>Go.
85-1	13802-13806	Data	_	
85-2	13807-13815	Analyses	_	
85-3	13816-13820	Stop	_	
85-4	13821-13827	Signal	_	
85-5	13828-13832	Task	_	
85-6	13833-13835	We	_	
85-7	13836-13845	conducted	_	
85-8	13846-13847	a	_	
85-9	13848-13860	second-level	_	
85-10	13860-13861	,	_	
85-11	13862-13868	random	_	
85-12	13869-13876	effects	_	
85-13	13877-13880	one	_	
85-14	13881-13887	sample	_	
85-15	13888-13894	t-test	_	
85-16	13895-13898	for	_	
85-17	13899-13906	StopInh	_	
85-18	13906-13907	>	_	
85-19	13907-13909	Go	_	
85-20	13909-13910	.	_	

#Text=As our hypotheses were specific to frontal regions, statistical inferences were made based on peak voxel significance within a frontal-insular-subcortical (FIS) mask previously used for analyses with this task.
86-1	13911-13913	As	_	
86-2	13914-13917	our	_	
86-3	13918-13928	hypotheses	_	
86-4	13929-13933	were	_	
86-5	13934-13942	specific	_	
86-6	13943-13945	to	_	
86-7	13946-13953	frontal	_	
86-8	13954-13961	regions	_	
86-9	13961-13962	,	_	
86-10	13963-13974	statistical	_	
86-11	13975-13985	inferences	_	
86-12	13986-13990	were	_	
86-13	13991-13995	made	_	
86-14	13996-14001	based	_	
86-15	14002-14004	on	_	
86-16	14005-14009	peak	_	
86-17	14010-14015	voxel	_	
86-18	14016-14028	significance	_	
86-19	14029-14035	within	_	
86-20	14036-14037	a	_	
86-21	14038-14065	frontal-insular-subcortical	_	
86-22	14066-14067	(	_	
86-23	14067-14070	FIS	_	
86-24	14070-14071	)	_	
86-25	14072-14076	mask	_	
86-26	14077-14087	previously	_	
86-27	14088-14092	used	_	
86-28	14093-14096	for	_	
86-29	14097-14105	analyses	_	
86-30	14106-14110	with	_	
86-31	14111-14115	this	_	
86-32	14116-14120	task	_	
86-33	14120-14121	.	_	

#Text=This 382,584 mm3 (47,823 voxels) mask included the following structural regions from AAL library available in MarsBar: medial and lateral frontal and orbital regions, bilateral precentral gyri, anterior and middle cingulate cortex, anterior insula, and subcortical motor regions consisting of bilateral putamen, pallidum, and caudate.
87-1	14122-14126	This	_	
87-2	14127-14134	382,584	_	
87-3	14135-14138	mm3	_	
87-4	14139-14140	(	_	
87-5	14140-14146	47,823	_	
87-6	14147-14153	voxels	_	
87-7	14153-14154	)	_	
87-8	14155-14159	mask	_	
87-9	14160-14168	included	_	
87-10	14169-14172	the	_	
87-11	14173-14182	following	_	
87-12	14183-14193	structural	_	
87-13	14194-14201	regions	_	
87-14	14202-14206	from	_	
87-15	14207-14210	AAL	_	
87-16	14211-14218	library	_	
87-17	14219-14228	available	_	
87-18	14229-14231	in	_	
87-19	14232-14239	MarsBar	_	
87-20	14239-14240	:	_	
87-21	14241-14247	medial	_	
87-22	14248-14251	and	_	
87-23	14252-14259	lateral	_	
87-24	14260-14267	frontal	_	
87-25	14268-14271	and	_	
87-26	14272-14279	orbital	_	
87-27	14280-14287	regions	_	
87-28	14287-14288	,	_	
87-29	14289-14298	bilateral	_	
87-30	14299-14309	precentral	_	
87-31	14310-14314	gyri	_	
87-32	14314-14315	,	_	
87-33	14316-14324	anterior	_	
87-34	14325-14328	and	_	
87-35	14329-14335	middle	_	
87-36	14336-14345	cingulate	_	
87-37	14346-14352	cortex	_	
87-38	14352-14353	,	_	
87-39	14354-14362	anterior	_	
87-40	14363-14369	insula	_	
87-41	14369-14370	,	_	
87-42	14371-14374	and	_	
87-43	14375-14386	subcortical	_	
87-44	14387-14392	motor	_	
87-45	14393-14400	regions	_	
87-46	14401-14411	consisting	_	
87-47	14412-14414	of	_	
87-48	14415-14424	bilateral	_	
87-49	14425-14432	putamen	_	
87-50	14432-14433	,	_	
87-51	14434-14442	pallidum	_	
87-52	14442-14443	,	_	
87-53	14444-14447	and	_	
87-54	14448-14455	caudate	_	
87-55	14455-14456	.	_	

#Text=Peak voxel activation (pFWE < 0.05) within the FIS mask was used as the statistical threshold.
88-1	14457-14461	Peak	_	
88-2	14462-14467	voxel	_	
88-3	14468-14478	activation	_	
88-4	14479-14480	(	_	
88-5	14480-14484	pFWE	_	
88-6	14485-14486	<	_	
88-7	14487-14491	0.05	_	
88-8	14491-14492	)	_	
88-9	14493-14499	within	_	
88-10	14500-14503	the	_	
88-11	14504-14507	FIS	_	
88-12	14508-14512	mask	_	
88-13	14513-14516	was	_	
88-14	14517-14521	used	_	
88-15	14522-14524	as	_	
88-16	14525-14528	the	_	
88-17	14529-14540	statistical	_	
88-18	14541-14550	threshold	_	
88-19	14550-14551	.	_	

#Text=Doors Task
#Text=We conducted a second-level, random effects one sample t-test for Win>Loss.
89-1	14552-14557	Doors	_	
89-2	14558-14562	Task	_	
89-3	14563-14565	We	_	
89-4	14566-14575	conducted	_	
89-5	14576-14577	a	_	
89-6	14578-14590	second-level	_	
89-7	14590-14591	,	_	
89-8	14592-14598	random	_	
89-9	14599-14606	effects	_	
89-10	14607-14610	one	_	
89-11	14611-14617	sample	_	
89-12	14618-14624	t-test	_	
89-13	14625-14628	for	_	
89-14	14629-14632	Win	_	
89-15	14632-14633	>	_	
89-16	14633-14637	Loss	_	
89-17	14637-14638	.	_	

#Text=The doors task does not include a Neutral condition, and so we were not able to compare Win to Neutral.
90-1	14639-14642	The	_	
90-2	14643-14648	doors	_	
90-3	14649-14653	task	_	
90-4	14654-14658	does	_	
90-5	14659-14662	not	_	
90-6	14663-14670	include	_	
90-7	14671-14672	a	_	
90-8	14673-14680	Neutral	_	
90-9	14681-14690	condition	_	
90-10	14690-14691	,	_	
90-11	14692-14695	and	_	
90-12	14696-14698	so	_	
90-13	14699-14701	we	_	
90-14	14702-14706	were	_	
90-15	14707-14710	not	_	
90-16	14711-14715	able	_	
90-17	14716-14718	to	_	
90-18	14719-14726	compare	_	
90-19	14727-14730	Win	_	
90-20	14731-14733	to	_	
90-21	14734-14741	Neutral	_	
90-22	14741-14742	.	_	

#Text=It is important to note, however, that the Win>Loss contrast is a more sensitive indicator of neural activation during reward processing than examining Win or Loss individually.
91-1	14743-14745	It	_	
91-2	14746-14748	is	_	
91-3	14749-14758	important	_	
91-4	14759-14761	to	_	
91-5	14762-14766	note	_	
91-6	14766-14767	,	_	
91-7	14768-14775	however	_	
91-8	14775-14776	,	_	
91-9	14777-14781	that	_	
91-10	14782-14785	the	_	
91-11	14786-14789	Win	_	
91-12	14789-14790	>	_	
91-13	14790-14794	Loss	_	
91-14	14795-14803	contrast	_	
91-15	14804-14806	is	_	
91-16	14807-14808	a	_	
91-17	14809-14813	more	_	
91-18	14814-14823	sensitive	_	
91-19	14824-14833	indicator	_	
91-20	14834-14836	of	_	
91-21	14837-14843	neural	_	
91-22	14844-14854	activation	_	
91-23	14855-14861	during	_	
91-24	14862-14868	reward	_	
91-25	14869-14879	processing	_	
91-26	14880-14884	than	_	
91-27	14885-14894	examining	_	
91-28	14895-14898	Win	_	
91-29	14899-14901	or	_	
91-30	14902-14906	Loss	_	
91-31	14907-14919	individually	_	
91-32	14919-14920	.	_	

#Text=As our hypotheses were specific to regions implicated in reward, statistical inferences were made based on peak voxel significance within a functional reward mask downloaded from Neurosynth.
92-1	14921-14923	As	_	
92-2	14924-14927	our	_	
92-3	14928-14938	hypotheses	_	
92-4	14939-14943	were	_	
92-5	14944-14952	specific	_	
92-6	14953-14955	to	_	
92-7	14956-14963	regions	_	
92-8	14964-14974	implicated	_	
92-9	14975-14977	in	_	
92-10	14978-14984	reward	_	
92-11	14984-14985	,	_	
92-12	14986-14997	statistical	_	
92-13	14998-15008	inferences	_	
92-14	15009-15013	were	_	
92-15	15014-15018	made	_	
92-16	15019-15024	based	_	
92-17	15025-15027	on	_	
92-18	15028-15032	peak	_	
92-19	15033-15038	voxel	_	
92-20	15039-15051	significance	_	
92-21	15052-15058	within	_	
92-22	15059-15060	a	_	
92-23	15061-15071	functional	_	
92-24	15072-15078	reward	_	
92-25	15079-15083	mask	_	
92-26	15084-15094	downloaded	_	
92-27	15095-15099	from	_	
92-28	15100-15110	Neurosynth	_	
92-29	15110-15111	.	_	

#Text=The mask was based on a meta-analysis of 532 studies with 100 terms relating to ‘reward’ and displaying regions that are reported more often in studies that load highly on ‘reward’ (http://neurosynth.org/analyses/topics/v4-topics-100/99).
93-1	15112-15115	The	_	
93-2	15116-15120	mask	_	
93-3	15121-15124	was	_	
93-4	15125-15130	based	_	
93-5	15131-15133	on	_	
93-6	15134-15135	a	_	
93-7	15136-15149	meta-analysis	_	
93-8	15150-15152	of	_	
93-9	15153-15156	532	_	
93-10	15157-15164	studies	_	
93-11	15165-15169	with	_	
93-12	15170-15173	100	_	
93-13	15174-15179	terms	_	
93-14	15180-15188	relating	_	
93-15	15189-15191	to	_	
93-16	15192-15193	‘	_	
93-17	15193-15199	reward	_	
93-18	15199-15200	’	_	
93-19	15201-15204	and	_	
93-20	15205-15215	displaying	_	
93-21	15216-15223	regions	_	
93-22	15224-15228	that	_	
93-23	15229-15232	are	_	
93-24	15233-15241	reported	_	
93-25	15242-15246	more	_	
93-26	15247-15252	often	_	
93-27	15253-15255	in	_	
93-28	15256-15263	studies	_	
93-29	15264-15268	that	_	
93-30	15269-15273	load	_	
93-31	15274-15280	highly	_	
93-32	15281-15283	on	_	
93-33	15284-15285	‘	_	
93-34	15285-15291	reward	_	
93-35	15291-15292	’	_	
93-36	15293-15294	(	_	
93-37	15294-15298	http	_	
93-38	15298-15299	:	_	
93-39	15299-15300	/	_	
93-40	15300-15301	/	_	
93-41	15301-15315	neurosynth.org	_	
93-42	15315-15316	/	_	
93-43	15316-15324	analyses	_	
93-44	15324-15325	/	_	
93-45	15325-15331	topics	_	
93-46	15331-15332	/	_	
93-47	15332-15334	v4	_	
93-48	15334-15335	-	_	
93-49	15335-15341	topics	_	
93-50	15341-15342	-	_	
93-51	15342-15345	100	_	
93-52	15345-15346	/	_	
93-53	15346-15348	99	_	
93-54	15348-15349	)	_	
93-55	15349-15350	.	_	

#Text=Peak voxel activation (pFWE < 0.05) within the reward mask was used as the statistical threshold.
94-1	15351-15355	Peak	_	
94-2	15356-15361	voxel	_	
94-3	15362-15372	activation	_	
94-4	15373-15374	(	_	
94-5	15374-15378	pFWE	_	
94-6	15379-15380	<	_	
94-7	15381-15385	0.05	_	
94-8	15385-15386	)	_	
94-9	15387-15393	within	_	
94-10	15394-15397	the	_	
94-11	15398-15404	reward	_	
94-12	15405-15409	mask	_	
94-13	15410-15413	was	_	
94-14	15414-15418	used	_	
94-15	15419-15421	as	_	
94-16	15422-15425	the	_	
94-17	15426-15437	statistical	_	
94-18	15438-15447	threshold	_	
94-19	15447-15448	.	_	

#Text=Associations between brain activation during inhibition and monetary reward
#Text=We extracted parameter estimates/β-weights representing BOLD response activation in arbitrary units averaged across all voxels within a 10-mm radius sphere surrounding peak areas of activation (pFWE < 0.05) for both tasks.
95-1	15449-15461	Associations	_	
95-2	15462-15469	between	_	
95-3	15470-15475	brain	_	
95-4	15476-15486	activation	_	
95-5	15487-15493	during	_	
95-6	15494-15504	inhibition	_	
95-7	15505-15508	and	_	
95-8	15509-15517	monetary	_	
95-9	15518-15524	reward	_	
95-10	15525-15527	We	_	
95-11	15528-15537	extracted	_	
95-12	15538-15547	parameter	_	
95-13	15548-15557	estimates	_	
95-14	15557-15558	/	_	
95-15	15558-15567	β-weights	_	
95-16	15568-15580	representing	_	
95-17	15581-15585	BOLD	_	
95-18	15586-15594	response	_	
95-19	15595-15605	activation	_	
95-20	15606-15608	in	_	
95-21	15609-15618	arbitrary	_	
95-22	15619-15624	units	_	
95-23	15625-15633	averaged	_	
95-24	15634-15640	across	_	
95-25	15641-15644	all	_	
95-26	15645-15651	voxels	_	
95-27	15652-15658	within	_	
95-28	15659-15660	a	_	
95-29	15661-15663	10	_	
95-30	15663-15664	-	_	
95-31	15664-15666	mm	_	
95-32	15667-15673	radius	_	
95-33	15674-15680	sphere	_	
95-34	15681-15692	surrounding	_	
95-35	15693-15697	peak	_	
95-36	15698-15703	areas	_	
95-37	15704-15706	of	_	
95-38	15707-15717	activation	_	
95-39	15718-15719	(	_	
95-40	15719-15723	pFWE	_	
95-41	15724-15725	<	_	
95-42	15726-15730	0.05	_	
95-43	15730-15731	)	_	
95-44	15732-15735	for	_	
95-45	15736-15740	both	_	
95-46	15741-15746	tasks	_	
95-47	15746-15747	.	_	

#Text=For the stop signal task, we focused our analyses on significant peaks within well-established inhibitory control regions, including right IFG, MFG, insula, and SMA.
96-1	15748-15751	For	_	
96-2	15752-15755	the	_	
96-3	15756-15760	stop	_	
96-4	15761-15767	signal	_	
96-5	15768-15772	task	_	
96-6	15772-15773	,	_	
96-7	15774-15776	we	_	
96-8	15777-15784	focused	_	
96-9	15785-15788	our	_	
96-10	15789-15797	analyses	_	
96-11	15798-15800	on	_	
96-12	15801-15812	significant	_	
96-13	15813-15818	peaks	_	
96-14	15819-15825	within	_	
96-15	15826-15842	well-established	_	
96-16	15843-15853	inhibitory	_	
96-17	15854-15861	control	_	
96-18	15862-15869	regions	_	
96-19	15869-15870	,	_	
96-20	15871-15880	including	_	
96-21	15881-15886	right	_	
96-22	15887-15890	IFG	_	
96-23	15890-15891	,	_	
96-24	15892-15895	MFG	_	
96-25	15895-15896	,	_	
96-26	15897-15903	insula	_	
96-27	15903-15904	,	_	
96-28	15905-15908	and	_	
96-29	15909-15912	SMA	_	
96-30	15912-15913	.	_	

#Text=For the doors task, we focused our analyses on significant peaks within VS, given this region’s well-established role in reward (see Supplementary Table 3 for correlations among all significant regions of activation).
97-1	15914-15917	For	_	
97-2	15918-15921	the	_	
97-3	15922-15927	doors	_	
97-4	15928-15932	task	_	
97-5	15932-15933	,	_	
97-6	15934-15936	we	_	
97-7	15937-15944	focused	_	
97-8	15945-15948	our	_	
97-9	15949-15957	analyses	_	
97-10	15958-15960	on	_	
97-11	15961-15972	significant	_	
97-12	15973-15978	peaks	_	
97-13	15979-15985	within	_	
97-14	15986-15988	VS	_	
97-15	15988-15989	,	_	
97-16	15990-15995	given	_	
97-17	15996-16000	this	_	
97-18	16001-16007	region	_	
97-19	16007-16008	’	_	
97-20	16008-16009	s	_	
97-21	16010-16026	well-established	_	
97-22	16027-16031	role	_	
97-23	16032-16034	in	_	
97-24	16035-16041	reward	_	
97-25	16042-16043	(	_	
97-26	16043-16046	see	_	
97-27	16047-16060	Supplementary	_	
97-28	16061-16066	Table	_	
97-29	16067-16068	3	_	
97-30	16069-16072	for	_	
97-31	16073-16085	correlations	_	
97-32	16086-16091	among	_	
97-33	16092-16095	all	_	
97-34	16096-16107	significant	_	
97-35	16108-16115	regions	_	
97-36	16116-16118	of	_	
97-37	16119-16129	activation	_	
97-38	16129-16130	)	_	
97-39	16130-16131	.	_	

#Text=We also extracted significant peaks in visual regions to serve as control regions.
98-1	16132-16134	We	_	
98-2	16135-16139	also	_	
98-3	16140-16149	extracted	_	
98-4	16150-16161	significant	_	
98-5	16162-16167	peaks	_	
98-6	16168-16170	in	_	
98-7	16171-16177	visual	_	
98-8	16178-16185	regions	_	
98-9	16186-16188	to	_	
98-10	16189-16194	serve	_	
98-11	16195-16197	as	_	
98-12	16198-16205	control	_	
98-13	16206-16213	regions	_	
98-14	16213-16214	.	_	

#Text=We first examined the activation distributions to identify any potential outliers, defined as >3 standard deviations above or below the mean.
99-1	16215-16217	We	_	
99-2	16218-16223	first	_	
99-3	16224-16232	examined	_	
99-4	16233-16236	the	_	
99-5	16237-16247	activation	_	
99-6	16248-16261	distributions	_	
99-7	16262-16264	to	_	
99-8	16265-16273	identify	_	
99-9	16274-16277	any	_	
99-10	16278-16287	potential	_	
99-11	16288-16296	outliers	_	
99-12	16296-16297	,	_	
99-13	16298-16305	defined	_	
99-14	16306-16308	as	_	
99-15	16309-16310	>	_	
99-16	16310-16311	3	_	
99-17	16312-16320	standard	_	
99-18	16321-16331	deviations	_	
99-19	16332-16337	above	_	
99-20	16338-16340	or	_	
99-21	16341-16346	below	_	
99-22	16347-16350	the	_	
99-23	16351-16355	mean	_	
99-24	16355-16356	.	_	

#Text=We then conducted bivariate correlational analyses to determine the degree to which BOLD activation in inhibitory regions during response inhibition was associated with BOLD activation in reward regions during monetary reward.
100-1	16357-16359	We	_	
100-2	16360-16364	then	_	
100-3	16365-16374	conducted	_	
100-4	16375-16384	bivariate	_	
100-5	16385-16398	correlational	_	
100-6	16399-16407	analyses	_	
100-7	16408-16410	to	_	
100-8	16411-16420	determine	_	
100-9	16421-16424	the	_	
100-10	16425-16431	degree	_	
100-11	16432-16434	to	_	
100-12	16435-16440	which	_	
100-13	16441-16445	BOLD	_	
100-14	16446-16456	activation	_	
100-15	16457-16459	in	_	
100-16	16460-16470	inhibitory	_	
100-17	16471-16478	regions	_	
100-18	16479-16485	during	_	
100-19	16486-16494	response	_	
100-20	16495-16505	inhibition	_	
100-21	16506-16509	was	_	
100-22	16510-16520	associated	_	
100-23	16521-16525	with	_	
100-24	16526-16530	BOLD	_	
100-25	16531-16541	activation	_	
100-26	16542-16544	in	_	
100-27	16545-16551	reward	_	
100-28	16552-16559	regions	_	
100-29	16560-16566	during	_	
100-30	16567-16575	monetary	_	
100-31	16576-16582	reward	_	
100-32	16582-16583	.	_	

#Text=Association between inhibition-reward relationships in binge and non-binge drinkers
#Text=To examine the degree to which associations between brain activity during inhibition and reward related to risk for addictive behaviors, we tested associations separately in binge and non-binge drinkers.
101-1	16584-16595	Association	_	
101-2	16596-16603	between	_	
101-3	16604-16621	inhibition-reward	_	
101-4	16622-16635	relationships	_	
101-5	16636-16638	in	_	
101-6	16639-16644	binge	_	
101-7	16645-16648	and	_	
101-8	16649-16658	non-binge	_	
101-9	16659-16667	drinkers	_	
101-10	16668-16670	To	_	
101-11	16671-16678	examine	_	
101-12	16679-16682	the	_	
101-13	16683-16689	degree	_	
101-14	16690-16692	to	_	
101-15	16693-16698	which	_	
101-16	16699-16711	associations	_	
101-17	16712-16719	between	_	
101-18	16720-16725	brain	_	
101-19	16726-16734	activity	_	
101-20	16735-16741	during	_	
101-21	16742-16752	inhibition	_	
101-22	16753-16756	and	_	
101-23	16757-16763	reward	_	
101-24	16764-16771	related	_	
101-25	16772-16774	to	_	
101-26	16775-16779	risk	_	
101-27	16780-16783	for	_	
101-28	16784-16793	addictive	_	
101-29	16794-16803	behaviors	_	
101-30	16803-16804	,	_	
101-31	16805-16807	we	_	
101-32	16808-16814	tested	_	
101-33	16815-16827	associations	_	
101-34	16828-16838	separately	_	
101-35	16839-16841	in	_	
101-36	16842-16847	binge	_	
101-37	16848-16851	and	_	
101-38	16852-16861	non-binge	_	
101-39	16862-16870	drinkers	_	
101-40	16870-16871	.	_	

#Text=Binge drinkers were defined as participants who reported at least one binge episode in the last month on the TLFB and non-binge drinkers were defined as participants who reported no binge episodes in the past month.
102-1	16872-16877	Binge	_	
102-2	16878-16886	drinkers	_	
102-3	16887-16891	were	_	
102-4	16892-16899	defined	_	
102-5	16900-16902	as	_	
102-6	16903-16915	participants	_	
102-7	16916-16919	who	_	
102-8	16920-16928	reported	_	
102-9	16929-16931	at	_	
102-10	16932-16937	least	_	
102-11	16938-16941	one	_	
102-12	16942-16947	binge	_	
102-13	16948-16955	episode	_	
102-14	16956-16958	in	_	
102-15	16959-16962	the	_	
102-16	16963-16967	last	_	
102-17	16968-16973	month	_	
102-18	16974-16976	on	_	
102-19	16977-16980	the	_	
102-20	16981-16985	TLFB	_	
102-21	16986-16989	and	_	
102-22	16990-16999	non-binge	_	
102-23	17000-17008	drinkers	_	
102-24	17009-17013	were	_	
102-25	17014-17021	defined	_	
102-26	17022-17024	as	_	
102-27	17025-17037	participants	_	
102-28	17038-17041	who	_	
102-29	17042-17050	reported	_	
102-30	17051-17053	no	_	
102-31	17054-17059	binge	_	
102-32	17060-17068	episodes	_	
102-33	17069-17071	in	_	
102-34	17072-17075	the	_	
102-35	17076-17080	past	_	
102-36	17081-17086	month	_	
102-37	17086-17087	.	_	

#Text=Results
#Text=Sample characteristics
#Text=A total of 67 healthy young adults (33 men and 34 women) took part in this study.
103-1	17088-17095	Results	_	
103-2	17096-17102	Sample	_	
103-3	17103-17118	characteristics	_	
103-4	17119-17120	A	_	
103-5	17121-17126	total	_	
103-6	17127-17129	of	_	
103-7	17130-17132	67	_	
103-8	17133-17140	healthy	_	
103-9	17141-17146	young	_	
103-10	17147-17153	adults	_	
103-11	17154-17155	(	_	
103-12	17155-17157	33	_	
103-13	17158-17161	men	_	
103-14	17162-17165	and	_	
103-15	17166-17168	34	_	
103-16	17169-17174	women	_	
103-17	17174-17175	)	_	
103-18	17176-17180	took	_	
103-19	17181-17185	part	_	
103-20	17186-17188	in	_	
103-21	17189-17193	this	_	
103-22	17194-17199	study	_	
103-23	17199-17200	.	_	

#Text=Demographic and substance use data for the sample are presented in Table 1.
104-1	17201-17212	Demographic	_	
104-2	17213-17216	and	_	
104-3	17217-17226	substance	_	
104-4	17227-17230	use	_	
104-5	17231-17235	data	_	
104-6	17236-17239	for	_	
104-7	17240-17243	the	_	
104-8	17244-17250	sample	_	
104-9	17251-17254	are	_	
104-10	17255-17264	presented	_	
104-11	17265-17267	in	_	
104-12	17268-17273	Table	_	
104-13	17274-17275	1	_	
104-14	17275-17276	.	_	

#Text=Brain activation during response inhibition
#Text=Behavioral data for the stop signal task were lost from 11 subjects due to computer error, and 3 additional subjects had incomplete behavioral or fMRI data.
105-1	17277-17282	Brain	_	
105-2	17283-17293	activation	_	
105-3	17294-17300	during	_	
105-4	17301-17309	response	_	
105-5	17310-17320	inhibition	_	
105-6	17321-17331	Behavioral	_	
105-7	17332-17336	data	_	
105-8	17337-17340	for	_	
105-9	17341-17344	the	_	
105-10	17345-17349	stop	_	
105-11	17350-17356	signal	_	
105-12	17357-17361	task	_	
105-13	17362-17366	were	_	
105-14	17367-17371	lost	_	
105-15	17372-17376	from	_	
105-16	17377-17379	11	_	
105-17	17380-17388	subjects	_	
105-18	17389-17392	due	_	
105-19	17393-17395	to	_	
105-20	17396-17404	computer	_	
105-21	17405-17410	error	_	
105-22	17410-17411	,	_	
105-23	17412-17415	and	_	
105-24	17416-17417	3	_	
105-25	17418-17428	additional	_	
105-26	17429-17437	subjects	_	
105-27	17438-17441	had	_	
105-28	17442-17452	incomplete	_	
105-29	17453-17463	behavioral	_	
105-30	17464-17466	or	_	
105-31	17467-17471	fMRI	_	
105-32	17472-17476	data	_	
105-33	17476-17477	.	_	

#Text=Five participants were excluded from stop signal task fMRI analyses due to invalid behavioral performance (mean Go reaction time > 800ms, n=3; Go accuracy < 75%, n=1; Stop Accuracy < 25%, n=1), resulting in a final sample size of n=48.
106-1	17478-17482	Five	_	
106-2	17483-17495	participants	_	
106-3	17496-17500	were	_	
106-4	17501-17509	excluded	_	
106-5	17510-17514	from	_	
106-6	17515-17519	stop	_	
106-7	17520-17526	signal	_	
106-8	17527-17531	task	_	
106-9	17532-17536	fMRI	_	
106-10	17537-17545	analyses	_	
106-11	17546-17549	due	_	
106-12	17550-17552	to	_	
106-13	17553-17560	invalid	_	
106-14	17561-17571	behavioral	_	
106-15	17572-17583	performance	_	
106-16	17584-17585	(	_	
106-17	17585-17589	mean	_	
106-18	17590-17592	Go	_	
106-19	17593-17601	reaction	_	
106-20	17602-17606	time	_	
106-21	17607-17608	>	_	
106-22	17609-17614	800ms	_	
106-23	17614-17615	,	_	
106-24	17616-17617	n	_	
106-25	17617-17618	=	_	
106-26	17618-17619	3	_	
106-27	17619-17620	;	_	
106-28	17621-17623	Go	_	
106-29	17624-17632	accuracy	_	
106-30	17633-17634	<	_	
106-31	17635-17638	75%	_	
106-32	17638-17639	,	_	
106-33	17640-17641	n	_	
106-34	17641-17642	=	_	
106-35	17642-17643	1	_	
106-36	17643-17644	;	_	
106-37	17645-17649	Stop	_	
106-38	17650-17658	Accuracy	_	
106-39	17659-17660	<	_	
106-40	17661-17664	25%	_	
106-41	17664-17665	,	_	
106-42	17666-17667	n	_	
106-43	17667-17668	=	_	
106-44	17668-17669	1	_	
106-45	17669-17670	)	_	
106-46	17670-17671	,	_	
106-47	17672-17681	resulting	_	
106-48	17682-17684	in	_	
106-49	17685-17686	a	_	
106-50	17687-17692	final	_	
106-51	17693-17699	sample	_	
106-52	17700-17704	size	_	
106-53	17705-17707	of	_	
106-54	17708-17709	n	_	
106-55	17709-17710	=	_	
106-56	17710-17712	48	_	
106-57	17712-17713	.	_	

#Text=Behavioral task performance measures were as follows: mean SSRT = 305.7 ms; mean inhibition rate = 52.7%; mean go accuracy = 96.0%; and mean go RT = 462.1 ms.
107-1	17714-17724	Behavioral	_	
107-2	17725-17729	task	_	
107-3	17730-17741	performance	_	
107-4	17742-17750	measures	_	
107-5	17751-17755	were	_	
107-6	17756-17758	as	_	
107-7	17759-17766	follows	_	
107-8	17766-17767	:	_	
107-9	17768-17772	mean	_	
107-10	17773-17777	SSRT	_	
107-11	17778-17779	=	_	
107-12	17780-17785	305.7	_	
107-13	17786-17788	ms	_	
107-14	17788-17789	;	_	
107-15	17790-17794	mean	_	
107-16	17795-17805	inhibition	_	
107-17	17806-17810	rate	_	
107-18	17811-17812	=	_	
107-19	17813-17818	52.7%	_	
107-20	17818-17819	;	_	
107-21	17820-17824	mean	_	
107-22	17825-17827	go	_	
107-23	17828-17836	accuracy	_	
107-24	17837-17838	=	_	
107-25	17839-17844	96.0%	_	
107-26	17844-17845	;	_	
107-27	17846-17849	and	_	
107-28	17850-17854	mean	_	
107-29	17855-17857	go	_	
107-30	17858-17860	RT	_	
107-31	17861-17862	=	_	
107-32	17863-17868	462.1	_	
107-33	17869-17871	ms	_	
107-34	17871-17872	.	_	

#Text=As previously reported in this sample, the StopInh>Go contrast activated inhibitory control regions, including right IFG, insula, MFG, and SMA (Figure 1B and 1C; Supplementary Table 1).
108-1	17873-17875	As	_	
108-2	17876-17886	previously	_	
108-3	17887-17895	reported	_	
108-4	17896-17898	in	_	
108-5	17899-17903	this	_	
108-6	17904-17910	sample	_	
108-7	17910-17911	,	_	
108-8	17912-17915	the	_	
108-9	17916-17923	StopInh	_	
108-10	17923-17924	>	_	
108-11	17924-17926	Go	_	
108-12	17927-17935	contrast	_	
108-13	17936-17945	activated	_	
108-14	17946-17956	inhibitory	_	
108-15	17957-17964	control	_	
108-16	17965-17972	regions	_	
108-17	17972-17973	,	_	
108-18	17974-17983	including	_	
108-19	17984-17989	right	_	
108-20	17990-17993	IFG	_	
108-21	17993-17994	,	_	
108-22	17995-18001	insula	_	
108-23	18001-18002	,	_	
108-24	18003-18006	MFG	_	
108-25	18006-18007	,	_	
108-26	18008-18011	and	_	
108-27	18012-18015	SMA	_	
108-28	18016-18017	(	_	
108-29	18017-18023	Figure	_	
108-30	18024-18026	1B	_	
108-31	18027-18030	and	_	
108-32	18031-18033	1C	_	
108-33	18033-18034	;	_	
108-34	18035-18048	Supplementary	_	
108-35	18049-18054	Table	_	
108-36	18055-18056	1	_	
108-37	18056-18057	)	_	
108-38	18057-18058	.	_	

#Text=Brain activation during monetary reward
#Text=As previously reported in this sample, fMRI analyses of the doors task showed that the Win>Loss contrast activated bilateral VS (Figure 1A; Supplementary Table 2), as well as bilateral middle and inferior occipital gyri (Supplementary Table 2).
109-1	18059-18064	Brain	_	
109-2	18065-18075	activation	_	
109-3	18076-18082	during	_	
109-4	18083-18091	monetary	_	
109-5	18092-18098	reward	_	
109-6	18099-18101	As	_	
109-7	18102-18112	previously	_	
109-8	18113-18121	reported	_	
109-9	18122-18124	in	_	
109-10	18125-18129	this	_	
109-11	18130-18136	sample	_	
109-12	18136-18137	,	_	
109-13	18138-18142	fMRI	_	
109-14	18143-18151	analyses	_	
109-15	18152-18154	of	_	
109-16	18155-18158	the	_	
109-17	18159-18164	doors	_	
109-18	18165-18169	task	_	
109-19	18170-18176	showed	_	
109-20	18177-18181	that	_	
109-21	18182-18185	the	_	
109-22	18186-18189	Win	_	
109-23	18189-18190	>	_	
109-24	18190-18194	Loss	_	
109-25	18195-18203	contrast	_	
109-26	18204-18213	activated	_	
109-27	18214-18223	bilateral	_	
109-28	18224-18226	VS	_	
109-29	18227-18228	(	_	
109-30	18228-18234	Figure	_	
109-31	18235-18237	1A	_	
109-32	18237-18238	;	_	
109-33	18239-18252	Supplementary	_	
109-34	18253-18258	Table	_	
109-35	18259-18260	2	_	
109-36	18260-18261	)	_	
109-37	18261-18262	,	_	
109-38	18263-18265	as	_	
109-39	18266-18270	well	_	
109-40	18271-18273	as	_	
109-41	18274-18283	bilateral	_	
109-42	18284-18290	middle	_	
109-43	18291-18294	and	_	
109-44	18295-18303	inferior	_	
109-45	18304-18313	occipital	_	
109-46	18314-18318	gyri	_	
109-47	18319-18320	(	_	
109-48	18320-18333	Supplementary	_	
109-49	18334-18339	Table	_	
109-50	18340-18341	2	_	
109-51	18341-18342	)	_	
109-52	18342-18343	.	_	

#Text=Associations between brain activation during inhibition and monetary reward
#Text=We extracted parameter estimates/β-weights representing BOLD activation within a 10 mm-radius sphere surrounding the following regions of significant peak activation for the stop signal task: right IFG [42 4 32], insula [34 24 4], MFG [28 2 50], and SMA [14 12 64].
110-1	18344-18356	Associations	_	
110-2	18357-18364	between	_	
110-3	18365-18370	brain	_	
110-4	18371-18381	activation	_	
110-5	18382-18388	during	_	
110-6	18389-18399	inhibition	_	
110-7	18400-18403	and	_	
110-8	18404-18412	monetary	_	
110-9	18413-18419	reward	_	
110-10	18420-18422	We	_	
110-11	18423-18432	extracted	_	
110-12	18433-18442	parameter	_	
110-13	18443-18452	estimates	_	
110-14	18452-18453	/	_	
110-15	18453-18462	β-weights	_	
110-16	18463-18475	representing	_	
110-17	18476-18480	BOLD	_	
110-18	18481-18491	activation	_	
110-19	18492-18498	within	_	
110-20	18499-18500	a	_	
110-21	18501-18503	10	_	
110-22	18504-18513	mm-radius	_	
110-23	18514-18520	sphere	_	
110-24	18521-18532	surrounding	_	
110-25	18533-18536	the	_	
110-26	18537-18546	following	_	
110-27	18547-18554	regions	_	
110-28	18555-18557	of	_	
110-29	18558-18569	significant	_	
110-30	18570-18574	peak	_	
110-31	18575-18585	activation	_	
110-32	18586-18589	for	_	
110-33	18590-18593	the	_	
110-34	18594-18598	stop	_	
110-35	18599-18605	signal	_	
110-36	18606-18610	task	_	
110-37	18610-18611	:	_	
110-38	18612-18617	right	_	
110-39	18618-18621	IFG	_	
110-40	18622-18623	[	_	
110-41	18623-18625	42	_	
110-42	18626-18627	4	_	
110-43	18628-18630	32	_	
110-44	18630-18631	]	_	
110-45	18631-18632	,	_	
110-46	18633-18639	insula	_	
110-47	18640-18641	[	_	
110-48	18641-18643	34	_	
110-49	18644-18646	24	_	
110-50	18647-18648	4	_	
110-51	18648-18649	]	_	
110-52	18649-18650	,	_	
110-53	18651-18654	MFG	_	
110-54	18655-18656	[	_	
110-55	18656-18658	28	_	
110-56	18659-18660	2	_	
110-57	18661-18663	50	_	
110-58	18663-18664	]	_	
110-59	18664-18665	,	_	
110-60	18666-18669	and	_	
110-61	18670-18673	SMA	_	
110-62	18674-18675	[	_	
110-63	18675-18677	14	_	
110-64	18678-18680	12	_	
110-65	18681-18683	64	_	
110-66	18683-18684	]	_	
110-67	18684-18685	.	_	

#Text=No outliers were present.
111-1	18686-18688	No	_	
111-2	18689-18697	outliers	_	
111-3	18698-18702	were	_	
111-4	18703-18710	present	_	
111-5	18710-18711	.	_	

#Text=For the doors task, we extracted activation surrounding the following peaks: bilateral VS [−6 18 −2] and [10 22 −2], as well as bilateral visual cortex [−30 −86 −8] and [34 −86 −6] to serve as control regions.
112-1	18712-18715	For	_	
112-2	18716-18719	the	_	
112-3	18720-18725	doors	_	
112-4	18726-18730	task	_	
112-5	18730-18731	,	_	
112-6	18732-18734	we	_	
112-7	18735-18744	extracted	_	
112-8	18745-18755	activation	_	
112-9	18756-18767	surrounding	_	
112-10	18768-18771	the	_	
112-11	18772-18781	following	_	
112-12	18782-18787	peaks	_	
112-13	18787-18788	:	_	
112-14	18789-18798	bilateral	_	
112-15	18799-18801	VS	_	
112-16	18802-18803	[	_	
112-17	18803-18804	−	_	
112-18	18804-18805	6	_	
112-19	18806-18808	18	_	
112-20	18809-18810	−	_	
112-21	18810-18811	2	_	
112-22	18811-18812	]	_	
112-23	18813-18816	and	_	
112-24	18817-18818	[	_	
112-25	18818-18820	10	_	
112-26	18821-18823	22	_	
112-27	18824-18825	−	_	
112-28	18825-18826	2	_	
112-29	18826-18827	]	_	
112-30	18827-18828	,	_	
112-31	18829-18831	as	_	
112-32	18832-18836	well	_	
112-33	18837-18839	as	_	
112-34	18840-18849	bilateral	_	
112-35	18850-18856	visual	_	
112-36	18857-18863	cortex	_	
112-37	18864-18865	[	_	
112-38	18865-18866	−	_	
112-39	18866-18868	30	_	
112-40	18869-18870	−	_	
112-41	18870-18872	86	_	
112-42	18873-18874	−	_	
112-43	18874-18875	8	_	
112-44	18875-18876	]	_	
112-45	18877-18880	and	_	
112-46	18881-18882	[	_	
112-47	18882-18884	34	_	
112-48	18885-18886	−	_	
112-49	18886-18888	86	_	
112-50	18889-18890	−	_	
112-51	18890-18891	6	_	
112-52	18891-18892	]	_	
112-53	18893-18895	to	_	
112-54	18896-18901	serve	_	
112-55	18902-18904	as	_	
112-56	18905-18912	control	_	
112-57	18913-18920	regions	_	
112-58	18920-18921	.	_	

#Text=Outlier analyses (activation exceeding 3 standard deviations from the mean) identified two outliers for the [−6 18 −2] peak and two outliers for the [10 22 −2] peak.
113-1	18922-18929	Outlier	_	
113-2	18930-18938	analyses	_	
113-3	18939-18940	(	_	
113-4	18940-18950	activation	_	
113-5	18951-18960	exceeding	_	
113-6	18961-18962	3	_	
113-7	18963-18971	standard	_	
113-8	18972-18982	deviations	_	
113-9	18983-18987	from	_	
113-10	18988-18991	the	_	
113-11	18992-18996	mean	_	
113-12	18996-18997	)	_	
113-13	18998-19008	identified	_	
113-14	19009-19012	two	_	
113-15	19013-19021	outliers	_	
113-16	19022-19025	for	_	
113-17	19026-19029	the	_	
113-18	19030-19031	[	_	
113-19	19031-19032	−	_	
113-20	19032-19033	6	_	
113-21	19034-19036	18	_	
113-22	19037-19038	−	_	
113-23	19038-19039	2	_	
113-24	19039-19040	]	_	
113-25	19041-19045	peak	_	
113-26	19046-19049	and	_	
113-27	19050-19053	two	_	
113-28	19054-19062	outliers	_	
113-29	19063-19066	for	_	
113-30	19067-19070	the	_	
113-31	19071-19072	[	_	
113-32	19072-19074	10	_	
113-33	19075-19077	22	_	
113-34	19078-19079	−	_	
113-35	19079-19080	2	_	
113-36	19080-19081	]	_	
113-37	19082-19086	peak	_	
113-38	19086-19087	.	_	

#Text=After confirming that the second level model remained unchanged after removing these four participants, we excluded them from subsequent analyses.
114-1	19088-19093	After	_	
114-2	19094-19104	confirming	_	
114-3	19105-19109	that	_	
114-4	19110-19113	the	_	
114-5	19114-19120	second	_	
114-6	19121-19126	level	_	
114-7	19127-19132	model	_	
114-8	19133-19141	remained	_	
114-9	19142-19151	unchanged	_	
114-10	19152-19157	after	_	
114-11	19158-19166	removing	_	
114-12	19167-19172	these	_	
114-13	19173-19177	four	_	
114-14	19178-19190	participants	_	
114-15	19190-19191	,	_	
114-16	19192-19194	we	_	
114-17	19195-19203	excluded	_	
114-18	19204-19208	them	_	
114-19	19209-19213	from	_	
114-20	19214-19224	subsequent	_	
114-21	19225-19233	analyses	_	
114-22	19233-19234	.	_	

#Text=As we tested correlations for each region of activation from the doors task with four inhibitory control regions, we applied a Bonferroni correction of p < 0.0125 (.05/4).
115-1	19235-19237	As	_	
115-2	19238-19240	we	_	
115-3	19241-19247	tested	_	
115-4	19248-19260	correlations	_	
115-5	19261-19264	for	_	
115-6	19265-19269	each	_	
115-7	19270-19276	region	_	
115-8	19277-19279	of	_	
115-9	19280-19290	activation	_	
115-10	19291-19295	from	_	
115-11	19296-19299	the	_	
115-12	19300-19305	doors	_	
115-13	19306-19310	task	_	
115-14	19311-19315	with	_	
115-15	19316-19320	four	_	
115-16	19321-19331	inhibitory	_	
115-17	19332-19339	control	_	
115-18	19340-19347	regions	_	
115-19	19347-19348	,	_	
115-20	19349-19351	we	_	
115-21	19352-19359	applied	_	
115-22	19360-19361	a	_	
115-23	19362-19372	Bonferroni	_	
115-24	19373-19383	correction	_	
115-25	19384-19386	of	_	
115-26	19387-19388	p	_	
115-27	19389-19390	<	_	
115-28	19391-19397	0.0125	_	
115-29	19398-19399	(	_	
115-30	19399-19402	.05	_	
115-31	19402-19403	/	_	
115-32	19403-19404	4	_	
115-33	19404-19405	)	_	
115-34	19405-19406	.	_	

#Text=Bivariate correlational analyses showed a negative association between brain activation during response inhibition and receipt of monetary reward.
116-1	19407-19416	Bivariate	_	
116-2	19417-19430	correlational	_	
116-3	19431-19439	analyses	_	
116-4	19440-19446	showed	_	
116-5	19447-19448	a	_	
116-6	19449-19457	negative	_	
116-7	19458-19469	association	_	
116-8	19470-19477	between	_	
116-9	19478-19483	brain	_	
116-10	19484-19494	activation	_	
116-11	19495-19501	during	_	
116-12	19502-19510	response	_	
116-13	19511-19521	inhibition	_	
116-14	19522-19525	and	_	
116-15	19526-19533	receipt	_	
116-16	19534-19536	of	_	
116-17	19537-19545	monetary	_	
116-18	19546-19552	reward	_	
116-19	19552-19553	.	_	

#Text=Specifically, less brain activation in right prefrontal regions during inhibition, including right IFG, MFG, and SMA, was associated with greater brain activation in left, but not right, VS during receipt of monetary reward (Figure 1; Table 2).
117-1	19554-19566	Specifically	_	
117-2	19566-19567	,	_	
117-3	19568-19572	less	_	
117-4	19573-19578	brain	_	
117-5	19579-19589	activation	_	
117-6	19590-19592	in	_	
117-7	19593-19598	right	_	
117-8	19599-19609	prefrontal	_	
117-9	19610-19617	regions	_	
117-10	19618-19624	during	_	
117-11	19625-19635	inhibition	_	
117-12	19635-19636	,	_	
117-13	19637-19646	including	_	
117-14	19647-19652	right	_	
117-15	19653-19656	IFG	_	
117-16	19656-19657	,	_	
117-17	19658-19661	MFG	_	
117-18	19661-19662	,	_	
117-19	19663-19666	and	_	
117-20	19667-19670	SMA	_	
117-21	19670-19671	,	_	
117-22	19672-19675	was	_	
117-23	19676-19686	associated	_	
117-24	19687-19691	with	_	
117-25	19692-19699	greater	_	
117-26	19700-19705	brain	_	
117-27	19706-19716	activation	_	
117-28	19717-19719	in	_	
117-29	19720-19724	left	_	
117-30	19724-19725	,	_	
117-31	19726-19729	but	_	
117-32	19730-19733	not	_	
117-33	19734-19739	right	_	
117-34	19739-19740	,	_	
117-35	19741-19743	VS	_	
117-36	19744-19750	during	_	
117-37	19751-19758	receipt	_	
117-38	19759-19761	of	_	
117-39	19762-19770	monetary	_	
117-40	19771-19777	reward	_	
117-41	19778-19779	(	_	
117-42	19779-19785	Figure	_	
117-43	19786-19787	1	_	
117-44	19787-19788	;	_	
117-45	19789-19794	Table	_	
117-46	19795-19796	2	_	
117-47	19796-19797	)	_	
117-48	19797-19798	.	_	

#Text=By contrast, right insula activation during inhibition was not related to VS activation during monetary reward.
118-1	19799-19801	By	_	
118-2	19802-19810	contrast	_	
118-3	19810-19811	,	_	
118-4	19812-19817	right	_	
118-5	19818-19824	insula	_	
118-6	19825-19835	activation	_	
118-7	19836-19842	during	_	
118-8	19843-19853	inhibition	_	
118-9	19854-19857	was	_	
118-10	19858-19861	not	_	
118-11	19862-19869	related	_	
118-12	19870-19872	to	_	
118-13	19873-19875	VS	_	
118-14	19876-19886	activation	_	
118-15	19887-19893	during	_	
118-16	19894-19902	monetary	_	
118-17	19903-19909	reward	_	
118-18	19909-19910	.	_	

#Text=We also examined correlations between brain activation during inhibition and activation in visual cortex during reward processing to serve as a control region.
119-1	19911-19913	We	_	
119-2	19914-19918	also	_	
119-3	19919-19927	examined	_	
119-4	19928-19940	correlations	_	
119-5	19941-19948	between	_	
119-6	19949-19954	brain	_	
119-7	19955-19965	activation	_	
119-8	19966-19972	during	_	
119-9	19973-19983	inhibition	_	
119-10	19984-19987	and	_	
119-11	19988-19998	activation	_	
119-12	19999-20001	in	_	
119-13	20002-20008	visual	_	
119-14	20009-20015	cortex	_	
119-15	20016-20022	during	_	
119-16	20023-20029	reward	_	
119-17	20030-20040	processing	_	
119-18	20041-20043	to	_	
119-19	20044-20049	serve	_	
119-20	20050-20052	as	_	
119-21	20053-20054	a	_	
119-22	20055-20062	control	_	
119-23	20063-20069	region	_	
119-24	20069-20070	.	_	

#Text=Table 2 shows that no significant associations were observed between prefrontal and visual regions (ps > 0.27), suggesting that prefrontal activation during inhibition was specifically correlated with regions known to be implicated in reward.
120-1	20071-20076	Table	_	
120-2	20077-20078	2	_	
120-3	20079-20084	shows	_	
120-4	20085-20089	that	_	
120-5	20090-20092	no	_	
120-6	20093-20104	significant	_	
120-7	20105-20117	associations	_	
120-8	20118-20122	were	_	
120-9	20123-20131	observed	_	
120-10	20132-20139	between	_	
120-11	20140-20150	prefrontal	_	
120-12	20151-20154	and	_	
120-13	20155-20161	visual	_	
120-14	20162-20169	regions	_	
120-15	20170-20171	(	_	
120-16	20171-20173	ps	_	
120-17	20174-20175	>	_	
120-18	20176-20180	0.27	_	
120-19	20180-20181	)	_	
120-20	20181-20182	,	_	
120-21	20183-20193	suggesting	_	
120-22	20194-20198	that	_	
120-23	20199-20209	prefrontal	_	
120-24	20210-20220	activation	_	
120-25	20221-20227	during	_	
120-26	20228-20238	inhibition	_	
120-27	20239-20242	was	_	
120-28	20243-20255	specifically	_	
120-29	20256-20266	correlated	_	
120-30	20267-20271	with	_	
120-31	20272-20279	regions	_	
120-32	20280-20285	known	_	
120-33	20286-20288	to	_	
120-34	20289-20291	be	_	
120-35	20292-20302	implicated	_	
120-36	20303-20305	in	_	
120-37	20306-20312	reward	_	
120-38	20312-20313	.	_	

#Text=No significant associations were detected between the in-scanner behavioral measure of inhibition (SSRT) and brain activation during inhibition or reward (ps > 0.05).
121-1	20314-20316	No	_	
121-2	20317-20328	significant	_	
121-3	20329-20341	associations	_	
121-4	20342-20346	were	_	
121-5	20347-20355	detected	_	
121-6	20356-20363	between	_	
121-7	20364-20367	the	_	
121-8	20368-20378	in-scanner	_	
121-9	20379-20389	behavioral	_	
121-10	20390-20397	measure	_	
121-11	20398-20400	of	_	
121-12	20401-20411	inhibition	_	
121-13	20412-20413	(	_	
121-14	20413-20417	SSRT	_	
121-15	20417-20418	)	_	
121-16	20419-20422	and	_	
121-17	20423-20428	brain	_	
121-18	20429-20439	activation	_	
121-19	20440-20446	during	_	
121-20	20447-20457	inhibition	_	
121-21	20458-20460	or	_	
121-22	20461-20467	reward	_	
121-23	20468-20469	(	_	
121-24	20469-20471	ps	_	
121-25	20472-20473	>	_	
121-26	20474-20478	0.05	_	
121-27	20478-20479	)	_	
121-28	20479-20480	.	_	

#Text=Association between inhibition-reward relationships in binge and non-binge drinkers
#Text=Twenty-three participants were classified as binge drinkers (at least one binge episode in the last month) and 21 were classified as non-binge drinkers (no binge episodes in the past month).
122-1	20481-20492	Association	_	
122-2	20493-20500	between	_	
122-3	20501-20518	inhibition-reward	_	
122-4	20519-20532	relationships	_	
122-5	20533-20535	in	_	
122-6	20536-20541	binge	_	
122-7	20542-20545	and	_	
122-8	20546-20555	non-binge	_	
122-9	20556-20564	drinkers	_	
122-10	20565-20577	Twenty-three	_	
122-11	20578-20590	participants	_	
122-12	20591-20595	were	_	
122-13	20596-20606	classified	_	
122-14	20607-20609	as	_	
122-15	20610-20615	binge	_	
122-16	20616-20624	drinkers	_	
122-17	20625-20626	(	_	
122-18	20626-20628	at	_	
122-19	20629-20634	least	_	
122-20	20635-20638	one	_	
122-21	20639-20644	binge	_	
122-22	20645-20652	episode	_	
122-23	20653-20655	in	_	
122-24	20656-20659	the	_	
122-25	20660-20664	last	_	
122-26	20665-20670	month	_	
122-27	20670-20671	)	_	
122-28	20672-20675	and	_	
122-29	20676-20678	21	_	
122-30	20679-20683	were	_	
122-31	20684-20694	classified	_	
122-32	20695-20697	as	_	
122-33	20698-20707	non-binge	_	
122-34	20708-20716	drinkers	_	
122-35	20717-20718	(	_	
122-36	20718-20720	no	_	
122-37	20721-20726	binge	_	
122-38	20727-20735	episodes	_	
122-39	20736-20738	in	_	
122-40	20739-20742	the	_	
122-41	20743-20747	past	_	
122-42	20748-20753	month	_	
122-43	20753-20754	)	_	
122-44	20754-20755	.	_	

#Text=Among the binge drinkers, greater brain activation in left VS during reward was associated with less brain activation in right SMA (r = −0.60, p = 0.003) and IFG (r = −0.53; p = 0.009), but not the MFG (r = −0.26, p = 0.23) during inhibition.
123-1	20756-20761	Among	_	
123-2	20762-20765	the	_	
123-3	20766-20771	binge	_	
123-4	20772-20780	drinkers	_	
123-5	20780-20781	,	_	
123-6	20782-20789	greater	_	
123-7	20790-20795	brain	_	
123-8	20796-20806	activation	_	
123-9	20807-20809	in	_	
123-10	20810-20814	left	_	
123-11	20815-20817	VS	_	
123-12	20818-20824	during	_	
123-13	20825-20831	reward	_	
123-14	20832-20835	was	_	
123-15	20836-20846	associated	_	
123-16	20847-20851	with	_	
123-17	20852-20856	less	_	
123-18	20857-20862	brain	_	
123-19	20863-20873	activation	_	
123-20	20874-20876	in	_	
123-21	20877-20882	right	_	
123-22	20883-20886	SMA	_	
123-23	20887-20888	(	_	
123-24	20888-20889	r	_	
123-25	20890-20891	=	_	
123-26	20892-20893	−	_	
123-27	20893-20897	0.60	_	
123-28	20897-20898	,	_	
123-29	20899-20900	p	_	
123-30	20901-20902	=	_	
123-31	20903-20908	0.003	_	
123-32	20908-20909	)	_	
123-33	20910-20913	and	_	
123-34	20914-20917	IFG	_	
123-35	20918-20919	(	_	
123-36	20919-20920	r	_	
123-37	20921-20922	=	_	
123-38	20923-20924	−	_	
123-39	20924-20928	0.53	_	
123-40	20928-20929	;	_	
123-41	20930-20931	p	_	
123-42	20932-20933	=	_	
123-43	20934-20939	0.009	_	
123-44	20939-20940	)	_	
123-45	20940-20941	,	_	
123-46	20942-20945	but	_	
123-47	20946-20949	not	_	
123-48	20950-20953	the	_	
123-49	20954-20957	MFG	_	
123-50	20958-20959	(	_	
123-51	20959-20960	r	_	
123-52	20961-20962	=	_	
123-53	20963-20964	−	_	
123-54	20964-20968	0.26	_	
123-55	20968-20969	,	_	
123-56	20970-20971	p	_	
123-57	20972-20973	=	_	
123-58	20974-20978	0.23	_	
123-59	20978-20979	)	_	
123-60	20980-20986	during	_	
123-61	20987-20997	inhibition	_	
123-62	20997-20998	.	_	

#Text=By contrast, no significant correlations were observed at the corrected p-value of 0.0125 among the non-binge drinkers (SMA: r = −0.22, p = 0.34; IFG: r = −0.12, p = 0.62; MFG: r = −0.46; p = 0.03).
124-1	20999-21001	By	_	
124-2	21002-21010	contrast	_	
124-3	21010-21011	,	_	
124-4	21012-21014	no	_	
124-5	21015-21026	significant	_	
124-6	21027-21039	correlations	_	
124-7	21040-21044	were	_	
124-8	21045-21053	observed	_	
124-9	21054-21056	at	_	
124-10	21057-21060	the	_	
124-11	21061-21070	corrected	_	
124-12	21071-21078	p-value	_	
124-13	21079-21081	of	_	
124-14	21082-21088	0.0125	_	
124-15	21089-21094	among	_	
124-16	21095-21098	the	_	
124-17	21099-21108	non-binge	_	
124-18	21109-21117	drinkers	_	
124-19	21118-21119	(	_	
124-20	21119-21122	SMA	_	
124-21	21122-21123	:	_	
124-22	21124-21125	r	_	
124-23	21126-21127	=	_	
124-24	21128-21129	−	_	
124-25	21129-21133	0.22	_	
124-26	21133-21134	,	_	
124-27	21135-21136	p	_	
124-28	21137-21138	=	_	
124-29	21139-21143	0.34	_	
124-30	21143-21144	;	_	
124-31	21145-21148	IFG	_	
124-32	21148-21149	:	_	
124-33	21150-21151	r	_	
124-34	21152-21153	=	_	
124-35	21154-21155	−	_	
124-36	21155-21159	0.12	_	
124-37	21159-21160	,	_	
124-38	21161-21162	p	_	
124-39	21163-21164	=	_	
124-40	21165-21169	0.62	_	
124-41	21169-21170	;	_	
124-42	21171-21174	MFG	_	
124-43	21174-21175	:	_	
124-44	21176-21177	r	_	
124-45	21178-21179	=	_	
124-46	21180-21181	−	_	
124-47	21181-21185	0.46	_	
124-48	21185-21186	;	_	
124-49	21187-21188	p	_	
124-50	21189-21190	=	_	
124-51	21191-21195	0.03	_	
124-52	21195-21196	)	_	
124-53	21196-21197	.	_	

#Text=Discussion
#Text=This study revealed a novel association between brain activation underlying two seemingly independent constructs: response inhibition and reward sensitivity.
125-1	21198-21208	Discussion	_	
125-2	21209-21213	This	_	
125-3	21214-21219	study	_	
125-4	21220-21228	revealed	_	
125-5	21229-21230	a	_	
125-6	21231-21236	novel	_	
125-7	21237-21248	association	_	
125-8	21249-21256	between	_	
125-9	21257-21262	brain	_	
125-10	21263-21273	activation	_	
125-11	21274-21284	underlying	_	
125-12	21285-21288	two	_	
125-13	21289-21298	seemingly	_	
125-14	21299-21310	independent	_	
125-15	21311-21321	constructs	_	
125-16	21321-21322	:	_	
125-17	21323-21331	response	_	
125-18	21332-21342	inhibition	_	
125-19	21343-21346	and	_	
125-20	21347-21353	reward	_	
125-21	21354-21365	sensitivity	_	
125-22	21365-21366	.	_	

#Text=Both inhibition and reward sensitivity have long been linked to propensity for impulsive and addictive behaviors; however, few studies have examined how the two risk factors might be related to one another.
126-1	21367-21371	Both	_	
126-2	21372-21382	inhibition	_	
126-3	21383-21386	and	_	
126-4	21387-21393	reward	_	
126-5	21394-21405	sensitivity	_	
126-6	21406-21410	have	_	
126-7	21411-21415	long	_	
126-8	21416-21420	been	_	
126-9	21421-21427	linked	_	
126-10	21428-21430	to	_	
126-11	21431-21441	propensity	_	
126-12	21442-21445	for	_	
126-13	21446-21455	impulsive	_	
126-14	21456-21459	and	_	
126-15	21460-21469	addictive	_	
126-16	21470-21479	behaviors	_	
126-17	21479-21480	;	_	
126-18	21481-21488	however	_	
126-19	21488-21489	,	_	
126-20	21490-21493	few	_	
126-21	21494-21501	studies	_	
126-22	21502-21506	have	_	
126-23	21507-21515	examined	_	
126-24	21516-21519	how	_	
126-25	21520-21523	the	_	
126-26	21524-21527	two	_	
126-27	21528-21532	risk	_	
126-28	21533-21540	factors	_	
126-29	21541-21546	might	_	
126-30	21547-21549	be	_	
126-31	21550-21557	related	_	
126-32	21558-21560	to	_	
126-33	21561-21564	one	_	
126-34	21565-21572	another	_	
126-35	21572-21573	.	_	

#Text=The current study provides the first evidence of a negative correlation between brain activation during inhibition and reward.
127-1	21574-21577	The	_	
127-2	21578-21585	current	_	
127-3	21586-21591	study	_	
127-4	21592-21600	provides	_	
127-5	21601-21604	the	_	
127-6	21605-21610	first	_	
127-7	21611-21619	evidence	_	
127-8	21620-21622	of	_	
127-9	21623-21624	a	_	
127-10	21625-21633	negative	_	
127-11	21634-21645	correlation	_	
127-12	21646-21653	between	_	
127-13	21654-21659	brain	_	
127-14	21660-21670	activation	_	
127-15	21671-21677	during	_	
127-16	21678-21688	inhibition	_	
127-17	21689-21692	and	_	
127-18	21693-21699	reward	_	
127-19	21699-21700	.	_	

#Text=Specifically, individuals with less prefrontal engagement during response inhibition displayed greater engagement of reward circuitry during monetary reward.
128-1	21701-21713	Specifically	_	
128-2	21713-21714	,	_	
128-3	21715-21726	individuals	_	
128-4	21727-21731	with	_	
128-5	21732-21736	less	_	
128-6	21737-21747	prefrontal	_	
128-7	21748-21758	engagement	_	
128-8	21759-21765	during	_	
128-9	21766-21774	response	_	
128-10	21775-21785	inhibition	_	
128-11	21786-21795	displayed	_	
128-12	21796-21803	greater	_	
128-13	21804-21814	engagement	_	
128-14	21815-21817	of	_	
128-15	21818-21824	reward	_	
128-16	21825-21834	circuitry	_	
128-17	21835-21841	during	_	
128-18	21842-21850	monetary	_	
128-19	21851-21857	reward	_	
128-20	21857-21858	.	_	

#Text=Additionally, these associations were more pronounced in binge drinkers, a population at risk for addictive disorders, compared to non-binge drinkers.
129-1	21859-21871	Additionally	_	
129-2	21871-21872	,	_	
129-3	21873-21878	these	_	
129-4	21879-21891	associations	_	
129-5	21892-21896	were	_	
129-6	21897-21901	more	_	
129-7	21902-21912	pronounced	_	
129-8	21913-21915	in	_	
129-9	21916-21921	binge	_	
129-10	21922-21930	drinkers	_	
129-11	21930-21931	,	_	
129-12	21932-21933	a	_	
129-13	21934-21944	population	_	
129-14	21945-21947	at	_	
129-15	21948-21952	risk	_	
129-16	21953-21956	for	_	
129-17	21957-21966	addictive	_	
129-18	21967-21976	disorders	_	
129-19	21976-21977	,	_	
129-20	21978-21986	compared	_	
129-21	21987-21989	to	_	
129-22	21990-21999	non-binge	_	
129-23	22000-22008	drinkers	_	
129-24	22008-22009	.	_	

#Text=These findings have important implications for understanding interactions between brain engagement during inhibition and reward processing, and how a potential imbalance between the two might confer increased risk for problematic and maladaptive behaviors.
130-1	22010-22015	These	_	
130-2	22016-22024	findings	_	
130-3	22025-22029	have	_	
130-4	22030-22039	important	_	
130-5	22040-22052	implications	_	
130-6	22053-22056	for	_	
130-7	22057-22070	understanding	_	
130-8	22071-22083	interactions	_	
130-9	22084-22091	between	_	
130-10	22092-22097	brain	_	
130-11	22098-22108	engagement	_	
130-12	22109-22115	during	_	
130-13	22116-22126	inhibition	_	
130-14	22127-22130	and	_	
130-15	22131-22137	reward	_	
130-16	22138-22148	processing	_	
130-17	22148-22149	,	_	
130-18	22150-22153	and	_	
130-19	22154-22157	how	_	
130-20	22158-22159	a	_	
130-21	22160-22169	potential	_	
130-22	22170-22179	imbalance	_	
130-23	22180-22187	between	_	
130-24	22188-22191	the	_	
130-25	22192-22195	two	_	
130-26	22196-22201	might	_	
130-27	22202-22208	confer	_	
130-28	22209-22218	increased	_	
130-29	22219-22223	risk	_	
130-30	22224-22227	for	_	
130-31	22228-22239	problematic	_	
130-32	22240-22243	and	_	
130-33	22244-22255	maladaptive	_	
130-34	22256-22265	behaviors	_	
130-35	22265-22266	.	_	

#Text=Our finding that underactive inhibitory engagement is coupled with overactive reward circuitry among healthy adults, and that the association is more pronounced in binge drinkers compared to non-binge drinkers, has important implications for understanding disrupted inhibitory and reward processing in addiction and other impulse control disorders.
131-1	22267-22270	Our	_	
131-2	22271-22278	finding	_	
131-3	22279-22283	that	_	
131-4	22284-22295	underactive	_	
131-5	22296-22306	inhibitory	_	
131-6	22307-22317	engagement	_	
131-7	22318-22320	is	_	
131-8	22321-22328	coupled	_	
131-9	22329-22333	with	_	
131-10	22334-22344	overactive	_	
131-11	22345-22351	reward	_	
131-12	22352-22361	circuitry	_	
131-13	22362-22367	among	_	
131-14	22368-22375	healthy	_	
131-15	22376-22382	adults	_	
131-16	22382-22383	,	_	
131-17	22384-22387	and	_	
131-18	22388-22392	that	_	
131-19	22393-22396	the	_	
131-20	22397-22408	association	_	
131-21	22409-22411	is	_	
131-22	22412-22416	more	_	
131-23	22417-22427	pronounced	_	
131-24	22428-22430	in	_	
131-25	22431-22436	binge	_	
131-26	22437-22445	drinkers	_	
131-27	22446-22454	compared	_	
131-28	22455-22457	to	_	
131-29	22458-22467	non-binge	_	
131-30	22468-22476	drinkers	_	
131-31	22476-22477	,	_	
131-32	22478-22481	has	_	
131-33	22482-22491	important	_	
131-34	22492-22504	implications	_	
131-35	22505-22508	for	_	
131-36	22509-22522	understanding	_	
131-37	22523-22532	disrupted	_	
131-38	22533-22543	inhibitory	_	
131-39	22544-22547	and	_	
131-40	22548-22554	reward	_	
131-41	22555-22565	processing	_	
131-42	22566-22568	in	_	
131-43	22569-22578	addiction	_	
131-44	22579-22582	and	_	
131-45	22583-22588	other	_	
131-46	22589-22596	impulse	_	
131-47	22597-22604	control	_	
131-48	22605-22614	disorders	_	
131-49	22614-22615	.	_	

#Text=Specifically, the imbalance observed in individuals with these disorders may not be entirely a consequence of the disorder.
132-1	22616-22628	Specifically	_	
132-2	22628-22629	,	_	
132-3	22630-22633	the	_	
132-4	22634-22643	imbalance	_	
132-5	22644-22652	observed	_	
132-6	22653-22655	in	_	
132-7	22656-22667	individuals	_	
132-8	22668-22672	with	_	
132-9	22673-22678	these	_	
132-10	22679-22688	disorders	_	
132-11	22689-22692	may	_	
132-12	22693-22696	not	_	
132-13	22697-22699	be	_	
132-14	22700-22708	entirely	_	
132-15	22709-22710	a	_	
132-16	22711-22722	consequence	_	
132-17	22723-22725	of	_	
132-18	22726-22729	the	_	
132-19	22730-22738	disorder	_	
132-20	22738-22739	.	_	

#Text=Instead, it may be a prospective risk factor and could even play a causal role in the onset of problematic behaviors.
133-1	22740-22747	Instead	_	
133-2	22747-22748	,	_	
133-3	22749-22751	it	_	
133-4	22752-22755	may	_	
133-5	22756-22758	be	_	
133-6	22759-22760	a	_	
133-7	22761-22772	prospective	_	
133-8	22773-22777	risk	_	
133-9	22778-22784	factor	_	
133-10	22785-22788	and	_	
133-11	22789-22794	could	_	
133-12	22795-22799	even	_	
133-13	22800-22804	play	_	
133-14	22805-22806	a	_	
133-15	22807-22813	causal	_	
133-16	22814-22818	role	_	
133-17	22819-22821	in	_	
133-18	22822-22825	the	_	
133-19	22826-22831	onset	_	
133-20	22832-22834	of	_	
133-21	22835-22846	problematic	_	
133-22	22847-22856	behaviors	_	
133-23	22856-22857	.	_	

#Text=Indeed, prospective studies have shown that neural circuitry underlying inhibitory control and reward sensitivity both predict the development of drug-related problems independently.
134-1	22858-22864	Indeed	_	
134-2	22864-22865	,	_	
134-3	22866-22877	prospective	_	
134-4	22878-22885	studies	_	
134-5	22886-22890	have	_	
134-6	22891-22896	shown	_	
134-7	22897-22901	that	_	
134-8	22902-22908	neural	_	
134-9	22909-22918	circuitry	_	
134-10	22919-22929	underlying	_	
134-11	22930-22940	inhibitory	_	
134-12	22941-22948	control	_	
134-13	22949-22952	and	_	
134-14	22953-22959	reward	_	
134-15	22960-22971	sensitivity	_	
134-16	22972-22976	both	_	
134-17	22977-22984	predict	_	
134-18	22985-22988	the	_	
134-19	22989-23000	development	_	
134-20	23001-23003	of	_	
134-21	23004-23016	drug-related	_	
134-22	23017-23025	problems	_	
134-23	23026-23039	independently	_	
134-24	23039-23040	.	_	

#Text=It will be important for future longitudinal studies to assess the relative balance between inhibition and reward functioning as a predictor of addictive and other impulse control disorders, as individuals who experience both poor inhibition and overactive reward are likely at greater risk.
135-1	23041-23043	It	_	
135-2	23044-23048	will	_	
135-3	23049-23051	be	_	
135-4	23052-23061	important	_	
135-5	23062-23065	for	_	
135-6	23066-23072	future	_	
135-7	23073-23085	longitudinal	_	
135-8	23086-23093	studies	_	
135-9	23094-23096	to	_	
135-10	23097-23103	assess	_	
135-11	23104-23107	the	_	
135-12	23108-23116	relative	_	
135-13	23117-23124	balance	_	
135-14	23125-23132	between	_	
135-15	23133-23143	inhibition	_	
135-16	23144-23147	and	_	
135-17	23148-23154	reward	_	
135-18	23155-23166	functioning	_	
135-19	23167-23169	as	_	
135-20	23170-23171	a	_	
135-21	23172-23181	predictor	_	
135-22	23182-23184	of	_	
135-23	23185-23194	addictive	_	
135-24	23195-23198	and	_	
135-25	23199-23204	other	_	
135-26	23205-23212	impulse	_	
135-27	23213-23220	control	_	
135-28	23221-23230	disorders	_	
135-29	23230-23231	,	_	
135-30	23232-23234	as	_	
135-31	23235-23246	individuals	_	
135-32	23247-23250	who	_	
135-33	23251-23261	experience	_	
135-34	23262-23266	both	_	
135-35	23267-23271	poor	_	
135-36	23272-23282	inhibition	_	
135-37	23283-23286	and	_	
135-38	23287-23297	overactive	_	
135-39	23298-23304	reward	_	
135-40	23305-23308	are	_	
135-41	23309-23315	likely	_	
135-42	23316-23318	at	_	
135-43	23319-23326	greater	_	
135-44	23327-23331	risk	_	
135-45	23331-23332	.	_	

#Text=It is important to note that the current analyses are correlational, and thus do not directly speak to the mechanisms underlying the negative association between prefrontal inhibitory and sub-cortical reward processing observed here.
136-1	23333-23335	It	_	
136-2	23336-23338	is	_	
136-3	23339-23348	important	_	
136-4	23349-23351	to	_	
136-5	23352-23356	note	_	
136-6	23357-23361	that	_	
136-7	23362-23365	the	_	
136-8	23366-23373	current	_	
136-9	23374-23382	analyses	_	
136-10	23383-23386	are	_	
136-11	23387-23400	correlational	_	
136-12	23400-23401	,	_	
136-13	23402-23405	and	_	
136-14	23406-23410	thus	_	
136-15	23411-23413	do	_	
136-16	23414-23417	not	_	
136-17	23418-23426	directly	_	
136-18	23427-23432	speak	_	
136-19	23433-23435	to	_	
136-20	23436-23439	the	_	
136-21	23440-23450	mechanisms	_	
136-22	23451-23461	underlying	_	
136-23	23462-23465	the	_	
136-24	23466-23474	negative	_	
136-25	23475-23486	association	_	
136-26	23487-23494	between	_	
136-27	23495-23505	prefrontal	_	
136-28	23506-23516	inhibitory	_	
136-29	23517-23520	and	_	
136-30	23521-23533	sub-cortical	_	
136-31	23534-23540	reward	_	
136-32	23541-23551	processing	_	
136-33	23552-23560	observed	_	
136-34	23561-23565	here	_	
136-35	23565-23566	.	_	

#Text=Although speculative, one potential explanation is that prefrontal functioning could serve a regulatory role in reward processing, similar to its regulatory role in motor inhibition.
137-1	23567-23575	Although	_	
137-2	23576-23587	speculative	_	
137-3	23587-23588	,	_	
137-4	23589-23592	one	_	
137-5	23593-23602	potential	_	
137-6	23603-23614	explanation	_	
137-7	23615-23617	is	_	
137-8	23618-23622	that	_	
137-9	23623-23633	prefrontal	_	
137-10	23634-23645	functioning	_	
137-11	23646-23651	could	_	
137-12	23652-23657	serve	_	
137-13	23658-23659	a	_	
137-14	23660-23670	regulatory	_	
137-15	23671-23675	role	_	
137-16	23676-23678	in	_	
137-17	23679-23685	reward	_	
137-18	23686-23696	processing	_	
137-19	23696-23697	,	_	
137-20	23698-23705	similar	_	
137-21	23706-23708	to	_	
137-22	23709-23712	its	_	
137-23	23713-23723	regulatory	_	
137-24	23724-23728	role	_	
137-25	23729-23731	in	_	
137-26	23732-23737	motor	_	
137-27	23738-23748	inhibition	_	
137-28	23748-23749	.	_	

#Text=In the context of motor inhibition, frontal regions are thought to exert ‘top-down’ executive control over lower level, sub-cortical regions, including the striatum.
138-1	23750-23752	In	_	
138-2	23753-23756	the	_	
138-3	23757-23764	context	_	
138-4	23765-23767	of	_	
138-5	23768-23773	motor	_	
138-6	23774-23784	inhibition	_	
138-7	23784-23785	,	_	
138-8	23786-23793	frontal	_	
138-9	23794-23801	regions	_	
138-10	23802-23805	are	_	
138-11	23806-23813	thought	_	
138-12	23814-23816	to	_	
138-13	23817-23822	exert	_	
138-14	23823-23824	‘	_	
138-15	23824-23832	top-down	_	
138-16	23832-23833	’	_	
138-17	23834-23843	executive	_	
138-18	23844-23851	control	_	
138-19	23852-23856	over	_	
138-20	23857-23862	lower	_	
138-21	23863-23868	level	_	
138-22	23868-23869	,	_	
138-23	23870-23882	sub-cortical	_	
138-24	23883-23890	regions	_	
138-25	23890-23891	,	_	
138-26	23892-23901	including	_	
138-27	23902-23905	the	_	
138-28	23906-23914	striatum	_	
138-29	23914-23915	.	_	

#Text=This frontal-striatal circuitry primarily encompasses dorsal striatal regions involved in motor control, and deficits in prefrontal engagement and weakened frontal-dorsal striatal connectivity are associated with impaired response inhibition.
139-1	23916-23920	This	_	
139-2	23921-23937	frontal-striatal	_	
139-3	23938-23947	circuitry	_	
139-4	23948-23957	primarily	_	
139-5	23958-23969	encompasses	_	
139-6	23970-23976	dorsal	_	
139-7	23977-23985	striatal	_	
139-8	23986-23993	regions	_	
139-9	23994-24002	involved	_	
139-10	24003-24005	in	_	
139-11	24006-24011	motor	_	
139-12	24012-24019	control	_	
139-13	24019-24020	,	_	
139-14	24021-24024	and	_	
139-15	24025-24033	deficits	_	
139-16	24034-24036	in	_	
139-17	24037-24047	prefrontal	_	
139-18	24048-24058	engagement	_	
139-19	24059-24062	and	_	
139-20	24063-24071	weakened	_	
139-21	24072-24086	frontal-dorsal	_	
139-22	24087-24095	striatal	_	
139-23	24096-24108	connectivity	_	
139-24	24109-24112	are	_	
139-25	24113-24123	associated	_	
139-26	24124-24128	with	_	
139-27	24129-24137	impaired	_	
139-28	24138-24146	response	_	
139-29	24147-24157	inhibition	_	
139-30	24157-24158	.	_	

#Text=It is possible that such downstream inhibitory projections could extend to ventral striatal regions implicated in reward as well.
140-1	24159-24161	It	_	
140-2	24162-24164	is	_	
140-3	24165-24173	possible	_	
140-4	24174-24178	that	_	
140-5	24179-24183	such	_	
140-6	24184-24194	downstream	_	
140-7	24195-24205	inhibitory	_	
140-8	24206-24217	projections	_	
140-9	24218-24223	could	_	
140-10	24224-24230	extend	_	
140-11	24231-24233	to	_	
140-12	24234-24241	ventral	_	
140-13	24242-24250	striatal	_	
140-14	24251-24258	regions	_	
140-15	24259-24269	implicated	_	
140-16	24270-24272	in	_	
140-17	24273-24279	reward	_	
140-18	24280-24282	as	_	
140-19	24283-24287	well	_	
140-20	24287-24288	.	_	

#Text=This idea is consistent with the current findings, as well as reports in both healthy and addicted populations showing that weakened frontal-ventral striatal connectivity during reward processing is associated with greater striatal activation during reward.
141-1	24289-24293	This	_	
141-2	24294-24298	idea	_	
141-3	24299-24301	is	_	
141-4	24302-24312	consistent	_	
141-5	24313-24317	with	_	
141-6	24318-24321	the	_	
141-7	24322-24329	current	_	
141-8	24330-24338	findings	_	
141-9	24338-24339	,	_	
141-10	24340-24342	as	_	
141-11	24343-24347	well	_	
141-12	24348-24350	as	_	
141-13	24351-24358	reports	_	
141-14	24359-24361	in	_	
141-15	24362-24366	both	_	
141-16	24367-24374	healthy	_	
141-17	24375-24378	and	_	
141-18	24379-24387	addicted	_	
141-19	24388-24399	populations	_	
141-20	24400-24407	showing	_	
141-21	24408-24412	that	_	
141-22	24413-24421	weakened	_	
141-23	24422-24437	frontal-ventral	_	
141-24	24438-24446	striatal	_	
141-25	24447-24459	connectivity	_	
141-26	24460-24466	during	_	
141-27	24467-24473	reward	_	
141-28	24474-24484	processing	_	
141-29	24485-24487	is	_	
141-30	24488-24498	associated	_	
141-31	24499-24503	with	_	
141-32	24504-24511	greater	_	
141-33	24512-24520	striatal	_	
141-34	24521-24531	activation	_	
141-35	24532-24538	during	_	
141-36	24539-24545	reward	_	
141-37	24545-24546	.	_	

#Text=In order to test whether prefrontal inhibitory functioning does indeed exert top-down regulation over striatal reward regions, future studies should assess reward reactivity following direct manipulations of prefrontal functioning.
142-1	24547-24549	In	_	
142-2	24550-24555	order	_	
142-3	24556-24558	to	_	
142-4	24559-24563	test	_	
142-5	24564-24571	whether	_	
142-6	24572-24582	prefrontal	_	
142-7	24583-24593	inhibitory	_	
142-8	24594-24605	functioning	_	
142-9	24606-24610	does	_	
142-10	24611-24617	indeed	_	
142-11	24618-24623	exert	_	
142-12	24624-24632	top-down	_	
142-13	24633-24643	regulation	_	
142-14	24644-24648	over	_	
142-15	24649-24657	striatal	_	
142-16	24658-24664	reward	_	
142-17	24665-24672	regions	_	
142-18	24672-24673	,	_	
142-19	24674-24680	future	_	
142-20	24681-24688	studies	_	
142-21	24689-24695	should	_	
142-22	24696-24702	assess	_	
142-23	24703-24709	reward	_	
142-24	24710-24720	reactivity	_	
142-25	24721-24730	following	_	
142-26	24731-24737	direct	_	
142-27	24738-24751	manipulations	_	
142-28	24752-24754	of	_	
142-29	24755-24765	prefrontal	_	
142-30	24766-24777	functioning	_	
142-31	24777-24778	.	_	

#Text=For example, engagement of inhibitory brain regions can be acutely enhanced using transcranial magnetic stimulation (TMS) or pharmacotherapy.
143-1	24779-24782	For	_	
143-2	24783-24790	example	_	
143-3	24790-24791	,	_	
143-4	24792-24802	engagement	_	
143-5	24803-24805	of	_	
143-6	24806-24816	inhibitory	_	
143-7	24817-24822	brain	_	
143-8	24823-24830	regions	_	
143-9	24831-24834	can	_	
143-10	24835-24837	be	_	
143-11	24838-24845	acutely	_	
143-12	24846-24854	enhanced	_	
143-13	24855-24860	using	_	
143-14	24861-24873	transcranial	_	
143-15	24874-24882	magnetic	_	
143-16	24883-24894	stimulation	_	
143-17	24895-24896	(	_	
143-18	24896-24899	TMS	_	
143-19	24899-24900	)	_	
143-20	24901-24903	or	_	
143-21	24904-24919	pharmacotherapy	_	
143-22	24919-24920	.	_	

#Text=These methods could be used to test the causal effects of increased inhibitory functioning on activation of reward circuitry.
144-1	24921-24926	These	_	
144-2	24927-24934	methods	_	
144-3	24935-24940	could	_	
144-4	24941-24943	be	_	
144-5	24944-24948	used	_	
144-6	24949-24951	to	_	
144-7	24952-24956	test	_	
144-8	24957-24960	the	_	
144-9	24961-24967	causal	_	
144-10	24968-24975	effects	_	
144-11	24976-24978	of	_	
144-12	24979-24988	increased	_	
144-13	24989-24999	inhibitory	_	
144-14	25000-25011	functioning	_	
144-15	25012-25014	on	_	
144-16	25015-25025	activation	_	
144-17	25026-25028	of	_	
144-18	25029-25035	reward	_	
144-19	25036-25045	circuitry	_	
144-20	25045-25046	.	_	

#Text=If, as hypothesized, enhanced prefrontal functioning dampens reward activation, then targeting inhibitory functioning could be a promising means of preventing drug abuse problems in at-risk individuals.
145-1	25047-25049	If	_	
145-2	25049-25050	,	_	
145-3	25051-25053	as	_	
145-4	25054-25066	hypothesized	_	
145-5	25066-25067	,	_	
145-6	25068-25076	enhanced	_	
145-7	25077-25087	prefrontal	_	
145-8	25088-25099	functioning	_	
145-9	25100-25107	dampens	_	
145-10	25108-25114	reward	_	
145-11	25115-25125	activation	_	
145-12	25125-25126	,	_	
145-13	25127-25131	then	_	
145-14	25132-25141	targeting	_	
145-15	25142-25152	inhibitory	_	
145-16	25153-25164	functioning	_	
145-17	25165-25170	could	_	
145-18	25171-25173	be	_	
145-19	25174-25175	a	_	
145-20	25176-25185	promising	_	
145-21	25186-25191	means	_	
145-22	25192-25194	of	_	
145-23	25195-25205	preventing	_	
145-24	25206-25210	drug	_	
145-25	25211-25216	abuse	_	
145-26	25217-25225	problems	_	
145-27	25226-25228	in	_	
145-28	25229-25236	at-risk	_	
145-29	25237-25248	individuals	_	
145-30	25248-25249	.	_	

#Text=A second potential explanation for the association between neural correlates of inhibition and reward is that the two are connected by an as-yet unidentified common mechanism, such as fewer striatal dopamine D2 receptors, which have been separately linked to both inhibition and reward.
146-1	25250-25251	A	_	
146-2	25252-25258	second	_	
146-3	25259-25268	potential	_	
146-4	25269-25280	explanation	_	
146-5	25281-25284	for	_	
146-6	25285-25288	the	_	
146-7	25289-25300	association	_	
146-8	25301-25308	between	_	
146-9	25309-25315	neural	_	
146-10	25316-25326	correlates	_	
146-11	25327-25329	of	_	
146-12	25330-25340	inhibition	_	
146-13	25341-25344	and	_	
146-14	25345-25351	reward	_	
146-15	25352-25354	is	_	
146-16	25355-25359	that	_	
146-17	25360-25363	the	_	
146-18	25364-25367	two	_	
146-19	25368-25371	are	_	
146-20	25372-25381	connected	_	
146-21	25382-25384	by	_	
146-22	25385-25387	an	_	
146-23	25388-25394	as-yet	_	
146-24	25395-25407	unidentified	_	
146-25	25408-25414	common	_	
146-26	25415-25424	mechanism	_	
146-27	25424-25425	,	_	
146-28	25426-25430	such	_	
146-29	25431-25433	as	_	
146-30	25434-25439	fewer	_	
146-31	25440-25448	striatal	_	
146-32	25449-25457	dopamine	_	
146-33	25458-25460	D2	_	
146-34	25461-25470	receptors	_	
146-35	25470-25471	,	_	
146-36	25472-25477	which	_	
146-37	25478-25482	have	_	
146-38	25483-25487	been	_	
146-39	25488-25498	separately	_	
146-40	25499-25505	linked	_	
146-41	25506-25508	to	_	
146-42	25509-25513	both	_	
146-43	25514-25524	inhibition	_	
146-44	25525-25528	and	_	
146-45	25529-25535	reward	_	
146-46	25535-25536	.	_	

#Text=Animals with fewer striatal D2 receptors commit more inhibitory errors on response inhibition tasks and self-administer greater amounts of stimulant drugs, suggesting a link between D2 receptor number and drug reward sensitivity.
147-1	25537-25544	Animals	_	
147-2	25545-25549	with	_	
147-3	25550-25555	fewer	_	
147-4	25556-25564	striatal	_	
147-5	25565-25567	D2	_	
147-6	25568-25577	receptors	_	
147-7	25578-25584	commit	_	
147-8	25585-25589	more	_	
147-9	25590-25600	inhibitory	_	
147-10	25601-25607	errors	_	
147-11	25608-25610	on	_	
147-12	25611-25619	response	_	
147-13	25620-25630	inhibition	_	
147-14	25631-25636	tasks	_	
147-15	25637-25640	and	_	
147-16	25641-25656	self-administer	_	
147-17	25657-25664	greater	_	
147-18	25665-25672	amounts	_	
147-19	25673-25675	of	_	
147-20	25676-25685	stimulant	_	
147-21	25686-25691	drugs	_	
147-22	25691-25692	,	_	
147-23	25693-25703	suggesting	_	
147-24	25704-25705	a	_	
147-25	25706-25710	link	_	
147-26	25711-25718	between	_	
147-27	25719-25721	D2	_	
147-28	25722-25730	receptor	_	
147-29	25731-25737	number	_	
147-30	25738-25741	and	_	
147-31	25742-25746	drug	_	
147-32	25747-25753	reward	_	
147-33	25754-25765	sensitivity	_	
147-34	25765-25766	.	_	

#Text=In humans, individuals with fewer striatal D2 receptors exhibit poorer inhibitory control and less brain activation during response inhibition and report greater positive subjective response to stimulant drugs and sweet tastes.
148-1	25767-25769	In	_	
148-2	25770-25776	humans	_	
148-3	25776-25777	,	_	
148-4	25778-25789	individuals	_	
148-5	25790-25794	with	_	
148-6	25795-25800	fewer	_	
148-7	25801-25809	striatal	_	
148-8	25810-25812	D2	_	
148-9	25813-25822	receptors	_	
148-10	25823-25830	exhibit	_	
148-11	25831-25837	poorer	_	
148-12	25838-25848	inhibitory	_	
148-13	25849-25856	control	_	
148-14	25857-25860	and	_	
148-15	25861-25865	less	_	
148-16	25866-25871	brain	_	
148-17	25872-25882	activation	_	
148-18	25883-25889	during	_	
148-19	25890-25898	response	_	
148-20	25899-25909	inhibition	_	
148-21	25910-25913	and	_	
148-22	25914-25920	report	_	
148-23	25921-25928	greater	_	
148-24	25929-25937	positive	_	
148-25	25938-25948	subjective	_	
148-26	25949-25957	response	_	
148-27	25958-25960	to	_	
148-28	25961-25970	stimulant	_	
148-29	25971-25976	drugs	_	
148-30	25977-25980	and	_	
148-31	25981-25986	sweet	_	
148-32	25987-25993	tastes	_	
148-33	25993-25994	.	_	

#Text=Thus, it could be that low levels of D2 receptors contribute to both low levels of brain engagement during inhibition and heightened engagement during reward.
149-1	25995-25999	Thus	_	
149-2	25999-26000	,	_	
149-3	26001-26003	it	_	
149-4	26004-26009	could	_	
149-5	26010-26012	be	_	
149-6	26013-26017	that	_	
149-7	26018-26021	low	_	
149-8	26022-26028	levels	_	
149-9	26029-26031	of	_	
149-10	26032-26034	D2	_	
149-11	26035-26044	receptors	_	
149-12	26045-26055	contribute	_	
149-13	26056-26058	to	_	
149-14	26059-26063	both	_	
149-15	26064-26067	low	_	
149-16	26068-26074	levels	_	
149-17	26075-26077	of	_	
149-18	26078-26083	brain	_	
149-19	26084-26094	engagement	_	
149-20	26095-26101	during	_	
149-21	26102-26112	inhibition	_	
149-22	26113-26116	and	_	
149-23	26117-26127	heightened	_	
149-24	26128-26138	engagement	_	
149-25	26139-26145	during	_	
149-26	26146-26152	reward	_	
149-27	26152-26153	.	_	

#Text=It will be important for future multimodal imaging studies to combine PET and fMRI to directly test associations between striatal D2 receptor availability and neural correlates of inhibition and reward.
150-1	26154-26156	It	_	
150-2	26157-26161	will	_	
150-3	26162-26164	be	_	
150-4	26165-26174	important	_	
150-5	26175-26178	for	_	
150-6	26179-26185	future	_	
150-7	26186-26196	multimodal	_	
150-8	26197-26204	imaging	_	
150-9	26205-26212	studies	_	
150-10	26213-26215	to	_	
150-11	26216-26223	combine	_	
150-12	26224-26227	PET	_	
150-13	26228-26231	and	_	
150-14	26232-26236	fMRI	_	
150-15	26237-26239	to	_	
150-16	26240-26248	directly	_	
150-17	26249-26253	test	_	
150-18	26254-26266	associations	_	
150-19	26267-26274	between	_	
150-20	26275-26283	striatal	_	
150-21	26284-26286	D2	_	
150-22	26287-26295	receptor	_	
150-23	26296-26308	availability	_	
150-24	26309-26312	and	_	
150-25	26313-26319	neural	_	
150-26	26320-26330	correlates	_	
150-27	26331-26333	of	_	
150-28	26334-26344	inhibition	_	
150-29	26345-26348	and	_	
150-30	26349-26355	reward	_	
150-31	26355-26356	.	_	

#Text=This study has some limitations.
151-1	26357-26361	This	_	
151-2	26362-26367	study	_	
151-3	26368-26371	has	_	
151-4	26372-26376	some	_	
151-5	26377-26388	limitations	_	
151-6	26388-26389	.	_	

#Text=First, this sample was comprised of healthy adults without addictive or impulse control disorders.
152-1	26390-26395	First	_	
152-2	26395-26396	,	_	
152-3	26397-26401	this	_	
152-4	26402-26408	sample	_	
152-5	26409-26412	was	_	
152-6	26413-26422	comprised	_	
152-7	26423-26425	of	_	
152-8	26426-26433	healthy	_	
152-9	26434-26440	adults	_	
152-10	26441-26448	without	_	
152-11	26449-26458	addictive	_	
152-12	26459-26461	or	_	
152-13	26462-26469	impulse	_	
152-14	26470-26477	control	_	
152-15	26478-26487	disorders	_	
152-16	26487-26488	.	_	

#Text=Without longitudinal follow-up data, we can only speculate about the associations between inhibition and reward as a predictor of addictive behaviors.
153-1	26489-26496	Without	_	
153-2	26497-26509	longitudinal	_	
153-3	26510-26519	follow-up	_	
153-4	26520-26524	data	_	
153-5	26524-26525	,	_	
153-6	26526-26528	we	_	
153-7	26529-26532	can	_	
153-8	26533-26537	only	_	
153-9	26538-26547	speculate	_	
153-10	26548-26553	about	_	
153-11	26554-26557	the	_	
153-12	26558-26570	associations	_	
153-13	26571-26578	between	_	
153-14	26579-26589	inhibition	_	
153-15	26590-26593	and	_	
153-16	26594-26600	reward	_	
153-17	26601-26603	as	_	
153-18	26604-26605	a	_	
153-19	26606-26615	predictor	_	
153-20	26616-26618	of	_	
153-21	26619-26628	addictive	_	
153-22	26629-26638	behaviors	_	
153-23	26638-26639	.	_	

#Text=Second, while our finding that the association is stronger in binge drinkers supports the idea that associations between inhibition and reward may be a prospective marker of risk, this finding also raises the possibility that the association in binge drinkers is a result of heavy alcohol consumption.
154-1	26640-26646	Second	_	
154-2	26646-26647	,	_	
154-3	26648-26653	while	_	
154-4	26654-26657	our	_	
154-5	26658-26665	finding	_	
154-6	26666-26670	that	_	
154-7	26671-26674	the	_	
154-8	26675-26686	association	_	
154-9	26687-26689	is	_	
154-10	26690-26698	stronger	_	
154-11	26699-26701	in	_	
154-12	26702-26707	binge	_	
154-13	26708-26716	drinkers	_	
154-14	26717-26725	supports	_	
154-15	26726-26729	the	_	
154-16	26730-26734	idea	_	
154-17	26735-26739	that	_	
154-18	26740-26752	associations	_	
154-19	26753-26760	between	_	
154-20	26761-26771	inhibition	_	
154-21	26772-26775	and	_	
154-22	26776-26782	reward	_	
154-23	26783-26786	may	_	
154-24	26787-26789	be	_	
154-25	26790-26791	a	_	
154-26	26792-26803	prospective	_	
154-27	26804-26810	marker	_	
154-28	26811-26813	of	_	
154-29	26814-26818	risk	_	
154-30	26818-26819	,	_	
154-31	26820-26824	this	_	
154-32	26825-26832	finding	_	
154-33	26833-26837	also	_	
154-34	26838-26844	raises	_	
154-35	26845-26848	the	_	
154-36	26849-26860	possibility	_	
154-37	26861-26865	that	_	
154-38	26866-26869	the	_	
154-39	26870-26881	association	_	
154-40	26882-26884	in	_	
154-41	26885-26890	binge	_	
154-42	26891-26899	drinkers	_	
154-43	26900-26902	is	_	
154-44	26903-26904	a	_	
154-45	26905-26911	result	_	
154-46	26912-26914	of	_	
154-47	26915-26920	heavy	_	
154-48	26921-26928	alcohol	_	
154-49	26929-26940	consumption	_	
154-50	26940-26941	.	_	

#Text=Again, longitudinal studies are needed to assess associations between inhibition and reward before the onset of any substance use to directly address this question.
155-1	26942-26947	Again	_	
155-2	26947-26948	,	_	
155-3	26949-26961	longitudinal	_	
155-4	26962-26969	studies	_	
155-5	26970-26973	are	_	
155-6	26974-26980	needed	_	
155-7	26981-26983	to	_	
155-8	26984-26990	assess	_	
155-9	26991-27003	associations	_	
155-10	27004-27011	between	_	
155-11	27012-27022	inhibition	_	
155-12	27023-27026	and	_	
155-13	27027-27033	reward	_	
155-14	27034-27040	before	_	
155-15	27041-27044	the	_	
155-16	27045-27050	onset	_	
155-17	27051-27053	of	_	
155-18	27054-27057	any	_	
155-19	27058-27067	substance	_	
155-20	27068-27071	use	_	
155-21	27072-27074	to	_	
155-22	27075-27083	directly	_	
155-23	27084-27091	address	_	
155-24	27092-27096	this	_	
155-25	27097-27105	question	_	
155-26	27105-27106	.	_	

#Text=Third, we probed activation of neural reward circuitry using monetary reward, yet hyperactivation of reward circuitry in addiction is often specific to drug- or disorder-related cues.
156-1	27107-27112	Third	_	
156-2	27112-27113	,	_	
156-3	27114-27116	we	_	
156-4	27117-27123	probed	_	
156-5	27124-27134	activation	_	
156-6	27135-27137	of	_	
156-7	27138-27144	neural	_	
156-8	27145-27151	reward	_	
156-9	27152-27161	circuitry	_	
156-10	27162-27167	using	_	
156-11	27168-27176	monetary	_	
156-12	27177-27183	reward	_	
156-13	27183-27184	,	_	
156-14	27185-27188	yet	_	
156-15	27189-27204	hyperactivation	_	
156-16	27205-27207	of	_	
156-17	27208-27214	reward	_	
156-18	27215-27224	circuitry	_	
156-19	27225-27227	in	_	
156-20	27228-27237	addiction	_	
156-21	27238-27240	is	_	
156-22	27241-27246	often	_	
156-23	27247-27255	specific	_	
156-24	27256-27258	to	_	
156-25	27259-27263	drug	_	
156-26	27263-27264	-	_	
156-27	27265-27267	or	_	
156-28	27268-27284	disorder-related	_	
156-29	27285-27289	cues	_	
156-30	27289-27290	.	_	

#Text=As such, it is not clear if our findings of responses to monetary reward generalize to responses to drug reward in addiction.
157-1	27291-27293	As	_	
157-2	27294-27298	such	_	
157-3	27298-27299	,	_	
157-4	27300-27302	it	_	
157-5	27303-27305	is	_	
157-6	27306-27309	not	_	
157-7	27310-27315	clear	_	
157-8	27316-27318	if	_	
157-9	27319-27322	our	_	
157-10	27323-27331	findings	_	
157-11	27332-27334	of	_	
157-12	27335-27344	responses	_	
157-13	27345-27347	to	_	
157-14	27348-27356	monetary	_	
157-15	27357-27363	reward	_	
157-16	27364-27374	generalize	_	
157-17	27375-27377	to	_	
157-18	27378-27387	responses	_	
157-19	27388-27390	to	_	
157-20	27391-27395	drug	_	
157-21	27396-27402	reward	_	
157-22	27403-27405	in	_	
157-23	27406-27415	addiction	_	
157-24	27415-27416	.	_	

#Text=Fourth, we did not include a behavioral measure of appetitive motivation, and the behavioral measure of response inhibition (SSRT) did not correlate with brain activity during response inhibition or reward.
158-1	27417-27423	Fourth	_	
158-2	27423-27424	,	_	
158-3	27425-27427	we	_	
158-4	27428-27431	did	_	
158-5	27432-27435	not	_	
158-6	27436-27443	include	_	
158-7	27444-27445	a	_	
158-8	27446-27456	behavioral	_	
158-9	27457-27464	measure	_	
158-10	27465-27467	of	_	
158-11	27468-27478	appetitive	_	
158-12	27479-27489	motivation	_	
158-13	27489-27490	,	_	
158-14	27491-27494	and	_	
158-15	27495-27498	the	_	
158-16	27499-27509	behavioral	_	
158-17	27510-27517	measure	_	
158-18	27518-27520	of	_	
158-19	27521-27529	response	_	
158-20	27530-27540	inhibition	_	
158-21	27541-27542	(	_	
158-22	27542-27546	SSRT	_	
158-23	27546-27547	)	_	
158-24	27548-27551	did	_	
158-25	27552-27555	not	_	
158-26	27556-27565	correlate	_	
158-27	27566-27570	with	_	
158-28	27571-27576	brain	_	
158-29	27577-27585	activity	_	
158-30	27586-27592	during	_	
158-31	27593-27601	response	_	
158-32	27602-27612	inhibition	_	
158-33	27613-27615	or	_	
158-34	27616-27622	reward	_	
158-35	27622-27623	.	_	

#Text=However, previous studies have also failed to observe robust correlations between SSRT and brain activation, likely due to the need for very large samples and sufficient power for voxelwise analyses.
159-1	27624-27631	However	_	
159-2	27631-27632	,	_	
159-3	27633-27641	previous	_	
159-4	27642-27649	studies	_	
159-5	27650-27654	have	_	
159-6	27655-27659	also	_	
159-7	27660-27666	failed	_	
159-8	27667-27669	to	_	
159-9	27670-27677	observe	_	
159-10	27678-27684	robust	_	
159-11	27685-27697	correlations	_	
159-12	27698-27705	between	_	
159-13	27706-27710	SSRT	_	
159-14	27711-27714	and	_	
159-15	27715-27720	brain	_	
159-16	27721-27731	activation	_	
159-17	27731-27732	,	_	
159-18	27733-27739	likely	_	
159-19	27740-27743	due	_	
159-20	27744-27746	to	_	
159-21	27747-27750	the	_	
159-22	27751-27755	need	_	
159-23	27756-27759	for	_	
159-24	27760-27764	very	_	
159-25	27765-27770	large	_	
159-26	27771-27778	samples	_	
159-27	27779-27782	and	_	
159-28	27783-27793	sufficient	_	
159-29	27794-27799	power	_	
159-30	27800-27803	for	_	
159-31	27804-27813	voxelwise	_	
159-32	27814-27822	analyses	_	
159-33	27822-27823	.	_	

#Text=Finally, this study did not include a resting state scan.
160-1	27824-27831	Finally	_	
160-2	27831-27832	,	_	
160-3	27833-27837	this	_	
160-4	27838-27843	study	_	
160-5	27844-27847	did	_	
160-6	27848-27851	not	_	
160-7	27852-27859	include	_	
160-8	27860-27861	a	_	
160-9	27862-27869	resting	_	
160-10	27870-27875	state	_	
160-11	27876-27880	scan	_	
160-12	27880-27881	.	_	

#Text=Future studies are needed that examine associations between inhibitory and reward circuitry when subjects are at rest, to determine whether these networks are coupled in the absence of any task manipulation.
161-1	27882-27888	Future	_	
161-2	27889-27896	studies	_	
161-3	27897-27900	are	_	
161-4	27901-27907	needed	_	
161-5	27908-27912	that	_	
161-6	27913-27920	examine	_	
161-7	27921-27933	associations	_	
161-8	27934-27941	between	_	
161-9	27942-27952	inhibitory	_	
161-10	27953-27956	and	_	
161-11	27957-27963	reward	_	
161-12	27964-27973	circuitry	_	
161-13	27974-27978	when	_	
161-14	27979-27987	subjects	_	
161-15	27988-27991	are	_	
161-16	27992-27994	at	_	
161-17	27995-27999	rest	_	
161-18	27999-28000	,	_	
161-19	28001-28003	to	_	
161-20	28004-28013	determine	_	
161-21	28014-28021	whether	_	
161-22	28022-28027	these	_	
161-23	28028-28036	networks	_	
161-24	28037-28040	are	_	
161-25	28041-28048	coupled	_	
161-26	28049-28051	in	_	
161-27	28052-28055	the	_	
161-28	28056-28063	absence	_	
161-29	28064-28066	of	_	
161-30	28067-28070	any	_	
161-31	28071-28075	task	_	
161-32	28076-28088	manipulation	_	
161-33	28088-28089	.	_	

#Text=In sum, this is the first study to show that individual differences in prefrontal engagement during response inhibition are related to individual differences in engagement of reward circuitry during receipt of monetary reward.
162-1	28090-28092	In	_	
162-2	28093-28096	sum	_	
162-3	28096-28097	,	_	
162-4	28098-28102	this	_	
162-5	28103-28105	is	_	
162-6	28106-28109	the	_	
162-7	28110-28115	first	_	
162-8	28116-28121	study	_	
162-9	28122-28124	to	_	
162-10	28125-28129	show	_	
162-11	28130-28134	that	_	
162-12	28135-28145	individual	_	
162-13	28146-28157	differences	_	
162-14	28158-28160	in	_	
162-15	28161-28171	prefrontal	_	
162-16	28172-28182	engagement	_	
162-17	28183-28189	during	_	
162-18	28190-28198	response	_	
162-19	28199-28209	inhibition	_	
162-20	28210-28213	are	_	
162-21	28214-28221	related	_	
162-22	28222-28224	to	_	
162-23	28225-28235	individual	_	
162-24	28236-28247	differences	_	
162-25	28248-28250	in	_	
162-26	28251-28261	engagement	_	
162-27	28262-28264	of	_	
162-28	28265-28271	reward	_	
162-29	28272-28281	circuitry	_	
162-30	28282-28288	during	_	
162-31	28289-28296	receipt	_	
162-32	28297-28299	of	_	
162-33	28300-28308	monetary	_	
162-34	28309-28315	reward	_	
162-35	28315-28316	.	_	

#Text=These findings have important implications for understanding risk for impulsive and addictive behaviors, particularly in individuals with compromised inhibitory functioning.
163-1	28317-28322	These	_	
163-2	28323-28331	findings	_	
163-3	28332-28336	have	_	
163-4	28337-28346	important	_	
163-5	28347-28359	implications	_	
163-6	28360-28363	for	_	
163-7	28364-28377	understanding	_	
163-8	28378-28382	risk	_	
163-9	28383-28386	for	_	
163-10	28387-28396	impulsive	_	
163-11	28397-28400	and	_	
163-12	28401-28410	addictive	_	
163-13	28411-28420	behaviors	_	
163-14	28420-28421	,	_	
163-15	28422-28434	particularly	_	
163-16	28435-28437	in	_	
163-17	28438-28449	individuals	_	
163-18	28450-28454	with	_	
163-19	28455-28466	compromised	_	
163-20	28467-28477	inhibitory	_	
163-21	28478-28489	functioning	_	
163-22	28489-28490	.	_	

#Text=It will be important for future longitudinal studies to examine interactions between inhibitory and reward functioning as prospective predictors of the onset and escalation of these disorders later in life.
164-1	28491-28493	It	_	
164-2	28494-28498	will	_	
164-3	28499-28501	be	_	
164-4	28502-28511	important	_	
164-5	28512-28515	for	_	
164-6	28516-28522	future	_	
164-7	28523-28535	longitudinal	_	
164-8	28536-28543	studies	_	
164-9	28544-28546	to	_	
164-10	28547-28554	examine	_	
164-11	28555-28567	interactions	_	
164-12	28568-28575	between	_	
164-13	28576-28586	inhibitory	_	
164-14	28587-28590	and	_	
164-15	28591-28597	reward	_	
164-16	28598-28609	functioning	_	
164-17	28610-28612	as	_	
164-18	28613-28624	prospective	_	
164-19	28625-28635	predictors	_	
164-20	28636-28638	of	_	
164-21	28639-28642	the	_	
164-22	28643-28648	onset	_	
164-23	28649-28652	and	_	
164-24	28653-28663	escalation	_	
164-25	28664-28666	of	_	
164-26	28667-28672	these	_	
164-27	28673-28682	disorders	_	
164-28	28683-28688	later	_	
164-29	28689-28691	in	_	
164-30	28692-28696	life	_	
164-31	28696-28697	.	_	

#Text=If, as hypothesized, poor inhibitory control mechanisms result in heightened sensitivity to reward, this will serve as an important target for prevention and treatment efforts in at-risk populations.
165-1	28698-28700	If	_	
165-2	28700-28701	,	_	
165-3	28702-28704	as	_	
165-4	28705-28717	hypothesized	_	
165-5	28717-28718	,	_	
165-6	28719-28723	poor	_	
165-7	28724-28734	inhibitory	_	
165-8	28735-28742	control	_	
165-9	28743-28753	mechanisms	_	
165-10	28754-28760	result	_	
165-11	28761-28763	in	_	
165-12	28764-28774	heightened	_	
165-13	28775-28786	sensitivity	_	
165-14	28787-28789	to	_	
165-15	28790-28796	reward	_	
165-16	28796-28797	,	_	
165-17	28798-28802	this	_	
165-18	28803-28807	will	_	
165-19	28808-28813	serve	_	
165-20	28814-28816	as	_	
165-21	28817-28819	an	_	
165-22	28820-28829	important	_	
165-23	28830-28836	target	_	
165-24	28837-28840	for	_	
165-25	28841-28851	prevention	_	
165-26	28852-28855	and	_	
165-27	28856-28865	treatment	_	
165-28	28866-28873	efforts	_	
165-29	28874-28876	in	_	
165-30	28877-28884	at-risk	_	
165-31	28885-28896	populations	_	
165-32	28896-28897	.	_	

#Text=Supplementary Material
#Text=This is a PDF file of an unedited manuscript that has been accepted for publication.
166-1	28898-28911	Supplementary	_	
166-2	28912-28920	Material	_	
166-3	28921-28925	This	_	
166-4	28926-28928	is	_	
166-5	28929-28930	a	_	
166-6	28931-28934	PDF	_	
166-7	28935-28939	file	_	
166-8	28940-28942	of	_	
166-9	28943-28945	an	_	
166-10	28946-28954	unedited	_	
166-11	28955-28965	manuscript	_	
166-12	28966-28970	that	_	
166-13	28971-28974	has	_	
166-14	28975-28979	been	_	
166-15	28980-28988	accepted	_	
166-16	28989-28992	for	_	
166-17	28993-29004	publication	_	
166-18	29004-29005	.	_	

#Text=As a service to our customers we are providing this early version of the manuscript.
167-1	29006-29008	As	_	
167-2	29009-29010	a	_	
167-3	29011-29018	service	_	
167-4	29019-29021	to	_	
167-5	29022-29025	our	_	
167-6	29026-29035	customers	_	
167-7	29036-29038	we	_	
167-8	29039-29042	are	_	
167-9	29043-29052	providing	_	
167-10	29053-29057	this	_	
167-11	29058-29063	early	_	
167-12	29064-29071	version	_	
167-13	29072-29074	of	_	
167-14	29075-29078	the	_	
167-15	29079-29089	manuscript	_	
167-16	29089-29090	.	_	

#Text=The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form.
168-1	29091-29094	The	_	
168-2	29095-29105	manuscript	_	
168-3	29106-29110	will	_	
168-4	29111-29118	undergo	_	
168-5	29119-29130	copyediting	_	
168-6	29130-29131	,	_	
168-7	29132-29143	typesetting	_	
168-8	29143-29144	,	_	
168-9	29145-29148	and	_	
168-10	29149-29155	review	_	
168-11	29156-29158	of	_	
168-12	29159-29162	the	_	
168-13	29163-29172	resulting	_	
168-14	29173-29178	proof	_	
168-15	29179-29185	before	_	
168-16	29186-29188	it	_	
168-17	29189-29191	is	_	
168-18	29192-29201	published	_	
168-19	29202-29204	in	_	
168-20	29205-29208	its	_	
168-21	29209-29214	final	_	
168-22	29215-29222	citable	_	
168-23	29223-29227	form	_	
168-24	29227-29228	.	_	

#Text=Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
169-1	29229-29235	Please	_	
169-2	29236-29240	note	_	
169-3	29241-29245	that	_	
169-4	29246-29252	during	_	
169-5	29253-29256	the	_	
169-6	29257-29267	production	_	
169-7	29268-29275	process	_	
169-8	29276-29282	errors	_	
169-9	29283-29286	may	_	
169-10	29287-29289	be	_	
169-11	29290-29300	discovered	_	
169-12	29301-29306	which	_	
169-13	29307-29312	could	_	
169-14	29313-29319	affect	_	
169-15	29320-29323	the	_	
169-16	29324-29331	content	_	
169-17	29331-29332	,	_	
169-18	29333-29336	and	_	
169-19	29337-29340	all	_	
169-20	29341-29346	legal	_	
169-21	29347-29358	disclaimers	_	
169-22	29359-29363	that	_	
169-23	29364-29369	apply	_	
169-24	29370-29372	to	_	
169-25	29373-29376	the	_	
169-26	29377-29384	journal	_	
169-27	29385-29392	pertain	_	
169-28	29392-29393	.	_	

#Text=Declarations of interest: none
#Text=References
#Text=Cortical and subcortical contributions to stop signal response inhibition: Role of the subthalamic nucleus
#Text=Inhibition and impulsivity: behavioral and neural basis of response control
#Text=Anticipatory reward processing in addicted populations: a focus on the monetary incentive delay task
#Text=Striatal activation and frontostriatal connectivity during non-drug reward anticipation in alcohol dependence
#Text=Right prefrontal and ventral striatum interactions underlying impulsive choice and impulsive responding
#Text=Liking, wanting, and the incentive-sensitization theory of addiction
#Text=Ventral striatal and medial prefrontal BOLD activation is correlated with reward-related electrocortical activity: A combined ERP and fMRI study
#Text=Brain correlates of response inhibition in Internet gaming disorder
#Text=Engagement of large-scale networks is related to individual differences in inhibitory control
#Text=Fronto-striatal functional connectivity during response inhibition in alcohol dependence
#Text=Preliminary evidence for disrupted nucleus accumbens reactivity and connectivity to reward in binge drinkers
#Text=Neural activation to monetary reward is associated with amphetamine reward sensitivity
#Text=Nucleus accumbens D2/3 receptors predict trait impulsivity and cocaine reinforcement
#Text=Similar hyporesponsiveness of the dorsomedial prefrontal cortex in problem gamblers and heavy smokers during an inhibitory control task
#Text=Impulsive choice and impulsive action predict vulnerability to distinct stages of nicotine seeking in rats
#Text=Motivated attention to cocaine and emotional cues in abstinent and current cocaine users-an ERP study
#Text=Neurobiological correlates of internet gaming disorder: Similarities to pathological gambling
#Text=Prefrontal response and frontostriatal functional connectivity to monetary reward in abstinent alcohol-dependent young adults
#Text=Event-related potential activity in the basal ganglia differentiates rewards from nonrewards: temporospatial principal components analysis and source localization of the feedback negativity
#Text=Cue-induced cocaine craving: neuroanatomical specificity for drug users and drug stimuli
#Text=Striatal dopamine D(2)/D(3) receptors mediate response inhibition and related activity in frontostriatal neural circuitry in humans
#Text=Drug addiction and its underlying neurobiological basis: neuroimaging evidence for the involvement of the frontal cortex
#Text=Dysfunction of the prefrontal cortex in addiction: neuroimaging findings and clinical implications
#Text=Neuroimaging risk markers for substance abuse: recent findings on inhibitory control and reward system functioning
#Text=Factors modulating neural reactivity to drug cues in addiction: a survey of human neuroimaging studies
#Text=Dissecting impulsivity and its relationships to drug addictions
#Text=Reward, interrupted: Inhibitory control and its relevance to addictions
#Text=Impulsivity resulting from frontostriatal dysfunction in drug abuse: implications for the control of behavior by reward-related stimuli
#Text=Family history of alcoholism interacts with alcohol to affect brain regions involved in behavioral inhibition
#Text=Does a shared neurobiology for foods and drugs of abuse contribute to extremes of food ingestion in anorexia and bulimia nervosa?
170-1	29394-29406	Declarations	_	
170-2	29407-29409	of	_	
170-3	29410-29418	interest	_	
170-4	29418-29419	:	_	
170-5	29420-29424	none	_	
170-6	29425-29435	References	_	
170-7	29436-29444	Cortical	_	
170-8	29445-29448	and	_	
170-9	29449-29460	subcortical	_	
170-10	29461-29474	contributions	_	
170-11	29475-29477	to	_	
170-12	29478-29482	stop	_	
170-13	29483-29489	signal	_	
170-14	29490-29498	response	_	
170-15	29499-29509	inhibition	_	
170-16	29509-29510	:	_	
170-17	29511-29515	Role	_	
170-18	29516-29518	of	_	
170-19	29519-29522	the	_	
170-20	29523-29534	subthalamic	_	
170-21	29535-29542	nucleus	_	
170-22	29543-29553	Inhibition	_	
170-23	29554-29557	and	_	
170-24	29558-29569	impulsivity	_	
170-25	29569-29570	:	_	
170-26	29571-29581	behavioral	_	
170-27	29582-29585	and	_	
170-28	29586-29592	neural	_	
170-29	29593-29598	basis	_	
170-30	29599-29601	of	_	
170-31	29602-29610	response	_	
170-32	29611-29618	control	_	
170-33	29619-29631	Anticipatory	_	
170-34	29632-29638	reward	_	
170-35	29639-29649	processing	_	
170-36	29650-29652	in	_	
170-37	29653-29661	addicted	_	
170-38	29662-29673	populations	_	
170-39	29673-29674	:	_	
170-40	29675-29676	a	_	
170-41	29677-29682	focus	_	
170-42	29683-29685	on	_	
170-43	29686-29689	the	_	
170-44	29690-29698	monetary	_	
170-45	29699-29708	incentive	_	
170-46	29709-29714	delay	_	
170-47	29715-29719	task	_	
170-48	29720-29728	Striatal	_	
170-49	29729-29739	activation	_	
170-50	29740-29743	and	_	
170-51	29744-29758	frontostriatal	_	
170-52	29759-29771	connectivity	_	
170-53	29772-29778	during	_	
170-54	29779-29787	non-drug	_	
170-55	29788-29794	reward	_	
170-56	29795-29807	anticipation	_	
170-57	29808-29810	in	_	
170-58	29811-29818	alcohol	_	
170-59	29819-29829	dependence	_	
170-60	29830-29835	Right	_	
170-61	29836-29846	prefrontal	_	
170-62	29847-29850	and	_	
170-63	29851-29858	ventral	_	
170-64	29859-29867	striatum	_	
170-65	29868-29880	interactions	_	
170-66	29881-29891	underlying	_	
170-67	29892-29901	impulsive	_	
170-68	29902-29908	choice	_	
170-69	29909-29912	and	_	
170-70	29913-29922	impulsive	_	
170-71	29923-29933	responding	_	
170-72	29934-29940	Liking	_	
170-73	29940-29941	,	_	
170-74	29942-29949	wanting	_	
170-75	29949-29950	,	_	
170-76	29951-29954	and	_	
170-77	29955-29958	the	_	
170-78	29959-29982	incentive-sensitization	_	
170-79	29983-29989	theory	_	
170-80	29990-29992	of	_	
170-81	29993-30002	addiction	_	
170-82	30003-30010	Ventral	_	
170-83	30011-30019	striatal	_	
170-84	30020-30023	and	_	
170-85	30024-30030	medial	_	
170-86	30031-30041	prefrontal	_	
170-87	30042-30046	BOLD	_	
170-88	30047-30057	activation	_	
170-89	30058-30060	is	_	
170-90	30061-30071	correlated	_	
170-91	30072-30076	with	_	
170-92	30077-30091	reward-related	_	
170-93	30092-30107	electrocortical	_	
170-94	30108-30116	activity	_	
170-95	30116-30117	:	_	
170-96	30118-30119	A	_	
170-97	30120-30128	combined	_	
170-98	30129-30132	ERP	_	
170-99	30133-30136	and	_	
170-100	30137-30141	fMRI	_	
170-101	30142-30147	study	_	
170-102	30148-30153	Brain	_	
170-103	30154-30164	correlates	_	
170-104	30165-30167	of	_	
170-105	30168-30176	response	_	
170-106	30177-30187	inhibition	_	
170-107	30188-30190	in	_	
170-108	30191-30199	Internet	_	
170-109	30200-30206	gaming	_	
170-110	30207-30215	disorder	_	
170-111	30216-30226	Engagement	_	
170-112	30227-30229	of	_	
170-113	30230-30241	large-scale	_	
170-114	30242-30250	networks	_	
170-115	30251-30253	is	_	
170-116	30254-30261	related	_	
170-117	30262-30264	to	_	
170-118	30265-30275	individual	_	
170-119	30276-30287	differences	_	
170-120	30288-30290	in	_	
170-121	30291-30301	inhibitory	_	
170-122	30302-30309	control	_	
170-123	30310-30325	Fronto-striatal	_	
170-124	30326-30336	functional	_	
170-125	30337-30349	connectivity	_	
170-126	30350-30356	during	_	
170-127	30357-30365	response	_	
170-128	30366-30376	inhibition	_	
170-129	30377-30379	in	_	
170-130	30380-30387	alcohol	_	
170-131	30388-30398	dependence	_	
170-132	30399-30410	Preliminary	_	
170-133	30411-30419	evidence	_	
170-134	30420-30423	for	_	
170-135	30424-30433	disrupted	_	
170-136	30434-30441	nucleus	_	
170-137	30442-30451	accumbens	_	
170-138	30452-30462	reactivity	_	
170-139	30463-30466	and	_	
170-140	30467-30479	connectivity	_	
170-141	30480-30482	to	_	
170-142	30483-30489	reward	_	
170-143	30490-30492	in	_	
170-144	30493-30498	binge	_	
170-145	30499-30507	drinkers	_	
170-146	30508-30514	Neural	_	
170-147	30515-30525	activation	_	
170-148	30526-30528	to	_	
170-149	30529-30537	monetary	_	
170-150	30538-30544	reward	_	
170-151	30545-30547	is	_	
170-152	30548-30558	associated	_	
170-153	30559-30563	with	_	
170-154	30564-30575	amphetamine	_	
170-155	30576-30582	reward	_	
170-156	30583-30594	sensitivity	_	
170-157	30595-30602	Nucleus	_	
170-158	30603-30612	accumbens	_	
170-159	30613-30615	D2	_	
170-160	30615-30616	/	_	
170-161	30616-30617	3	_	
170-162	30618-30627	receptors	_	
170-163	30628-30635	predict	_	
170-164	30636-30641	trait	_	
170-165	30642-30653	impulsivity	_	
170-166	30654-30657	and	_	
170-167	30658-30665	cocaine	_	
170-168	30666-30679	reinforcement	_	
170-169	30680-30687	Similar	_	
170-170	30688-30706	hyporesponsiveness	_	
170-171	30707-30709	of	_	
170-172	30710-30713	the	_	
170-173	30714-30725	dorsomedial	_	
170-174	30726-30736	prefrontal	_	
170-175	30737-30743	cortex	_	
170-176	30744-30746	in	_	
170-177	30747-30754	problem	_	
170-178	30755-30763	gamblers	_	
170-179	30764-30767	and	_	
170-180	30768-30773	heavy	_	
170-181	30774-30781	smokers	_	
170-182	30782-30788	during	_	
170-183	30789-30791	an	_	
170-184	30792-30802	inhibitory	_	
170-185	30803-30810	control	_	
170-186	30811-30815	task	_	
170-187	30816-30825	Impulsive	_	
170-188	30826-30832	choice	_	
170-189	30833-30836	and	_	
170-190	30837-30846	impulsive	_	
170-191	30847-30853	action	_	
170-192	30854-30861	predict	_	
170-193	30862-30875	vulnerability	_	
170-194	30876-30878	to	_	
170-195	30879-30887	distinct	_	
170-196	30888-30894	stages	_	
170-197	30895-30897	of	_	
170-198	30898-30906	nicotine	_	
170-199	30907-30914	seeking	_	
170-200	30915-30917	in	_	
170-201	30918-30922	rats	_	
170-202	30923-30932	Motivated	_	
170-203	30933-30942	attention	_	
170-204	30943-30945	to	_	
170-205	30946-30953	cocaine	_	
170-206	30954-30957	and	_	
170-207	30958-30967	emotional	_	
170-208	30968-30972	cues	_	
170-209	30973-30975	in	_	
170-210	30976-30985	abstinent	_	
170-211	30986-30989	and	_	
170-212	30990-30997	current	_	
170-213	30998-31005	cocaine	_	
170-214	31006-31014	users-an	_	
170-215	31015-31018	ERP	_	
170-216	31019-31024	study	_	
170-217	31025-31040	Neurobiological	_	
170-218	31041-31051	correlates	_	
170-219	31052-31054	of	_	
170-220	31055-31063	internet	_	
170-221	31064-31070	gaming	_	
170-222	31071-31079	disorder	_	
170-223	31079-31080	:	_	
170-224	31081-31093	Similarities	_	
170-225	31094-31096	to	_	
170-226	31097-31109	pathological	_	
170-227	31110-31118	gambling	_	
170-228	31119-31129	Prefrontal	_	
170-229	31130-31138	response	_	
170-230	31139-31142	and	_	
170-231	31143-31157	frontostriatal	_	
170-232	31158-31168	functional	_	
170-233	31169-31181	connectivity	_	
170-234	31182-31184	to	_	
170-235	31185-31193	monetary	_	
170-236	31194-31200	reward	_	
170-237	31201-31203	in	_	
170-238	31204-31213	abstinent	_	
170-239	31214-31231	alcohol-dependent	_	
170-240	31232-31237	young	_	
170-241	31238-31244	adults	_	
170-242	31245-31258	Event-related	_	
170-243	31259-31268	potential	_	
170-244	31269-31277	activity	_	
170-245	31278-31280	in	_	
170-246	31281-31284	the	_	
170-247	31285-31290	basal	_	
170-248	31291-31298	ganglia	_	
170-249	31299-31313	differentiates	_	
170-250	31314-31321	rewards	_	
170-251	31322-31326	from	_	
170-252	31327-31337	nonrewards	_	
170-253	31337-31338	:	_	
170-254	31339-31353	temporospatial	_	
170-255	31354-31363	principal	_	
170-256	31364-31374	components	_	
170-257	31375-31383	analysis	_	
170-258	31384-31387	and	_	
170-259	31388-31394	source	_	
170-260	31395-31407	localization	_	
170-261	31408-31410	of	_	
170-262	31411-31414	the	_	
170-263	31415-31423	feedback	_	
170-264	31424-31434	negativity	_	
170-265	31435-31446	Cue-induced	_	
170-266	31447-31454	cocaine	_	
170-267	31455-31462	craving	_	
170-268	31462-31463	:	_	
170-269	31464-31479	neuroanatomical	_	
170-270	31480-31491	specificity	_	
170-271	31492-31495	for	_	
170-272	31496-31500	drug	_	
170-273	31501-31506	users	_	
170-274	31507-31510	and	_	
170-275	31511-31515	drug	_	
170-276	31516-31523	stimuli	_	
170-277	31524-31532	Striatal	_	
170-278	31533-31541	dopamine	_	
170-279	31542-31543	D	_	
170-280	31543-31544	(	_	
170-281	31544-31545	2	_	
170-282	31545-31546	)	_	
170-283	31546-31547	/	_	
170-284	31547-31548	D	_	
170-285	31548-31549	(	_	
170-286	31549-31550	3	_	
170-287	31550-31551	)	_	
170-288	31552-31561	receptors	_	
170-289	31562-31569	mediate	_	
170-290	31570-31578	response	_	
170-291	31579-31589	inhibition	_	
170-292	31590-31593	and	_	
170-293	31594-31601	related	_	
170-294	31602-31610	activity	_	
170-295	31611-31613	in	_	
170-296	31614-31628	frontostriatal	_	
170-297	31629-31635	neural	_	
170-298	31636-31645	circuitry	_	
170-299	31646-31648	in	_	
170-300	31649-31655	humans	_	
170-301	31656-31660	Drug	_	
170-302	31661-31670	addiction	_	
170-303	31671-31674	and	_	
170-304	31675-31678	its	_	
170-305	31679-31689	underlying	_	
170-306	31690-31705	neurobiological	_	
170-307	31706-31711	basis	_	
170-308	31711-31712	:	_	
170-309	31713-31725	neuroimaging	_	
170-310	31726-31734	evidence	_	
170-311	31735-31738	for	_	
170-312	31739-31742	the	_	
170-313	31743-31754	involvement	_	
170-314	31755-31757	of	_	
170-315	31758-31761	the	_	
170-316	31762-31769	frontal	_	
170-317	31770-31776	cortex	_	
170-318	31777-31788	Dysfunction	_	
170-319	31789-31791	of	_	
170-320	31792-31795	the	_	
170-321	31796-31806	prefrontal	_	
170-322	31807-31813	cortex	_	
170-323	31814-31816	in	_	
170-324	31817-31826	addiction	_	
170-325	31826-31827	:	_	
170-326	31828-31840	neuroimaging	_	
170-327	31841-31849	findings	_	
170-328	31850-31853	and	_	
170-329	31854-31862	clinical	_	
170-330	31863-31875	implications	_	
170-331	31876-31888	Neuroimaging	_	
170-332	31889-31893	risk	_	
170-333	31894-31901	markers	_	
170-334	31902-31905	for	_	
170-335	31906-31915	substance	_	
170-336	31916-31921	abuse	_	
170-337	31921-31922	:	_	
170-338	31923-31929	recent	_	
170-339	31930-31938	findings	_	
170-340	31939-31941	on	_	
170-341	31942-31952	inhibitory	_	
170-342	31953-31960	control	_	
170-343	31961-31964	and	_	
170-344	31965-31971	reward	_	
170-345	31972-31978	system	_	
170-346	31979-31990	functioning	_	
170-347	31991-31998	Factors	_	
170-348	31999-32009	modulating	_	
170-349	32010-32016	neural	_	
170-350	32017-32027	reactivity	_	
170-351	32028-32030	to	_	
170-352	32031-32035	drug	_	
170-353	32036-32040	cues	_	
170-354	32041-32043	in	_	
170-355	32044-32053	addiction	_	
170-356	32053-32054	:	_	
170-357	32055-32056	a	_	
170-358	32057-32063	survey	_	
170-359	32064-32066	of	_	
170-360	32067-32072	human	_	
170-361	32073-32085	neuroimaging	_	
170-362	32086-32093	studies	_	
170-363	32094-32104	Dissecting	_	
170-364	32105-32116	impulsivity	_	
170-365	32117-32120	and	_	
170-366	32121-32124	its	_	
170-367	32125-32138	relationships	_	
170-368	32139-32141	to	_	
170-369	32142-32146	drug	_	
170-370	32147-32157	addictions	_	
170-371	32158-32164	Reward	_	
170-372	32164-32165	,	_	
170-373	32166-32177	interrupted	_	
170-374	32177-32178	:	_	
170-375	32179-32189	Inhibitory	_	
170-376	32190-32197	control	_	
170-377	32198-32201	and	_	
170-378	32202-32205	its	_	
170-379	32206-32215	relevance	_	
170-380	32216-32218	to	_	
170-381	32219-32229	addictions	_	
170-382	32230-32241	Impulsivity	_	
170-383	32242-32251	resulting	_	
170-384	32252-32256	from	_	
170-385	32257-32271	frontostriatal	_	
170-386	32272-32283	dysfunction	_	
170-387	32284-32286	in	_	
170-388	32287-32291	drug	_	
170-389	32292-32297	abuse	_	
170-390	32297-32298	:	_	
170-391	32299-32311	implications	_	
170-392	32312-32315	for	_	
170-393	32316-32319	the	_	
170-394	32320-32327	control	_	
170-395	32328-32330	of	_	
170-396	32331-32339	behavior	_	
170-397	32340-32342	by	_	
170-398	32343-32357	reward-related	_	
170-399	32358-32365	stimuli	_	
170-400	32366-32372	Family	_	
170-401	32373-32380	history	_	
170-402	32381-32383	of	_	
170-403	32384-32394	alcoholism	_	
170-404	32395-32404	interacts	_	
170-405	32405-32409	with	_	
170-406	32410-32417	alcohol	_	
170-407	32418-32420	to	_	
170-408	32421-32427	affect	_	
170-409	32428-32433	brain	_	
170-410	32434-32441	regions	_	
170-411	32442-32450	involved	_	
170-412	32451-32453	in	_	
170-413	32454-32464	behavioral	_	
170-414	32465-32475	inhibition	_	
170-415	32476-32480	Does	_	
170-416	32481-32482	a	_	
170-417	32483-32489	shared	_	
170-418	32490-32502	neurobiology	_	
170-419	32503-32506	for	_	
170-420	32507-32512	foods	_	
170-421	32513-32516	and	_	
170-422	32517-32522	drugs	_	
170-423	32523-32525	of	_	
170-424	32526-32531	abuse	_	
170-425	32532-32542	contribute	_	
170-426	32543-32545	to	_	
170-427	32546-32554	extremes	_	
170-428	32555-32557	of	_	
170-429	32558-32562	food	_	
170-430	32563-32572	ingestion	_	
170-431	32573-32575	in	_	
170-432	32576-32584	anorexia	_	
170-433	32585-32588	and	_	
170-434	32589-32596	bulimia	_	
170-435	32597-32604	nervosa	_	
170-436	32604-32605	?	_	

#Text=Brain activation for response inhibition under gaming cue distraction in internet gaming disorder
#Text=Impulsivity and inhibitory control
#Text=Systematic review of ERP and fMRI studies investigating inhibitory control and error processing in people with substance dependence and behavioural addictions
#Text=Adolescents’ fMRI activation to a response inhibition task predicts future substance use
#Text=An fMRI study of self-regulatory control and conflict resolution in adolescents with bulimia nervosa
#Text=Deficient activity in the neural systems that mediate self-regulatory control in bulimia nervosa
#Text=Positron emission tomography imaging studies of dopamine receptors in primate models of addiction
#Text=Neural activation during inhibition predicts initiation of substance use in adolescence
#Text=Sweet dopamine: sucrose preferences relate differentially to striatal D2 receptor binding and age in obesity
#Text=Spurious but systematic correlations in functional connectivity MRI networks arise from subject motion
#Text=Striatal D1- and D2-type dopamine receptors are linked to motor response inhibition in human subjects
#Text=Functional neuroimaging studies of alcohol cue reactivity: a quantitative meta-analysis and systematic review
#Text=Effects of modafinil on neural correlates of response inhibition in alcohol-dependent patients
#Text=Adolescent brain development and underage drinking in the United States: identifying risks of alcohol use in college populations
#Text=
#Text=Response inhibition and addiction medicine: from use to abstinence
#Text=Striatocortical pathway dysfunction in addiction and obesity: differences and similarities
#Text=Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain
#Text=Prediction of reinforcing responses to psychostimulants in humans by brain dopamine D2 receptor levels
#Text=Brain DA D2 receptors predict reinforcing effects of stimulants in humans: replication study
#Text=Effects of rTMS of pre-supplementary motor area on fronto basal ganglia network activity during stop-signal task
#Text=Associations between regional brain physiology and trait impulsivity, motor inhibition, and impaired control over drinking
#Text=Associations between behavioral and neural correlates of inhibitory control and amphetamine reward sensitivity
#Text=Sweet taste liking is associated with subjective response to amphetamine in women but not men
#Text=A longitudinal examination of adolescent response inhibition: neural differences before and after the initiation of heavy drinking
#Text=Neuropsychosocial profiles of current and future adolescent alcohol misusers
#Text=PreSMA stimulation changes task-free functional connectivity in the fronto-basal-ganglia that correlates with response inhibition efficiency
#Text=Large-scale automated synthesis of human functional neuroimaging data
#Text=(A) Brain activation during receipt of monetary reward (Doors task: Win>Loss) in left VS.
171-1	32606-32611	Brain	_	
171-2	32612-32622	activation	_	
171-3	32623-32626	for	_	
171-4	32627-32635	response	_	
171-5	32636-32646	inhibition	_	
171-6	32647-32652	under	_	
171-7	32653-32659	gaming	_	
171-8	32660-32663	cue	_	
171-9	32664-32675	distraction	_	
171-10	32676-32678	in	_	
171-11	32679-32687	internet	_	
171-12	32688-32694	gaming	_	
171-13	32695-32703	disorder	_	
171-14	32704-32715	Impulsivity	_	
171-15	32716-32719	and	_	
171-16	32720-32730	inhibitory	_	
171-17	32731-32738	control	_	
171-18	32739-32749	Systematic	_	
171-19	32750-32756	review	_	
171-20	32757-32759	of	_	
171-21	32760-32763	ERP	_	
171-22	32764-32767	and	_	
171-23	32768-32772	fMRI	_	
171-24	32773-32780	studies	_	
171-25	32781-32794	investigating	_	
171-26	32795-32805	inhibitory	_	
171-27	32806-32813	control	_	
171-28	32814-32817	and	_	
171-29	32818-32823	error	_	
171-30	32824-32834	processing	_	
171-31	32835-32837	in	_	
171-32	32838-32844	people	_	
171-33	32845-32849	with	_	
171-34	32850-32859	substance	_	
171-35	32860-32870	dependence	_	
171-36	32871-32874	and	_	
171-37	32875-32886	behavioural	_	
171-38	32887-32897	addictions	_	
171-39	32898-32909	Adolescents	_	
171-40	32909-32910	’	_	
171-41	32911-32915	fMRI	_	
171-42	32916-32926	activation	_	
171-43	32927-32929	to	_	
171-44	32930-32931	a	_	
171-45	32932-32940	response	_	
171-46	32941-32951	inhibition	_	
171-47	32952-32956	task	_	
171-48	32957-32965	predicts	_	
171-49	32966-32972	future	_	
171-50	32973-32982	substance	_	
171-51	32983-32986	use	_	
171-52	32987-32989	An	_	
171-53	32990-32994	fMRI	_	
171-54	32995-33000	study	_	
171-55	33001-33003	of	_	
171-56	33004-33019	self-regulatory	_	
171-57	33020-33027	control	_	
171-58	33028-33031	and	_	
171-59	33032-33040	conflict	_	
171-60	33041-33051	resolution	_	
171-61	33052-33054	in	_	
171-62	33055-33066	adolescents	_	
171-63	33067-33071	with	_	
171-64	33072-33079	bulimia	_	
171-65	33080-33087	nervosa	_	
171-66	33088-33097	Deficient	_	
171-67	33098-33106	activity	_	
171-68	33107-33109	in	_	
171-69	33110-33113	the	_	
171-70	33114-33120	neural	_	
171-71	33121-33128	systems	_	
171-72	33129-33133	that	_	
171-73	33134-33141	mediate	_	
171-74	33142-33157	self-regulatory	_	
171-75	33158-33165	control	_	
171-76	33166-33168	in	_	
171-77	33169-33176	bulimia	_	
171-78	33177-33184	nervosa	_	
171-79	33185-33193	Positron	_	
171-80	33194-33202	emission	_	
171-81	33203-33213	tomography	_	
171-82	33214-33221	imaging	_	
171-83	33222-33229	studies	_	
171-84	33230-33232	of	_	
171-85	33233-33241	dopamine	_	
171-86	33242-33251	receptors	_	
171-87	33252-33254	in	_	
171-88	33255-33262	primate	_	
171-89	33263-33269	models	_	
171-90	33270-33272	of	_	
171-91	33273-33282	addiction	_	
171-92	33283-33289	Neural	_	
171-93	33290-33300	activation	_	
171-94	33301-33307	during	_	
171-95	33308-33318	inhibition	_	
171-96	33319-33327	predicts	_	
171-97	33328-33338	initiation	_	
171-98	33339-33341	of	_	
171-99	33342-33351	substance	_	
171-100	33352-33355	use	_	
171-101	33356-33358	in	_	
171-102	33359-33370	adolescence	_	
171-103	33371-33376	Sweet	_	
171-104	33377-33385	dopamine	_	
171-105	33385-33386	:	_	
171-106	33387-33394	sucrose	_	
171-107	33395-33406	preferences	_	
171-108	33407-33413	relate	_	
171-109	33414-33428	differentially	_	
171-110	33429-33431	to	_	
171-111	33432-33440	striatal	_	
171-112	33441-33443	D2	_	
171-113	33444-33452	receptor	_	
171-114	33453-33460	binding	_	
171-115	33461-33464	and	_	
171-116	33465-33468	age	_	
171-117	33469-33471	in	_	
171-118	33472-33479	obesity	_	
171-119	33480-33488	Spurious	_	
171-120	33489-33492	but	_	
171-121	33493-33503	systematic	_	
171-122	33504-33516	correlations	_	
171-123	33517-33519	in	_	
171-124	33520-33530	functional	_	
171-125	33531-33543	connectivity	_	
171-126	33544-33547	MRI	_	
171-127	33548-33556	networks	_	
171-128	33557-33562	arise	_	
171-129	33563-33567	from	_	
171-130	33568-33575	subject	_	
171-131	33576-33582	motion	_	
171-132	33583-33591	Striatal	_	
171-133	33592-33594	D1	_	
171-134	33594-33595	-	_	
171-135	33596-33599	and	_	
171-136	33600-33602	D2	_	
171-137	33602-33603	-	_	
171-138	33603-33607	type	_	
171-139	33608-33616	dopamine	_	
171-140	33617-33626	receptors	_	
171-141	33627-33630	are	_	
171-142	33631-33637	linked	_	
171-143	33638-33640	to	_	
171-144	33641-33646	motor	_	
171-145	33647-33655	response	_	
171-146	33656-33666	inhibition	_	
171-147	33667-33669	in	_	
171-148	33670-33675	human	_	
171-149	33676-33684	subjects	_	
171-150	33685-33695	Functional	_	
171-151	33696-33708	neuroimaging	_	
171-152	33709-33716	studies	_	
171-153	33717-33719	of	_	
171-154	33720-33727	alcohol	_	
171-155	33728-33731	cue	_	
171-156	33732-33742	reactivity	_	
171-157	33742-33743	:	_	
171-158	33744-33745	a	_	
171-159	33746-33758	quantitative	_	
171-160	33759-33772	meta-analysis	_	
171-161	33773-33776	and	_	
171-162	33777-33787	systematic	_	
171-163	33788-33794	review	_	
171-164	33795-33802	Effects	_	
171-165	33803-33805	of	_	
171-166	33806-33815	modafinil	_	
171-167	33816-33818	on	_	
171-168	33819-33825	neural	_	
171-169	33826-33836	correlates	_	
171-170	33837-33839	of	_	
171-171	33840-33848	response	_	
171-172	33849-33859	inhibition	_	
171-173	33860-33862	in	_	
171-174	33863-33880	alcohol-dependent	_	
171-175	33881-33889	patients	_	
171-176	33890-33900	Adolescent	_	
171-177	33901-33906	brain	_	
171-178	33907-33918	development	_	
171-179	33919-33922	and	_	
171-180	33923-33931	underage	_	
171-181	33932-33940	drinking	_	
171-182	33941-33943	in	_	
171-183	33944-33947	the	_	
171-184	33948-33954	United	_	
171-185	33955-33961	States	_	
171-186	33961-33962	:	_	
171-187	33963-33974	identifying	_	
171-188	33975-33980	risks	_	
171-189	33981-33983	of	_	
171-190	33984-33991	alcohol	_	
171-191	33992-33995	use	_	
171-192	33996-33998	in	_	
171-193	33999-34006	college	_	
171-194	34007-34018	populations	_	
171-195	34020-34028	Response	_	
171-196	34029-34039	inhibition	_	
171-197	34040-34043	and	_	
171-198	34044-34053	addiction	_	
171-199	34054-34062	medicine	_	
171-200	34062-34063	:	_	
171-201	34064-34068	from	_	
171-202	34069-34072	use	_	
171-203	34073-34075	to	_	
171-204	34076-34086	abstinence	_	
171-205	34087-34102	Striatocortical	_	
171-206	34103-34110	pathway	_	
171-207	34111-34122	dysfunction	_	
171-208	34123-34125	in	_	
171-209	34126-34135	addiction	_	
171-210	34136-34139	and	_	
171-211	34140-34147	obesity	_	
171-212	34147-34148	:	_	
171-213	34149-34160	differences	_	
171-214	34161-34164	and	_	
171-215	34165-34177	similarities	_	
171-216	34178-34187	Automated	_	
171-217	34188-34198	anatomical	_	
171-218	34199-34207	labeling	_	
171-219	34208-34210	of	_	
171-220	34211-34222	activations	_	
171-221	34223-34225	in	_	
171-222	34226-34229	SPM	_	
171-223	34230-34235	using	_	
171-224	34236-34237	a	_	
171-225	34238-34249	macroscopic	_	
171-226	34250-34260	anatomical	_	
171-227	34261-34273	parcellation	_	
171-228	34274-34276	of	_	
171-229	34277-34280	the	_	
171-230	34281-34284	MNI	_	
171-231	34285-34288	MRI	_	
171-232	34289-34303	single-subject	_	
171-233	34304-34309	brain	_	
171-234	34310-34320	Prediction	_	
171-235	34321-34323	of	_	
171-236	34324-34335	reinforcing	_	
171-237	34336-34345	responses	_	
171-238	34346-34348	to	_	
171-239	34349-34365	psychostimulants	_	
171-240	34366-34368	in	_	
171-241	34369-34375	humans	_	
171-242	34376-34378	by	_	
171-243	34379-34384	brain	_	
171-244	34385-34393	dopamine	_	
171-245	34394-34396	D2	_	
171-246	34397-34405	receptor	_	
171-247	34406-34412	levels	_	
171-248	34413-34418	Brain	_	
171-249	34419-34421	DA	_	
171-250	34422-34424	D2	_	
171-251	34425-34434	receptors	_	
171-252	34435-34442	predict	_	
171-253	34443-34454	reinforcing	_	
171-254	34455-34462	effects	_	
171-255	34463-34465	of	_	
171-256	34466-34476	stimulants	_	
171-257	34477-34479	in	_	
171-258	34480-34486	humans	_	
171-259	34486-34487	:	_	
171-260	34488-34499	replication	_	
171-261	34500-34505	study	_	
171-262	34506-34513	Effects	_	
171-263	34514-34516	of	_	
171-264	34517-34521	rTMS	_	
171-265	34522-34524	of	_	
171-266	34525-34542	pre-supplementary	_	
171-267	34543-34548	motor	_	
171-268	34549-34553	area	_	
171-269	34554-34556	on	_	
171-270	34557-34563	fronto	_	
171-271	34564-34569	basal	_	
171-272	34570-34577	ganglia	_	
171-273	34578-34585	network	_	
171-274	34586-34594	activity	_	
171-275	34595-34601	during	_	
171-276	34602-34613	stop-signal	_	
171-277	34614-34618	task	_	
171-278	34619-34631	Associations	_	
171-279	34632-34639	between	_	
171-280	34640-34648	regional	_	
171-281	34649-34654	brain	_	
171-282	34655-34665	physiology	_	
171-283	34666-34669	and	_	
171-284	34670-34675	trait	_	
171-285	34676-34687	impulsivity	_	
171-286	34687-34688	,	_	
171-287	34689-34694	motor	_	
171-288	34695-34705	inhibition	_	
171-289	34705-34706	,	_	
171-290	34707-34710	and	_	
171-291	34711-34719	impaired	_	
171-292	34720-34727	control	_	
171-293	34728-34732	over	_	
171-294	34733-34741	drinking	_	
171-295	34742-34754	Associations	_	
171-296	34755-34762	between	_	
171-297	34763-34773	behavioral	_	
171-298	34774-34777	and	_	
171-299	34778-34784	neural	_	
171-300	34785-34795	correlates	_	
171-301	34796-34798	of	_	
171-302	34799-34809	inhibitory	_	
171-303	34810-34817	control	_	
171-304	34818-34821	and	_	
171-305	34822-34833	amphetamine	_	
171-306	34834-34840	reward	_	
171-307	34841-34852	sensitivity	_	
171-308	34853-34858	Sweet	_	
171-309	34859-34864	taste	_	
171-310	34865-34871	liking	_	
171-311	34872-34874	is	_	
171-312	34875-34885	associated	_	
171-313	34886-34890	with	_	
171-314	34891-34901	subjective	_	
171-315	34902-34910	response	_	
171-316	34911-34913	to	_	
171-317	34914-34925	amphetamine	_	
171-318	34926-34928	in	_	
171-319	34929-34934	women	_	
171-320	34935-34938	but	_	
171-321	34939-34942	not	_	
171-322	34943-34946	men	_	
171-323	34947-34948	A	_	
171-324	34949-34961	longitudinal	_	
171-325	34962-34973	examination	_	
171-326	34974-34976	of	_	
171-327	34977-34987	adolescent	_	
171-328	34988-34996	response	_	
171-329	34997-35007	inhibition	_	
171-330	35007-35008	:	_	
171-331	35009-35015	neural	_	
171-332	35016-35027	differences	_	
171-333	35028-35034	before	_	
171-334	35035-35038	and	_	
171-335	35039-35044	after	_	
171-336	35045-35048	the	_	
171-337	35049-35059	initiation	_	
171-338	35060-35062	of	_	
171-339	35063-35068	heavy	_	
171-340	35069-35077	drinking	_	
171-341	35078-35095	Neuropsychosocial	_	
171-342	35096-35104	profiles	_	
171-343	35105-35107	of	_	
171-344	35108-35115	current	_	
171-345	35116-35119	and	_	
171-346	35120-35126	future	_	
171-347	35127-35137	adolescent	_	
171-348	35138-35145	alcohol	_	
171-349	35146-35154	misusers	_	
171-350	35155-35161	PreSMA	_	
171-351	35162-35173	stimulation	_	
171-352	35174-35181	changes	_	
171-353	35182-35191	task-free	_	
171-354	35192-35202	functional	_	
171-355	35203-35215	connectivity	_	
171-356	35216-35218	in	_	
171-357	35219-35222	the	_	
171-358	35223-35243	fronto-basal-ganglia	_	
171-359	35244-35248	that	_	
171-360	35249-35259	correlates	_	
171-361	35260-35264	with	_	
171-362	35265-35273	response	_	
171-363	35274-35284	inhibition	_	
171-364	35285-35295	efficiency	_	
171-365	35296-35307	Large-scale	_	
171-366	35308-35317	automated	_	
171-367	35318-35327	synthesis	_	
171-368	35328-35330	of	_	
171-369	35331-35336	human	_	
171-370	35337-35347	functional	_	
171-371	35348-35360	neuroimaging	_	
171-372	35361-35365	data	_	
171-373	35366-35367	(	_	
171-374	35367-35368	A	_	
171-375	35368-35369	)	_	
171-376	35370-35375	Brain	_	
171-377	35376-35386	activation	_	
171-378	35387-35393	during	_	
171-379	35394-35401	receipt	_	
171-380	35402-35404	of	_	
171-381	35405-35413	monetary	_	
171-382	35414-35420	reward	_	
171-383	35421-35422	(	_	
171-384	35422-35427	Doors	_	
171-385	35428-35432	task	_	
171-386	35432-35433	:	_	
171-387	35434-35437	Win	_	
171-388	35437-35438	>	_	
171-389	35438-35442	Loss	_	
171-390	35442-35443	)	_	
171-391	35444-35446	in	_	
171-392	35447-35451	left	_	
171-393	35452-35454	VS	_	
171-394	35454-35455	.	_	

#Text=Significant peak activation was observed at the [−6 18 −2] MNI coordinate after correcting for family wise error (pFWE < 0.05) within the reward mask.
172-1	35456-35467	Significant	_	
172-2	35468-35472	peak	_	
172-3	35473-35483	activation	_	
172-4	35484-35487	was	_	
172-5	35488-35496	observed	_	
172-6	35497-35499	at	_	
172-7	35500-35503	the	_	
172-8	35504-35505	[	_	
172-9	35505-35506	−	_	
172-10	35506-35507	6	_	
172-11	35508-35510	18	_	
172-12	35511-35512	−	_	
172-13	35512-35513	2	_	
172-14	35513-35514	]	_	
172-15	35515-35518	MNI	_	
172-16	35519-35529	coordinate	_	
172-17	35530-35535	after	_	
172-18	35536-35546	correcting	_	
172-19	35547-35550	for	_	
172-20	35551-35557	family	_	
172-21	35558-35562	wise	_	
172-22	35563-35568	error	_	
172-23	35569-35570	(	_	
172-24	35570-35574	pFWE	_	
172-25	35575-35576	<	_	
172-26	35577-35581	0.05	_	
172-27	35581-35582	)	_	
172-28	35583-35589	within	_	
172-29	35590-35593	the	_	
172-30	35594-35600	reward	_	
172-31	35601-35605	mask	_	
172-32	35605-35606	.	_	

#Text=(B) Brain activation during successful response inhibition (StopInh>Go) within the frontal-insular-subcortical (FIS) mask.
173-1	35607-35608	(	_	
173-2	35608-35609	B	_	
173-3	35609-35610	)	_	
173-4	35611-35616	Brain	_	
173-5	35617-35627	activation	_	
173-6	35628-35634	during	_	
173-7	35635-35645	successful	_	
173-8	35646-35654	response	_	
173-9	35655-35665	inhibition	_	
173-10	35666-35667	(	_	
173-11	35667-35674	StopInh	_	
173-12	35674-35675	>	_	
173-13	35675-35677	Go	_	
173-14	35677-35678	)	_	
173-15	35679-35685	within	_	
173-16	35686-35689	the	_	
173-17	35690-35717	frontal-insular-subcortical	_	
173-18	35718-35719	(	_	
173-19	35719-35722	FIS	_	
173-20	35722-35723	)	_	
173-21	35724-35728	mask	_	
173-22	35728-35729	.	_	

#Text=Significant (pFWE < 0.05) peak activation was observed in a large right prefrontal cluster encompassing precentral, middle, and inferior gyri and anterior insula.
174-1	35730-35741	Significant	_	
174-2	35742-35743	(	_	
174-3	35743-35747	pFWE	_	
174-4	35748-35749	<	_	
174-5	35750-35754	0.05	_	
174-6	35754-35755	)	_	
174-7	35756-35760	peak	_	
174-8	35761-35771	activation	_	
174-9	35772-35775	was	_	
174-10	35776-35784	observed	_	
174-11	35785-35787	in	_	
174-12	35788-35789	a	_	
174-13	35790-35795	large	_	
174-14	35796-35801	right	_	
174-15	35802-35812	prefrontal	_	
174-16	35813-35820	cluster	_	
174-17	35821-35833	encompassing	_	
174-18	35834-35844	precentral	_	
174-19	35844-35845	,	_	
174-20	35846-35852	middle	_	
174-21	35852-35853	,	_	
174-22	35854-35857	and	_	
174-23	35858-35866	inferior	_	
174-24	35867-35871	gyri	_	
174-25	35872-35875	and	_	
174-26	35876-35884	anterior	_	
174-27	35885-35891	insula	_	
174-28	35891-35892	.	_	

#Text=The top scatter plot presents the negative relationship between extracted BOLD signal from a 10 mm radius spherical region centered at the [−6 18 −2] peak in the left VS (A) during receipt of monetary reward and extracted BOLD signal from a 10 mm radius spherical region centered at the [42 4 32] peak in the right IFG during response inhibition (B).
175-1	35893-35896	The	_	
175-2	35897-35900	top	_	
175-3	35901-35908	scatter	_	
175-4	35909-35913	plot	_	
175-5	35914-35922	presents	_	
175-6	35923-35926	the	_	
175-7	35927-35935	negative	_	
175-8	35936-35948	relationship	_	
175-9	35949-35956	between	_	
175-10	35957-35966	extracted	_	
175-11	35967-35971	BOLD	_	
175-12	35972-35978	signal	_	
175-13	35979-35983	from	_	
175-14	35984-35985	a	_	
175-15	35986-35988	10	_	
175-16	35989-35991	mm	_	
175-17	35992-35998	radius	_	
175-18	35999-36008	spherical	_	
175-19	36009-36015	region	_	
175-20	36016-36024	centered	_	
175-21	36025-36027	at	_	
175-22	36028-36031	the	_	
175-23	36032-36033	[	_	
175-24	36033-36034	−	_	
175-25	36034-36035	6	_	
175-26	36036-36038	18	_	
175-27	36039-36040	−	_	
175-28	36040-36041	2	_	
175-29	36041-36042	]	_	
175-30	36043-36047	peak	_	
175-31	36048-36050	in	_	
175-32	36051-36054	the	_	
175-33	36055-36059	left	_	
175-34	36060-36062	VS	_	
175-35	36063-36064	(	_	
175-36	36064-36065	A	_	
175-37	36065-36066	)	_	
175-38	36067-36073	during	_	
175-39	36074-36081	receipt	_	
175-40	36082-36084	of	_	
175-41	36085-36093	monetary	_	
175-42	36094-36100	reward	_	
175-43	36101-36104	and	_	
175-44	36105-36114	extracted	_	
175-45	36115-36119	BOLD	_	
175-46	36120-36126	signal	_	
175-47	36127-36131	from	_	
175-48	36132-36133	a	_	
175-49	36134-36136	10	_	
175-50	36137-36139	mm	_	
175-51	36140-36146	radius	_	
175-52	36147-36156	spherical	_	
175-53	36157-36163	region	_	
175-54	36164-36172	centered	_	
175-55	36173-36175	at	_	
175-56	36176-36179	the	_	
175-57	36180-36181	[	_	
175-58	36181-36183	42	_	
175-59	36184-36185	4	_	
175-60	36186-36188	32	_	
175-61	36188-36189	]	_	
175-62	36190-36194	peak	_	
175-63	36195-36197	in	_	
175-64	36198-36201	the	_	
175-65	36202-36207	right	_	
175-66	36208-36211	IFG	_	
175-67	36212-36218	during	_	
175-68	36219-36227	response	_	
175-69	36228-36238	inhibition	_	
175-70	36239-36240	(	_	
175-71	36240-36241	B	_	
175-72	36241-36242	)	_	
175-73	36242-36243	.	_	

#Text=The bottom scatter plot presents the negative relationship between extracted BOLD signal from the left VS (A) during receipt of monetary reward and extracted BOLD signal from a 10 mm radius spherical region centered at the [28 2 50] peak in the right MFG during response inhibition (C).
176-1	36244-36247	The	_	
176-2	36248-36254	bottom	_	
176-3	36255-36262	scatter	_	
176-4	36263-36267	plot	_	
176-5	36268-36276	presents	_	
176-6	36277-36280	the	_	
176-7	36281-36289	negative	_	
176-8	36290-36302	relationship	_	
176-9	36303-36310	between	_	
176-10	36311-36320	extracted	_	
176-11	36321-36325	BOLD	_	
176-12	36326-36332	signal	_	
176-13	36333-36337	from	_	
176-14	36338-36341	the	_	
176-15	36342-36346	left	_	
176-16	36347-36349	VS	_	
176-17	36350-36351	(	_	
176-18	36351-36352	A	_	
176-19	36352-36353	)	_	
176-20	36354-36360	during	_	
176-21	36361-36368	receipt	_	
176-22	36369-36371	of	_	
176-23	36372-36380	monetary	_	
176-24	36381-36387	reward	_	
176-25	36388-36391	and	_	
176-26	36392-36401	extracted	_	
176-27	36402-36406	BOLD	_	
176-28	36407-36413	signal	_	
176-29	36414-36418	from	_	
176-30	36419-36420	a	_	
176-31	36421-36423	10	_	
176-32	36424-36426	mm	_	
176-33	36427-36433	radius	_	
176-34	36434-36443	spherical	_	
176-35	36444-36450	region	_	
176-36	36451-36459	centered	_	
176-37	36460-36462	at	_	
176-38	36463-36466	the	_	
176-39	36467-36468	[	_	
176-40	36468-36470	28	_	
176-41	36471-36472	2	_	
176-42	36473-36475	50	_	
176-43	36475-36476	]	_	
176-44	36477-36481	peak	_	
176-45	36482-36484	in	_	
176-46	36485-36488	the	_	
176-47	36489-36494	right	_	
176-48	36495-36498	MFG	_	
176-49	36499-36505	during	_	
176-50	36506-36514	response	_	
176-51	36515-36525	inhibition	_	
176-52	36526-36527	(	_	
176-53	36527-36528	C	_	
176-54	36528-36529	)	_	
176-55	36529-36530	.	_	

#Text=The negative relationships indicate that less right frontal activation during response inhibition was associated with greater left VS activation during reward.
177-1	36531-36534	The	_	
177-2	36535-36543	negative	_	
177-3	36544-36557	relationships	_	
177-4	36558-36566	indicate	_	
177-5	36567-36571	that	_	
177-6	36572-36576	less	_	
177-7	36577-36582	right	_	
177-8	36583-36590	frontal	_	
177-9	36591-36601	activation	_	
177-10	36602-36608	during	_	
177-11	36609-36617	response	_	
177-12	36618-36628	inhibition	_	
177-13	36629-36632	was	_	
177-14	36633-36643	associated	_	
177-15	36644-36648	with	_	
177-16	36649-36656	greater	_	
177-17	36657-36661	left	_	
177-18	36662-36664	VS	_	
177-19	36665-36675	activation	_	
177-20	36676-36682	during	_	
177-21	36683-36689	reward	_	
177-22	36689-36690	.	_	

#Text=Sample characteristics (n=44)
#Text=\tMean (SD)\t \tSex (M:F)\t22:22\t \tAge\t24.7 (2.6)\t \tEducation (years)\t15.7 (1.4)\t \tRace\t\t \t Caucasian\t29\t \t More than one race\t6\t \t Asian\t5\t \t African-American\t3\t \t American Indian/Alaskan\t1\t \tAlcohol consumption (past 28 days)\t\t \t Binge episodes\t2.0 (3.0)\t \t Drinks per week\t7.0 (9.0)\t \t
#Text=Correlations between brain activation during response inhibition and receipt of monetary reward (n=44)
#Text=SST (StopInh>Go)\t\tDoors (Win>Loss)\t\t \t\tL VS\tR VS\tL Occipital\tR Occipital\t \tR IFG\t−0.382*\t−0.337\t0.060\t0.167\t \tR MFG\t−0.400*\t−0.294\t0.026\t0.024\t \tR Insula\t−0.111\t−0.075\t0.002\t−0.099\t \tR SMA\t−0.400*\t−0.322\t−0.020\t−0.047\t \t
#Text=Note.
#Text=p<0.0125.
178-1	36691-36697	Sample	_	
178-2	36698-36713	characteristics	_	
178-3	36714-36715	(	_	
178-4	36715-36716	n	_	
178-5	36716-36717	=	_	
178-6	36717-36719	44	_	
178-7	36719-36720	)	_	
178-8	36722-36726	Mean	_	
178-9	36727-36728	(	_	
178-10	36728-36730	SD	_	
178-11	36730-36731	)	_	
178-12	36734-36737	Sex	_	
178-13	36738-36739	(	_	
178-14	36739-36740	M	_	
178-15	36740-36741	:	_	
178-16	36741-36742	F	_	
178-17	36742-36743	)	_	
178-18	36744-36746	22	_	
178-19	36746-36747	:	_	
178-20	36747-36749	22	_	
178-21	36752-36755	Age	_	
178-22	36756-36760	24.7	_	
178-23	36761-36762	(	_	
178-24	36762-36765	2.6	_	
178-25	36765-36766	)	_	
178-26	36769-36778	Education	_	
178-27	36779-36780	(	_	
178-28	36780-36785	years	_	
178-29	36785-36786	)	_	
178-30	36787-36791	15.7	_	
178-31	36792-36793	(	_	
178-32	36793-36796	1.4	_	
178-33	36796-36797	)	_	
178-34	36800-36804	Race	_	
178-35	36809-36818	Caucasian	_	
178-36	36819-36821	29	_	
178-37	36825-36829	More	_	
178-38	36830-36834	than	_	
178-39	36835-36838	one	_	
178-40	36839-36843	race	_	
178-41	36844-36845	6	_	
178-42	36849-36854	Asian	_	
178-43	36855-36856	5	_	
178-44	36860-36876	African-American	_	
178-45	36877-36878	3	_	
178-46	36882-36890	American	_	
178-47	36891-36897	Indian	_	
178-48	36897-36898	/	_	
178-49	36898-36905	Alaskan	_	
178-50	36906-36907	1	_	
178-51	36910-36917	Alcohol	_	
178-52	36918-36929	consumption	_	
178-53	36930-36931	(	_	
178-54	36931-36935	past	_	
178-55	36936-36938	28	_	
178-56	36939-36943	days	_	
178-57	36943-36944	)	_	
178-58	36949-36954	Binge	_	
178-59	36955-36963	episodes	_	
178-60	36964-36967	2.0	_	
178-61	36968-36969	(	_	
178-62	36969-36972	3.0	_	
178-63	36972-36973	)	_	
178-64	36977-36983	Drinks	_	
178-65	36984-36987	per	_	
178-66	36988-36992	week	_	
178-67	36993-36996	7.0	_	
178-68	36997-36998	(	_	
178-69	36998-37001	9.0	_	
178-70	37001-37002	)	_	
178-71	37006-37018	Correlations	_	
178-72	37019-37026	between	_	
178-73	37027-37032	brain	_	
178-74	37033-37043	activation	_	
178-75	37044-37050	during	_	
178-76	37051-37059	response	_	
178-77	37060-37070	inhibition	_	
178-78	37071-37074	and	_	
178-79	37075-37082	receipt	_	
178-80	37083-37085	of	_	
178-81	37086-37094	monetary	_	
178-82	37095-37101	reward	_	
178-83	37102-37103	(	_	
178-84	37103-37104	n	_	
178-85	37104-37105	=	_	
178-86	37105-37107	44	_	
178-87	37107-37108	)	_	
178-88	37109-37112	SST	_	
178-89	37113-37114	(	_	
178-90	37114-37121	StopInh	_	
178-91	37121-37122	>	_	
178-92	37122-37124	Go	_	
178-93	37124-37125	)	_	
178-94	37127-37132	Doors	_	
178-95	37133-37134	(	_	
178-96	37134-37137	Win	_	
178-97	37137-37138	>	_	
178-98	37138-37142	Loss	_	
178-99	37142-37143	)	_	
178-100	37148-37149	L	_	
178-101	37150-37152	VS	_	
178-102	37153-37154	R	_	
178-103	37155-37157	VS	_	
178-104	37158-37159	L	_	
178-105	37160-37169	Occipital	_	
178-106	37170-37171	R	_	
178-107	37172-37181	Occipital	_	
178-108	37184-37185	R	_	
178-109	37186-37189	IFG	_	
178-110	37190-37191	−	_	
178-111	37191-37196	0.382	_	
178-112	37196-37197	*	_	
178-113	37198-37199	−	_	
178-114	37199-37204	0.337	_	
178-115	37205-37210	0.060	_	
178-116	37211-37216	0.167	_	
178-117	37219-37220	R	_	
178-118	37221-37224	MFG	_	
178-119	37225-37226	−	_	
178-120	37226-37231	0.400	_	
178-121	37231-37232	*	_	
178-122	37233-37234	−	_	
178-123	37234-37239	0.294	_	
178-124	37240-37245	0.026	_	
178-125	37246-37251	0.024	_	
178-126	37254-37255	R	_	
178-127	37256-37262	Insula	_	
178-128	37263-37264	−	_	
178-129	37264-37269	0.111	_	
178-130	37270-37271	−	_	
178-131	37271-37276	0.075	_	
178-132	37277-37282	0.002	_	
178-133	37283-37284	−	_	
178-134	37284-37289	0.099	_	
178-135	37292-37293	R	_	
178-136	37294-37297	SMA	_	
178-137	37298-37299	−	_	
178-138	37299-37304	0.400	_	
178-139	37304-37305	*	_	
178-140	37306-37307	−	_	
178-141	37307-37312	0.322	_	
178-142	37313-37314	−	_	
178-143	37314-37319	0.020	_	
178-144	37320-37321	−	_	
178-145	37321-37326	0.047	_	
178-146	37330-37334	Note	_	
178-147	37334-37335	.	_	
178-148	37336-37337	p	_	
178-149	37337-37338	<	_	
178-150	37338-37344	0.0125	_	
178-151	37344-37345	.	_	

#Text=SST = stop signal task; L = left; R = right; VS = ventral striatum; IFG = inferior frontal gyrus; MFG = middle frontal gyrus; SMA = supplementary motor area
179-1	37346-37349	SST	_	
179-2	37350-37351	=	_	
179-3	37352-37356	stop	_	
179-4	37357-37363	signal	_	
179-5	37364-37368	task	_	
179-6	37368-37369	;	_	
179-7	37370-37371	L	_	
179-8	37372-37373	=	_	
179-9	37374-37378	left	_	
179-10	37378-37379	;	_	
179-11	37380-37381	R	_	
179-12	37382-37383	=	_	
179-13	37384-37389	right	_	
179-14	37389-37390	;	_	
179-15	37391-37393	VS	_	
179-16	37394-37395	=	_	
179-17	37396-37403	ventral	_	
179-18	37404-37412	striatum	_	
179-19	37412-37413	;	_	
179-20	37414-37417	IFG	_	
179-21	37418-37419	=	_	
179-22	37420-37428	inferior	_	
179-23	37429-37436	frontal	_	
179-24	37437-37442	gyrus	_	
179-25	37442-37443	;	_	
179-26	37444-37447	MFG	_	
179-27	37448-37449	=	_	
179-28	37450-37456	middle	_	
179-29	37457-37464	frontal	_	
179-30	37465-37470	gyrus	_	
179-31	37470-37471	;	_	
179-32	37472-37475	SMA	_	
179-33	37476-37477	=	_	
179-34	37478-37491	supplementary	_	
179-35	37492-37497	motor	_	
179-36	37498-37502	area	_	
